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ABSTRACT 
Tissues such as liver, kidney, brain and intestine expresses membrane transporters which 
play a vital role in drug absorption, distribution, metabolism and excretion. Understanding of 
functionality and molecular expression of drug transporters can prove to be of utmost importance 
in drug delivery or drug design by targeting specific transporter proteins. It’s a well-known fact 
that drug transporters play an important role in governing drug disposition which act as potential 
piece of information during the drug discovery and development process. By exploring the 
transporter functionality chances of delivering a therapeutic agent to the target organ enhances. 
Transporter targeted drug delivery helps in improving the bioavailability, controlling the 
elimination process and also avoid distribution to non-specific organs, hence diminishes the odds 
of toxic adverse effects. It is always suitable to choose a potential molecule which may or may not 
interact with the membrane transporters, depending on whether such an interaction is of any use 
or not. Activity of individual transport process can be examined by exploring the expression 
system of transporters. Therapeutic efficacy many important drugs, directly or indirectly, get 
affected due to genetic polymorphisms and drug-drug interactions involving membrane 
transporters which ultimately effects the pharmacokinetics of a drug molecule. During the drug 
discovery and development process, knowledge about the contribution of these transporters 
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towards interindividual differences by regulating drug absorption, distribution, metabolism and 
excretion will act as an important tool. The objective of this dissertation project was to understand 
the role of hepatic uptake transporters (OATP-1B1 and -1B3) in governing the disposition of 
tyrosine kinase inhibitors (TKIs). Since selected TKIs are the substrates and/or inhibitors of 
OATP-1B1 and -1B3 expressed in hepatic tissue, these compounds can be regarded as molecular 
targets for transporter mediated drug-drug interactions (DDIs). Any alteration in the function of 
these hepatic OATPs might account for the pharmacokinetic variability of TKIs. These finding 
also provide the basis of further pre-clinical and clinical studies investigating the transporter based 
DDI potential of TKIs. 
As a secondary aim of this investigation we developed novel pentablock (PB) copolymer 
nanoparticles of pazopanib for treatment of ocular neovascularization. Our results indicated that 
PB copolymer based drug delivery systems can serve as a platform technology for the development 
of sustained release therapy along with evasion of drug efflux for the treatment of ocular 
neovascularization. This drug delivery system can also be utilized for other chronic diseases as 
well.  
We also investigated the presence of ascorbic acid-specific transport system and delineate 
the functional and molecular aspects of vitamin C transporter (SVCT2) in ocular and breast cancer 
cells. SVCT2 system can be targeted for the design of ascorbic acid prodrugs or for NPs surface 
modified with ascorbic acid to achieve enhanced permeability for highly potent but poorly 
bioavailable drugs by evading drug efflux in the treatment of cancer and ocular diseases.   
Interaction of TKIs with hepatic OATP-1B1 and -1B3 delineates the role of hepatic uptake 
transporters in drug disposition and drug-drug interactions. These OATP transporters in 
conjunction with the efflux proteins (P-gp, MRP and BCRP) may eventually decide on the overall 
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flux/loss of the therapeutic agents within the hepatic tissue. Similary, functionality of membrane 
tranporters have been exploited and examined in terms of drug delivery. Pazopanib encapsulated 
nanoparticles of novel pentablock polymers were successful in bypass drug efflux mediated via 
efflux proteins. Also, influx transporters (vitamin C transporter, SVCT2) on ocular cell lines can 
be further utilized as a potential target for enhancing absorption and permeability of AA-
conjugated drugs or drug delivery systems by evading drug efflux. 
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CHAPTER 1 
THE CONVOLUTIONS INVOLVED IN HEPATIC DRUG TRANSPORT: FOCUS ON 
MEMBRANE TRANSPORTERS 
 
Rationale 
Impact of hepatic transport systems in drug disposition [1] 
Liver is mainly responsible for the metabolism and/or excretion of many endogenous and 
exogenous compounds from the body. Research on the metabolic aspects of hepatic clearance has 
been a prime area of interest since many decades, although, currently the focus has also been also 
shifted to examine and evaluate the role of hepatic transport systems in the hepatobiliary 
disposition of drugs and metabolites. It’s a known fact that translocation of lipophilic molecules 
from plasma to hepatic cytosol is mediated via simple or facilitated diffusion. However, basolateral 
transport proteins consist of several membrane transporters were involved in uptake of 
amphipathic and polar organic compounds, in addition to some lipophilic molecules, from 
sinusoidal plasma to hepatic cytosol. Hepatobiliary disposition of some compounds is also 
influenced by hepatocellular protein binding and sequestration. As mentioned above that excretion 
of drugs and metabolites from the hepatocyte is mediated via hepatic transport proteins. 
Translocation of polar molecules from hepatic cytosol into blood is mediated via uni- or bi-
directional basolateral transport systems, however, biliary excretion of drugs and metabolites is 
mediated via active canalicular transport systems. Recently, there has been a surge of interest in 
the field of drug transport, and knowledge regarding hepatic transport systems has grown 
substantially. There is widespread interest in the hepatic transport of drugs and metabolites among 
pharmaceutical scientists, including medicinal chemists, pharmacologists, and clinicians, for 
several reasons: 
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Drug Design (Drug Delivery) 
Understanding of structure-transport relationships for hepatic transport proteins would 
provide an extra edge in designing of compounds with finest transport properties. For a potential 
drug candidate, extensive hepatic uptake or enhanced biliary excretion may be considered as 
appropriate characteristic, whereas in others, reduce systemic exposure and limit pharmacological 
activity due to extensive hepatic uptake and biliary excretion can be regarded as an unattractive 
property of the potential molecule. 
Bioavailability 
The liver is an important organ of first-pass elimination. Dietary, disease, or drug-induced 
alterations in hepatic transport systems may lead to reduced or erratic systemic availability of drugs 
after oral administration. In some cases, diminished systemic availability of a drug after oral 
administration has been attributed as an outcome of induction of a hepatic transport protein 
responsible for the hepatic uptake or biliary excretion of that drug. Besides liver, membrane 
transporters expressed on the basolateral and apical membranes of the gastrointestinal epithelial 
cells also play an important role in altering the bioavailability of several drug molecules. 
Biliary Excretion  
ATP-dependent canalicular transport proteins are responsible for biliary excretion of 
compounds. In humans, the degree to which most drugs and metabolites go through biliary 
excretion is not freely valued due to the innate difficulties in directly accessing bile drainage in 
healthy individuals. Extensive biliary secretion of therapeutic agents limits their systemic exposure 
which leads to the exclusion of possibly beneficial therapeutic agents in the early stages of drug 
development. Biliary excretion of drugs or metabolites can exert dose-limit toxicities on exposure 
of intestinal epithelia to pharmacologically active or toxic species. Compounds that experience 
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biliary excretion undergoes systemic reabsorption followed by metabolism or elimination in feces. 
Hepatic transport systems are considered as one of the critical factor of the enterohepatic recycling 
of compounds. 
Interindividual Variability In Drug Pharmacokinetics And Pharmacodynamics.  
Disposition of many endogenous and exogenous compounds, including drugs and 
metabolites may alter significantly on any disease-associated or genetic alterations in the 
expression and/or function of hepatic transport proteins. Hepatic transporters are known to be 
responsible for causing important variations in the disposition, pharmacological activity, and 
toxicity of many therapeutic agents. A major prerequisite in order to achieve therapeutic outcomes 
in varied patient population is the extensive knowledge about mechanism responsible causing 
interpatient variability via hepatic drug transport systems. 
Drug/Nutrient-Transport Interactions  
Activity of hepatic transport protein may be enhanced or impaired on interacting with drug 
and nutrients. These interactions may alter the expression and function of hepatic transporters and 
can be direct or indirect in nature. In future, revelation of clinically important interaction with 
hepatic transporters and the approaches to foresee these interactions may offer several exciting 
prospects for membrane transporter related research. 
Nomenclature [1] 
 Nomenclature of hepatic transport system is a challenging discipline. New proteins were 
promptly recognized and termed with the introduction of molecular biology methods. Early 
nomenclature of hepatic transporters is recognized as descriptive, cumbersome and duplicative. In 
order to avoid this timeworn convoluted nomenclature, guidelines approved by HUGO Gene 
Nomenclature Committee were employed. Hepatic transporters belongs two major families: (i) 
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solute carriers superfamily (SLC/SLCO) and (ii) ATP-binding cassette superfamily (ABC). As per 
guidelines, upper case refers to the human and lower case refers to the rodent genes and gene 
products. 
Drug or Membrane Transporters of the Hepatic Basolateral Membrane 
 Elimination via hepatic route is usually an order of events which involves uptake of 
xenobiotics from the sinusoidal blood followed by intracellular metabolism, and finally excretion. 
In humans, molecules excreted from hepatocytes into the bile were stored in the gallbladder and 
released intermittently into the upper small intestine or the basolateral membrane into sinusoidal 
blood followed by elimination by other excretory organs. Hepatocytes having dissimilar 
basolateral (sinusoidal and lateral) and apical (canalicular) membrane domains that be at variance 
in lipid and protein composition facilitates the flux of drug molecules/substrates through the 
hepatobiliary system. Gene superfamily of solute carriers (SLC) represents the basolateral hepatic 
transport proteins which helps in translocation of substrates to and from the sinusoidal blood 
(Fig.1.1). Selected substrates and inhibitors of the human transport proteins expressed on the 
hepatic basolateral and apical (canalicular) membranes are mentioned in Tables 1.1 and 1.2, 
respectively.  
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Fig.1.1: Human hepatic basolateral transport proteins. Schematic representation of three adjacent 
hepatocytes with interconnecting canalicular spaces sealed by tight junctions. Sinuosoidal blood 
flowing through the liver bathes hepatocytes and delivers solutes to the basolateral hepatic 
membrane for uptake. Important basolateral transport proteins (protein name is in bold type with 
gene symbol listed below) are depicted with arrows denoting the direction of transport and ATP-
dependent transporters designated by ●. For the OAT and OCT families, only mRNA have been 
detected in human liver. Typical substrates are listed (OA-, organic anions; OC+, organic cations; 
MTX, methotrexate; cAMP, adenosine 3’,5’-cyclic monophosphate; cGMP, guanosine 3’,5’cyclic 
monophosphate). (Reproduced with permission, Brouwer K.M. et al [1]) 
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Table 1.1: Human Hepatic Basolateral Transport Proteins 
(Reproduced and modified with permission, Brouwer K.M. et al [1]) 
 
Basolateral Protein Gene Symbol Substrates Inhibitors 
NTCP SLC10A1 Bromosulphophthalein, 
cholate, estrone-3-sulfate, 
glycocholate 
taurochenodeoxycholate, 
tauroursodeoxycholate, 
Cyclosporine, 
irbesartan, ritonavir, 
bendroflumethiazide, 
doxazosin, 
rifampicin 
OATP1A2 SLCO1A2 Bile acids, methotrexate, 
estrone-3-sulfate, n-methyl 
quinine; ouabain,  
dehydroepiandrosterone 
sulphate, fexofenadine, 
 bromosulphophthalein,  
digoxin, levofloxacin,statin 
Naringin, ritonavir, 
lopinavir, saquinavir, 
rifampicin 
OATP1B1 SLCO1B1 Bile acids, ouabain, 
estrone-3-sulfate, 
bromosulphophthalein, 
estradiol-17β-glucuronide, 
statins, repaglinide, 
valsartan, olmesartan, 
Saquinavir, ritonavir, 
lopinavir, rifampicin, 
cyclosporine 
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bilirubin glucuronide, 
bilirubin, 
OATP1B3 SLCO1B3 Bile acids, ouabain, 
estrone-3-sulfate, 
bromosulphophthalein, 
estradiol-17β-glucuronide, 
cholecystokinin 8, statins, 
digoxin, fexofenadine, 
telmisartan glucuronide, 
telmisartan, valsartan, 
olmesartan, 
Rifampicin, 
cyclosporine, 
ritonavir, 
lopinavir 
OATP2B1 SLCO2B1 Benzylpenicillin, estrone-3-
sulfate, bromosulphophthalein, 
taurocholate, statins, 
fexofenadine, glyburide, 
taurocholate 
Rifampicin, 
cyclosporine 
OAT2 SLC22A7 Prostaglandin E2, 
prostaglandin F2α, salicylate, 
tetracycline, 
zidovudine, paclitaxel, 
theophylline 
Diclofenac, 
mefenamic acid, 
bumetanide, 
cyclothiazide 
OAT4 SLC22A11 Bumetanide, estrone-3-sulfate 
ketoprofen, salicylate, 
Telmisartan, losartan, 
valsartan, 
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methotrexate, ochratoxin A 
prostaglandin E2, 
prostaglandin F2α, tetracycline, 
zidovudine, uric acid 
olmesartan, 
indomethacin, 
furosemide 
OCT1 SLC22A1 Azidoprocainamide 
methoiodide, n-methyl-
quinidine, n-methyl-quinine, 
tributylmethylammonium, 
tetraethylammonium, 1-
methyl-4-phenylpyridinium 
Imatinib, nilotinib, 
gefitinib, erlotinib, 
atropine, prazosin 
OCT3 SLC22A3 Adrenaline, noradrenaline, 
tyramine, agmatine, 1-methyl-
4-phenylpyridinium, 
metformin, pindolol, 
procainamide, ranitidine, 
varenicline 
Quinidine, 
cimetidine, 
testosterone 
MRP1 ABCC1 Daunorubicin, doxorubicin, 
etoposide, vincristine 
MK-571, probenecid, 
reversan, JS-2190 
MRP3 ABCC3  Estradiol-17β-glucuronide, 
methotrexate, fexofenadine, 
glucuronate conjugates, 
acetaminophen, monovalent 
and sulfated bile salts 
Delaviridine, 
efavirenz, 
emtricitabine 
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MRP4 ABCC4 Adefovir, tenofovir, 
dehydroepiandrosterone 
sulphate, methotrexate, 
topotecan, furosemide, 
adenosine 3’, 5’-cyclic 
monophosphate, guanosine 
3’,5’-cyclic monophosphate, 
bile acids plus glutathione, 
azidothymidine, 9-(2-
phosphonomethoxyethyl) 
adenine 
Celecoxib, 
diclofenac 
MRP5 ABCC5 adenosine 3’, 5’-cyclic 
monophosphate, guanosine 
3’,5’-cyclic monophosphate, 
pemetrexed 
Methotrexate, 
sildenafil, 5-
fluorodeoxyuridine 
monophosphate, 
dipyridamole, 
methotrexate 
MRP6 ABCC6 9-(2-phosphonomethoxyethyl) 
adenine, cisplatin, 
daunorubicin, Leukotriene C4, 
[cyclo(D-Trp-D-Asp-L-Pro-D-
Val-L-Leu)] 
Benzbromarone, 
indomethacin, 
probenecid 
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MRP7 ABCC10 Leukotriene C4, Estradiol-17β-
glucuronide 
Lapatinib, erlotinib, 
ponatinib, tariquidar 
MRP8 ABCC11 Adenosine and guanosine 3’, 
5’-cyclic monophosphate 
 
 
Table 1.2: Human Hepatic Apical (Canalicular) Transport Proteins 
(Reproduced and modified with permission, Brouwer K.M. et al [1]) 
 
Apical 
(Canalicular)  
Protein 
Gene Symbol Substrates Inhibitors 
BSEP ABCB11 Conjugated and unconjugated 
bile salts, taurocholate, 
pravastatin 
Cyclosporin A, 
rifampicin, 
glibenclamide 
MRP2 ABCC2 Acetaminophen glucuronide, 
carboxydichlorofluorescein, 
camptothecin, doxorubicin 
cisplatin, vincristine, 
etoposide, glibenclamide; 
indomethacin, rifampin, 
glucuronide, glutathione, and 
sulfate conjugates, leukotriene 
C4, methotrexate, pravastatin, 
valsartan, olmesartan, 
Cyclosporine, 
delaviridine, 
efavirenz, 
emtricitabine 
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glucuronidated SN-38 
MDR1 or P-gp ABCB1 Amprenavir, indinavir, 
nelfinavir, ritonavir, saquinavir 
Aldosterone, corticosterone, 
dexamethasone, digoxin, 
cyclosporin A, mitoxantrone,  
debrisosoquine, erythromycin, 
lovastatin, terfenadine, 
digoxin, quinidine, 
doxorubicin, paclitaxel, 
rhodamine 123, etoposide, 
fexofenadine, losartan, 
vinblastine, tacrolimus, 
talinolol, loperamide, 
berberine, irinotecan, 
Cyclosporine, 
quinidine, tariquidar, 
verapamil 
MDR3 ABCB4 Phosphatidylcholine, 
paclitaxel, digoxin, vinblastine, 
phospholipids 
Verapamil, 
cyclosporine 
BCRP ABCG2 Mitoxantrone, methotrexate, 
topotecan, imatinib, irinotecan, 
statins, sulphate conjugates, 
porphyrins, daunorubicin, 
doxorubicin 
Estrone, 17β-
estradiol, fumitre - 
morgin C 
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Na+-taurocholate co-transporting polypeptide (NTCP) 
 NTCP is a membrane transporter responsible for uptake of sodium-dependent bile salt [2]. 
This membrane transporters requires two sodium for translocation of each taurocholate (TC) 
molecule and is also responsible for uptake of bile salt in rodents [3]. NTCP shows higher affinity 
towards conjugated bile salts (TC, tauroursodeoxycholate, taurochenodeoxycholate) than 
unconjugated bile salts (cholate). Non-bile salt substrate for this transporter protein are 
dehydroepiandrosterone sulfate (DHEAS), thyroxine (T4), bromosulfophthalein (BSP), 3,3’,5-
triiodo-L-thyronine (T3) and estrone-3-sulfate [3] [4, 5]. 
Organic Anion Transporting Polypeptides (OATPs) 
 OATP family of transporter proteins play a vital role clearance of many drugs via hepatic 
route. Substrates of OATPs are unrestrained rather than specific, which includes variety of organic 
anions, few type II cations (bulky molecules with cationic groups located near the ring; e.g., 
quinidine) and neutral steroids. OATP transporter proteins may act in a bi-directional manner and 
are sodium independent. High concentration of reduced glutathione within the hepatocyte may act 
as the driving force for the translocation of substrates of hepatic OATPs [3, 6]. Eleven members 
of the OATP transporter proteins have been identified in humans Table 1.3. Expression of OATPs 
has been reported in various tissues including intestine, liver, kidney and brain, and are recognized 
to play an important role in drug absorption, distribution and the elimination of endogenous and 
exogenous compounds including drugs in clinical use [7]. 
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Table 1.3: Characteristics of human OATP family members 
(Reproduced and modified with permission, Jorg Konig [8]) 
 
Protein Name Gene Symbol Amino Acids Tissue Distribution 
OATP1A2 SLCO1A2 670 Brain, Kidney 
OATP1B1 SLCO1B1 691 Liver 
OATP1B3 SLCO1B3 702 Liver 
OATP1C1 SLCO1C1 712 Brain, Testis 
OATP2A1 SLCO2A1 643 Ubiquitous 
OATP2B1 SLCO2B1 709 Ubiquitous 
OATP3A1 SLCO3A1 710 Ubiquitous 
OATP4A1 SLCO4A1 722 Ubiquitous 
OATP4C1 SLCO4C1 724 Kidney 
OATP5A1 SLCO5A1 848 Kidney, Ovary 
OATP6A1 SLCO6A1 719 Testis 
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Expression of OATP1A2, OATP1B1 and OATP1B3 has been predominantly found in 
human liver. In comparison to OATP1A2 and OATP1B3, OATP1B1 plays a critical role in Na+-
independent bile salt uptake system in human liver, whereas OATP2B1 does not play any role in 
translocation of bile salts. All four human OATP proteins transports bromosulphophthalein (BSP), 
estrone-3-sulfate and dehydroepiandrosterone (DHEAS), however extent of uptake differs due to 
varied affinity [9]. Affinity of OATP isoforms of rodent and human species cannot be predicted 
on the basis of amino acid sequence, since the Slco gene products corresponding to rodents are not 
orthologs of human OATP proteins [10]. This poses a major challenge in the process of drug 
development as OATPs are involved in the hepatic uptake of many therapeutic agents. These 
variability in the affinity of substrates towards OATPs of different species will make it difficult to 
predict hepatic clearance or drug interactions in hepatic transport (if hepatic uptake is the rate-
limiting step in hepatic clearance of a compound) considering that distinct proteins exhibiting 
different substrate specificities may be involved. Deltorphin II is a specific substrate for rat 
Oatp1a1 whereas its other substrates include monovalent and sulfated bile salts, glucuronide, and 
glutathione conjugates [11, 12]. Rat Oatp1a1 shares this substrate specificity except sulfate 
conjugates with Oatp1a4. However, digoxin is a specific substrate of Oatp1b4 [3]. Oatp1b2 is 
expressed on the basolateral membrane of liver and expresses high affinity towards DHEAS, BSP, 
leukotriene C4 (LTC4), and anionic peptides [12]. mRNA expression of OATP3A1 and OATP4A1 
has been reported in hepatic tissue, also translocation of estrone-3-sulfate is mediated via 
OATP1B1, 2B1, 3A1, and 4A1 whereas OATP4A1 also was helps in transport of 3,3’,5-triiodo-
L-thyronine, thyroxine and taurocholate [10, 13]. Little information has been available so far 
regarding the transport and biochemical properties of OATP5A1 [14]. 
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Organic Anion Transporters (OATs) 
 OATs gene family (Slc22) was first cloned in kidney. Expression of Oat2 and Oat3 was 
found to be predominant in rat hepatic tissue and helps in translocation of prototypic anionic 
substrate paraaminohippurate. Also Oat 2 play a vital role in uptake of dicarboxylates, 
indomethacin, methotrexate, salicylate, prostaglandinE2 (PGE2), and nucleoside derivatives, 
whereas uptake of cimetidine, estrone-3-sulfate, and ochratoxin A is mediated via Oat3 [15] [16]. 
It has been postulated that Oat proteins expressed on basolateral membrane of hepatic tissue 
physiologically function as excretion system. mRNA expression of Oat3 has been reported in 
human liver [17, 18]. OAT2 and OAT4 exhibits overlapping substrate specificities including 
prostaglandin F2α (PGF2α), tetracycline, salicylate, zidovudine, and PGE2 [19-23], also OAT4 
shows its substrate specificity towards methotrexate and ochratoxin A [24, 25]. 
Organic Cation Transporters (OCTs and OCTNs) 
OCTs are responsible for hepatic uptake of smaller type I organic cations (e.g., 
tetraethylammonium, azidoprocainamide methoiodide) [26, 27]. Expression of Oct1 has been 
reported on basolateral membrane of rat hepatocytes [28]. Little information is available on the 
expression and function of OCT3, however it has been reported that OCT3 helps in transport of -
methyl-4-phenylpuridinium iodide in the HepG2 hepatoma cell line [29]. Novel organic cation 
transporters were classified as OCTN1 and OCTN2 of SLC22 gene family containing a nucleotide 
binding site sequence motif [30, 31]. Information is still missing on exact membrane localization 
and substrate specificity of these novel OCTs in rat and human liver.  
Multidrug Resistance Associated Protein1 (MRP1) 
 MRP subfamily may play a major role in excretion of drugs or metabolites from the human 
hepatocyte to sinusoidal blood. MRP family is classified into nine members, out of which, 7 
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members are responsible for hepatic elimination of organic anions. Expression of MRP1 is lower 
in lateral levels and is primarily expressed in intracellular vesicles in human hepatocytes [32-34]. 
It has been reported that intracellular GSH has one of the requirement for transport of drugs 
mediated via MRP1, however it’s not the case with the transport of conjugated drugs [35]. 
Multidrug Resistance Associated Protein3 (MRP3) 
 Mrp3 expressed on basolateral membrane of hepatic tissues mediates the hepatic 
elimination of monovalent (e.g., taurocholate and glycocholate) and sulfated bile salts, as well as 
other organic anions such as E217G, methotrexate and acetaminophen glucuronide [36-38]. Mrp3 
shows higher affinity towards glucuronide conjugates than glutathione conjugates [37]. 
Phenobarbital and cholestatic conditions induces the expression level of Mrp3 in rats [39]. Humans 
exhibiting naturally occurring hereditary defects in biliary excretion of organic anions shows 
induced levels of MRP3/Mrp3 [40]. Induced expression of MRP3/Mrp3 acts as a compensatory 
mechanism for the reduced ability to excrete organic anions into bile. Mrp3 is hypothesized to play 
a vital role in enterohepatic circulation of bile salts [37]. 
Multidrug Resistance Associated Protein4 and 5 (MRP4 and MRP 5) 
 Translocation of cyclic nucleotides adenosine 3’, 5’-cyclic monophosphate (cAMP) and 
guanosine 3’, 5’-cyclic monophosphate (cGMP) is mediated via MRP4 and MRP5 expressed on 
the basolateral membrane of hepatic tissue [41]. Due to utilization of different in vitro systems, 
various discrepancies has been reported in the Km values for MRP4 and MRP5 [42, 43]. These 
transporter proteins also translocates methotrexate (42), the antiviral agent 9-(2-
phosphonomethoxyethyl) adenine and the reverse transcriptase inhibitor azidothymidine [44, 45]. 
Sulfated bile acids and steroids competitively inhibit transport of MRP4 substrates. Induced level 
of expression of Mrp4 was reported with chronic elevation of bile acid levels [46, 47]. 
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Multidrug Resistance Associated Protein6 (MRP6) 
 Expression of Mrp6 has been reported on both apical and basolateral in rat hepatocytes. 
Mrp6 transporter protein does not play any vital role in governing hepatic excretion of phase II 
biotransformation products (e.g., glucuronide, sulfate, and glutathione conjugates), since it is not 
involved in the translocation of typical anionic substrates except cyclopentapeptide BQ-123. Mrp6 
transporter exhibit high levels of expression in human liver and kidney, although information is 
still lacking examining the role of this transporter in drug transport [48, 49]. 
Multidrug Resistance Associated Protein7 and 8 (MRP7 and MRP 8) 
 mRNA expression of MRP7 has been reported in various tissues including liver. Also, 
E217G and LTC4 exhibited their substrate specificity towards MRP7 [50, 51]. Liver shows higher 
mRNA expression of MRP8 in comparison to breast and testis. MRP8 shares overlapping substrate 
specificity with MRP5 including transport of cyclic nucleotides [52, 53]. 
Drug or Membrane Transporters of the Hepatic Apical (Canalicular) Membrane 
Bile Salt Export Pump (BSEP) 
 These export pumps transports xenobiotics and metabolites across the canalicular 
membrane into bile via unidirectional ATP-dependent process (Fig.1.2). These canalicular 
membrane transporters belong to the ABC superfamily of transporters [54]. This transporter is also 
referred as sister gene of P-glycoprotein and eliminates conjugated and unconjugated bile salts into 
the canalicular space [55]. Absence of BSEP from the apical membrane and mutation in ABCB11 
gene in patients with progressive familial intrahepatic cholestasis type 2 (PFIC2) leads to 
diminished biliary bile salt concentrations relative to normal patient [56, 57]. BSEP does not play 
any important role in hepatic excretion of therapeutic agents, however it may act as an important 
site for transporter mediated drug interactions. 
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Fig.1.2: Human hepatic canalicular transport proteins. Schematic representation of two adjacent 
hepatocytes as described in Fig.1.1. Important canalicular transport proteins (protein name is in 
bold type with gene symbol listed below) are depicted with arrows denoting the direction of 
transport and ATP-dependent transporters designated by ●. Typical substrates are listed (OA-, 
organic anions; OC+, organic cations; TC, taurocholate; MX, mitoxantrone). (Reproduced with 
permission, Brouwer K.M. et al [1]) 
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Multidrug Resistance Associated Protein2 (MRP2) 
 This membrane transporter was earlier referred as the canalicular multispecific organic 
anion transporter (cMOAT) and is the most extensively evaluated canalicular member of the 
MRP/Mrp family. It is responsible for biliary excretion of organic anions including LTC4, divalent 
bile salts, and glutathione, glucuronide, and sulfate conjugates [58].  In patients with Dubin-
Johnson syndrome, Groningen Yellow/Transport-deficient Wistar rats (GY/TR-) and Eisai 
hyperbilirubinemic Sprague-Dawley rats (EHBR), absence of these apical hepatic transporter 
forms the basis for the defect in biliary excretion of organic anions [40, 59-61]. In rats and patients 
with downregulated expression of Mrp2, biliary excretion of organic anions, including conjugated 
bile acids is compensated by upregulated expression of MRP3/Mrp3 which help in elimination of 
organic anions, including conjugated bile acids [62]. Elimination profile of compound, whether 
the compound gets eliminated in bile or urine, will determine its affinity towards canalicular and 
basolateral excretory transporters, as well as the activity of the respective transporters. Hepatic 
elimination of compounds get significantly influenced by altered transporter activity due to drug 
or nutrient interactions or patient-specific factors such as disease, genetics.  
Multidrug Resistance Protein1 or P-glycoprotein (MDR1 or P-gp) 
 It is the most widely studied and examined hepatic canalicular transporter. Interactio of 
anti-cancer agents with P-gp has been postulated as one of the major reason for the development 
of chemo resistance to an array of chemotherapeutic agents that exhibit a wide range of structures 
and mechanisms of action [63]. Translocation of hydrophobic cations is mediated via MDR1 
transporter protein. Characteristics of typical substrate of MDR1 are presence of planar aromatic 
rings which interacts with a hypothesized “flat” hydrophobic region of the MDR1 drug-binding 
domain, a cationic charge at physiological pH, a bulky structure having molecular weight >400 
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and a log partition coefficient >2 [64, 65]. Importance of MDR1 in the distribution and elimination 
of relatively small, aliphatic and aromatic, permanently charged cationic molecules has been 
demonstrated in several studies carried out on Mdr1 gene knockout mice [66, 67]. Various MDR1 
substrates include 
 daunorubicin, doxorubicin, etoposide, paclitaxel, vinblastine, vincristine, pazopanib, vandetanib, 
sorafenib, digoxin, methadone, morphine, rhodamine 123, cyclosporin A, etc [68]. In order to 
narrow down the substrate affinities, specificities, structural requirement, binding sites of 
modulators towards MDR1, a three-dimensional quantitative structure- activity relationship 
(QSAR) models for MDR1 have been developed [69-71]. Evidently, in the hepatic excretion of a 
xenobiotics including many drugs and metabolites, MDR1 plays an important role. 
Protein-calorie malnutrition downregulates levels of expression and activity of Mdr1 in rat 
canalicular plasma membrane vesicles by ∼22% and ∼35%, respectively [72]. Overexpression of 
COX-2 has been directly related to overexpression Mdr1 protein levels in renal rat mesangial cells, 
leading to increased Mdr1 activity as measured by rhodamine 123 efflux [73]. Also, upregulated 
levels of Mdr1 expression has been reported on exposure to ultraviolet irradiation and heat shock, 
however downregulation of Mdr1 expression has resulted in rodents from lipopolysaccharide 
induced endotoxemia [74, 75]. Release of cytokines such as interleukin-1β and -6 also modulates 
expression of Mdr1 [75]. In addition, Mdr1 may be regulated by a variety of factors. 
Multidrug Resistance Protein3 (MDR3) 
Uptake of phosphatidylcholine translocase is primarily mediated via MDR3 and its rodent 
ortholog Mdr2. Biliary phospholipid secretion is regulated via MDR3 and Mdr2 in humans and 
rodents, respectively. Mutation in ABCB4 gene has been reported in patients classified with PFIC 
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type 3 cholestasis. Still more information is needed in order to establish the physiologic role of 
MDR3 as a drug transporter [76]. 
Breast Cancer Resistance Protein (BCRP) 
Breast cancer resistance protein, a 72-kDa transporter protein also referred as half ABC 
transporter [77]. It confers resistance to mitoxantrone, doxorubicin, daunorubicin and sulfated 
conjugates by causing protein dimerization in the plasma membrane [78]. BCRP is reported to 
express in several tissues placenta, small intestine, blood-brain barrier, colon, hepatic canalicular 
membrane, breast, and venous and capillary endothelium [79]. Apart from other apical hepatic 
transporters, biliary excretion of the sulfated conjugates of steroids and xenobiotics is also 
mediated via BCRP. 
Hepatobiliary Drug Transport Model Systems 
 Absence of suitable model systems that replicate hepatic anatomy, hepatocyte function and 
bile formation is a major restriction in the field of hepatobiliary transport. The advantages of in 
vivo and isolated perfused liver techniques, in terms of reflecting the true physiologic state of the 
liver, are offset by difference in hepatic transport proteins and varied affinity of compounds may 
exist between rodents and humans. Also, it is very difficult to examine individual hepatic uptake 
and excretion mechanisms due to the complications associated with whole organ. It is very difficult 
to assess the role of individual hepatic transporter on drug disposition due to the non-existence of 
specific and potent inhibitors for the hepatic transport proteins. Relative to other in vitro systems, 
hepatocytes are more advantageous in terms of providing liver-specific cellular functions (plasma 
membrane vesicles; transport proteins transfected in non-mammalian cells) and can be utilized to 
study function of specific transport proteins. Also, hepatocytes of free of any concerns related to 
species differences in hepatobiliary disposition [80, 81]. For studying hepatic excretion, isolated 
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hepatocytes poses some challenges like loss of cell polarity and redistribution of canalicular 
membrane proteins, however, these cells have been extensively employed to evaluate hepatic 
transport mechanism [82]. In various transport trafficking and regulation studies, hepatocyte-
derived cell lines (WIF-B and HepG2) showing strong correlation to bile canaliculi has been 
utilized [83-86]. Sandwich culture hepatocytes that demonstrates strong and intact canalicular 
networks and also maintains hepatic transport protein expression and function are employed as an 
important in vitro model system to study hepatobiliary disposition of therapeutic agent and 
metabolites [87-89]. 
 For uptake transporter analysis, human embryonic kidneys (HEK) and Chinese hamster 
ovary (CHO) cells transfected with the respective transport protein were utilized. These cell 
systems are employed to standardize uptake assays and also for comparing, for example, regarding 
drug-drug interactions (DDIs). These analyzing of DDIs involves comparing the uptake of the 
single drug with the uptake of the single drug in the presence of a drug which can modulate the 
function of respective transporter protein. These cell systems provides great advantages regarding 
the standardization of the uptake assay, by using the same cell density, different uptake assays can 
be compared from different days. These in vitro model based systems are frequently employed for 
the analysis of DDIs and also for the functional consequences of polymorphisms [90, 91]. 
Although, these transfected cell lines play a major role in demonstrating the uptake of a compound 
via specific transporter but still may poses a challenge in predicting the role of specific transport 
protein in overall hepatobiliary disposition of a compound when multiple transport systems are 
present. 
 Sandwich cultured can be employed to evaluate analogs of specific transport properties 
(limited or enhanced hepatobiliary uptake or efflux) at the early stages of lead optimization and 
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candidate selection in the process of drug development. At later stages of drug development, 
tranfected cell lines or in vivo models systems may act beneficial in order to study the significance 
of transport inhibition and/or identify contrivances responsible for hepatotoxicity [1]. 
Advancements In Hepatobiliary Drug Transport 
 In order to enhance understanding hepatic transport biology and how drugs and/or disease 
affecting intracellular regulatory mechanisms may modify hepatic transport of endogenous and 
exogenous compounds, one should have knowledge about the basic regulation hepatic transport. 
Alteration in the membrane transporter function or deviations in the number of molecules 
translocate across membrane defines the mechanism governing membrane transport. Modulation 
of transporter protein expression can occur at any level protein synthesis including transcription, 
translation, and post-translation. Modulation of transporter gene expression in hepatocytes is 
governed by transcription factors [92]. Developmental as well as physiological responses to both 
endogenous and exogenous compounds is mediated via nuclear hormone receptors comprising of 
superfamily of ligand-activated transcription factors. Interaction of xenobiotics with these 
receptors results in formation of complex with regulatory region of the gene leading modification 
in expression these receptors. On binding of ligand to receptor, already formed complex binds with 
heterodimeric partner retinoic acid X receptor (RXR) leading to initiation of transcription. Various 
nuclear hormone receptor types were reported to be involved in the transcriptional regulation of 
hepatic transport proteins: pregnane X receptor (PXR), peroxisome proliferator-activated receptor 
α (PPARα), farnesoid X receptor (FXR), liver X receptor (LXR), and the constitutive androstane 
receptor (CAR). Till now, research is still ongoing in order to decode the ligands essential or 
required for these nuclear hormone receptors and the role they play in transcriptional control of 
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transporter gene expression. Table 1.4 summarizes the information on regulation of hepatic 
transport proteins. 
Table 1.4: Regulation of Hepatic Transport Proteins 
(Reproduced with permission, Brouwer K.M. et al [1]) 
 
 
*Abbreviations used: CAR, constitutive androstane receptor; FXR, farnesoid X receptor; 
PPAR, peroxisome proliferator-activated receptor; PXR, pregnane X receptor; RAR, 
retinoic acid receptor; SHP, small heterodimer partner 
Downregulation of Slc10a1 via an Fxr-mediated induction of shp (small heterodimeric 
protein) has been reported in primary rat hepatocytes and transfected HepG2 cells on bile acid 
treatment [93]. Transcriptional down regulation of Slc10a1 and Abcc2 gene expression by the 
retinoic acid receptor and RXR leads to cytokine-mediated inflammatory cholestasis [94]. On 
treating HepG2 cells with chenodeoxycholic acid, enhanced expression SLCO1B3 mRNA was 
reported, which was attributed to FXR mediated regulation of SLCO1B3 [95]. Also, studies 
reported on PXR negative mice showed that regulation of Slco1a4 is mediated via PXR dependent 
pathway. Enhanced expression of Abcc3 mRNA was observed on administering wild type mice 
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with pregnenolone-16α-carbonitrile (PXR ligand), however PXR knockout mice did not show any 
effect [96]. On the basis of studies carried out using Wistar Kyoto rats revealed that induction of 
Mrp3 by phenobarbital does not involve any active involvement of CAR [97]. FXR/RXRα 
heterodimer plays a vital role on transcriptional regulation of ABCB11 gene on exposure to bile 
acid chenodeoxycholic acid [98]. Induction of ABCC1 and ABCC2 gene expression on exposure 
to redox-active compounds has been reported by Kauffman et al [99]. On incubating rat 
hepatocytes and Abcc2 promotor-transfected HepG2 cells with agonists of these nuclear hormone 
receptors, induction in Abcc2 mRNA was observed in a PXR, CAR, and FXR-dependent manner 
[100]. Transcription regulation of CYP3A4 and MDR1 is mediated via PXR [101-103]. Studies 
using wild-type and PPARα-knockout mice demonstrated fibrates induced stimulation of the 
phospholipid flippase MDR3 is mediated by PPARα [104]. 
Short-term regulation and trafficking of hepatic transporters has been examined and 
reported in some of the recent work [105-107]. Recruitment and storage of transporters occurs 
from a compartment referred as intracellular vesicles in which membrane protein resides [108, 
109]. In response to several different cellular stimuli insertion or recruitment of transporter takes 
place. Internalization of Mrp2 occurs on disruption of cell-cell contacts in hepatocytes [110]. 
Internalization of Mrp2 molecules in hepatic intracellular vesicles occurs in hyperosmotic 
conditions, however increased Mrp2 content in the canalicular membrane was observed in 
hypoosmolarity [111]. Various signaling pathways governs the transporter translocation to and 
from the canalicular membrane. Protein content of Mdr1, Mdr2, Bsep, and Mrp2 increased 1.5-
fold by TC and 3-fold by 2’-O-dibutyryl adenosine 3’, 5’-cyclic monophosphate (DBcAMP), a 
cell-permeable cAMP analog in canalicular membrane vesicles [112]. On treating Mdr1, Mdr2, 
Bsep, and Mrp2 with colchicine (a microtubule inhibitor), the effect of TC was completed blocked 
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whereas the effect of DBcAMP was partially blocked, proposing that trafficking of these 
transporters to the apical (canalicular) membrane occurs moderately through microtubules. The 
short-term regulation of hepatic basolateral transporters also has been investigated. On treatment 
with cAMP, trafficking of Ntcp from endosomes to the basolateral membrane was revealed by 
employing cellular fractionation studies [106]. This mechanism involves several pathways 
including phosphoinositide 3-kinase and protein kinase B and was sensitive to cytochalasin D 
(actin filament formation inhibitor).  cAMP directly affects protein activity via direct 
phosphorylation of the transporter, apart from stimulating trafficking of proteins from endosomal 
compartments to their respective membrane. Increased phosphorylation without internalization of 
the protein has been recognized as a major reason for the loss of transport activity of Oatp1a1 
[113]. The examples mentioned before demonstrates that intracellular cAMP levels can be 
modulated in a therapeutic manner to regulate hepatocyte function in liver disease (i.e., 
cholestasis). Hepatic transport including the hepatobililary disposition and systemic exposure to 
drugs and metabolites is a highly governed process and can be influenced translocation of proteins. 
Drug Interactions Involved In Hepatic Transport 
 Several drug interaction in regards to hepatic transport have been reported in last decade 
(Table 1.5). Partial inhibition of uptake of cerivastatin in human hepatocytes was observed on 
treatment with cyclosporin A (CsA). CsA is an inhibitor of OATP1B1 transporter protein whereas 
cerivastatin is a substrate of same transporter. Inhibition of OATP1B1 transporter results in 3 to 4 
fold increase in the in the plasma AUC and Cmax of cerivastatin on coadministration of CsA in 
kidney transplant patients [114, 115]. Quinidine is an inhibitor of MDR1 transporter. Co-
administration quinidine with digoxin (MDR1 substrate) resulted in diminished biliary excretion 
of digoxin by 42% [116, 117]. Decrease in cumulative biliary excretion of doxorubicin and its 
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major metabolite, doxorubicinol, by 84% and 72%, respectively, was observed in comparison to 
control, when doxorubicin, a Mdr1 substrate, was coadministered with GF120918 (MDR1/Mdr1 
inhibitor) [118]. This transporter mediated drug interaction leading to diminished  biliary excretion 
of doxorubicin and doxorubicinol by 82% and 62%, respectively, in comparison to wild-type mice 
was confirmed in vivo with bile-duct cannulated Abcb1a(−/−) mice [119]. Besides inhibition 
interactions, increase biliary clearance of substrates of the hepatic transporters has been observed 
when the expression of these transporters get induced. Example, long term treatment of rats with 
tamoxifen (an Mdr1 substrate and inducer) leads to not only ∼12-fold increase in hepatic Abcb1b 
mRNA but also enhanced biliary excretion of tamoxifen and metabolites from 8–51% [120]. 
Transporter mediated drug interaction has also been held responsible for drug-induced 
hepatotoxicity. Inhibition of Bsep by bosentan leads to enhanced intracellular accumulation of 
cytotoxic bile salts which may cause bile salt-induced liver damage which ultimately causes 
cholestatic liver injury. Research is still going on in many laboratories in order to reveal the exact 
mechanism accountable for hepatic transporter mediated drug interactions [121]. 
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Table 1.5: Transporter based clinical drug–drug interactions 
(Modified from Giacomini KM et al [122] and Brouwer K.M. et al [1]) 
Drug Transporter Interacting Drug  
 
Affected Drug Clinical  Pharmacokinetic 
Impact On Affected Drug 
 
 
 
 
 
Organic Anion 
Transporting 
Polypeptides 
Cyclosporine Pravastatin AUC ↑890%  
and Cmax ↑678% 
Cyclosporine Rosuvastatin AUC ↑610% 
Cyclosporine Pitavastatin AUC ↑360%  
and Cmax ↑560% 
Cyclosporine Cerivastatin 3- to 4- fold ↑ in  
AUC and Cmax 
Rifampicin (single 
dose)  
Glyburide AUC ↑125% 
Rifampicin (single 
dose) 
Bosentan Ctrough ↑500% 
Lopinavir/ritonavir  Bosentan Day4: Ctrough ↑4,700% 
and day10: Ctrough ↑400% 
Lopinavir/ritonavir Rosuvastatin AUC ↑107%  
and Cmax ↑365% 
 
Organic Anion 
Transporters 
Probenecid Cidofovir CLr ↓32% 
Probenecid Furosemide CLr ↓66% 
Probenecid  Acyclovir CLr ↓32% and AUC ↑40% 
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Probenecid  Cidofovir CLr ↓32% 
Probenecid  Furosemide CLr ↓66% 
Probenecid Acyclovir CLr ↓32% and AUC ↑40% 
 
 
 
 
Organic Cation 
Transporters 
Cimetidine Metformin AUC ↑50% and CLr ↓ 27% 
Cimetidine Pindolol CLr ↓~34% 
Cimetidine Varenicline AUC ↑29% 
Cimetidine Pilsicainide AUC ↑33%, CLr ↓28% 
Cetirizine Pilsicainide CLr ↓41% 
Cimetidine Dofetilide CLr ↓33% 
Cimetidine Metformin AUC ↑50% and CLr ↓ 27% 
Cimetidine Pindolol CLr ↓~34% 
 
 
 
P-glycoprotein 
Quinidine Digoxin CLr ↓34–48% 
Ritonavir Digoxin AUC ↑86% 
Dronedarone Digoxin AUC ↑157%  
and Cmax ↑75% 
Ranolazine Digoxin AUC ↑60%  
and Cmax ↑46% 
Quinidine Digoxin CLr ↓34–48% 
GF120918 Doxorubicin CLr ↓ 84% 
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Breast Cancer 
Resistance Protein 
GF120918 Topotecan AUC ↑143% 
 
Hepatic Drug Transport And Metabolic Systems Correlation 
 It has been reported that many drugs or metabolites exhibits significant overlap in substrate 
specificities among MDR1 and CYP3A4 [123]. Induced levels of both intestinal Mdr1 and hepatic 
CYP3A levels have been reported on exposure to protease inhibitors such as amprenavir and 
nelfinavir [124]. Treatment with rifampin, reserpine, phenobarbital, and clotrimazole in a human 
colon carcinoma cell line leads to induced expression of MDR1 and CYP3A4 proteins [125]. These 
two proteins functions together in order to detoxify and eliminate xenobiotics from the body. Any 
alteration in the levels of expression of these proteins will modify the concentration-time profile 
and therapeutic effects of many drugs. Also, by changing the intracellular concentrations of 
substrates that induce CYP enzymes, MDR1 plays an important role in altering the expression of 
CYP3A4 [126]. This interaction may arise grave concerns for effective drug therapy. Combination 
of vincristine- doxorubicin-dexamethasone (VAD) is used in treatment multiple myeloma. 
Dexamethasone (inducer of both CYP3A4 and MDR1) induces MDR1 activity which will 
ultimately leads to diminished intracellular concentrations of vincristine and doxorubicin, and 
further lower intracellular concentrations of vincristine due to enhanced activity of CYP3A4 [123]. 
Also, dexamethasone long term treatment leads to induced levels both Mdr1 and CYP3A4 in male 
and female rat livers [127]. MDR1 and CYP3A4 not only shares similar substrate specificities but 
also have similar inhibitors too. Azole antifungals, ergot alkaloids, and macrolide antibiotics, not 
only inhibits CYP3A4 but also leads to varied degree of inhibition of MDR1 function [128]. 
Inhibition of Mdr1 by GF120918 in isolated perfused rat livers leads to enhanced metabolism of 
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tacrolimus because of the increased availability of tacrolimus to metabolizing enzymes backing up 
the idea of an relationship between CYP3A and Mdr1 [129]. Also, several reports were published 
demonstrating the elevated levels of hepatic CYP3A4 in Abcb1b(−/−) mice suggesting some level 
of coordinated regulation of both these proteins [130]. In Abcb1b(−/−) and Abcb1a(−/−) mice, 
AUC of erythromycin (substrate of MDR1 and CYP3A4) metabolites  was observed to be 1.9- and 
1.5-fold higher in comparison to wild-type mice. This interaction or results supports the elevated 
expression of CYP3A4 in Abcb1b(−/−) and Abcb1a(−/−) mice resulting in higher AUC of 
erythromycin metabolites [131].  
 Several PXR ligands are known substrate of MDR1 and also PXR is a well-known key 
modulator of CYP3A4 gene. Rifampicin induced MDR1 induction was identified because of 
presence of a distinct PXR binding site (DR4 nuclear response element) in the 5’-upstream region 
[102]. Similar to MDR1 knockout mice, diminished levels of Bsep and hence increased level of 
hepatic bile acid due to enhanced activity of CYP3A and CYP2B drug-metabolizing enzymes was 
observed in FXR nullizygous mice [47]. In order to have more advance knowledge about the 
coordinate regulation of hepatic drug metabolizing enzymes and transporters by PXR or other 
nuclear hormone receptors, in vitro models with hepatic transport and metabolic systems will be 
required to reveal the contrivances of these multifaceted interactions.  
Genetic Variations in Hepatic Transport 
 Alteration in disposition and pharmacokinetic parameters of several therapeutic agents 
which arise due to deviations in levels of expression and activity of hepatic transporter may 
significantly impact therapeutic efficacy of the drug molecule. Currently, many research based 
studies have focused their area on elucidating the mechanism involved in governing these hepatic 
transporters at protein level. In in vitro studies, polymorphisms in transport proteins resulted in 
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alteration of transport capacity of these proteins, whereas single nucleotide polymorphisms (SNPs) 
associated with hepatic transporters have shown its effect in vivo also. No functional evidence has 
been produced on various SNPs observed in the SLCO1A2 and SLCO1B3 genes in Japanese 
subjects [132]. Decreased transport capacity of OATP2B1 to 42.5% in comparison to control 
Japanese subjects has been attributed to the genetic polymorphism associated with SLCO2B1 gene 
[133]. Genetic polymorphisms associated with hepatic OATP1B1 (SLCO1B1) has been examined 
and evaluated comprehensively. In a study involving 81 human livers, genetic polymorphisms 
associated with SLCO1B1 leads to diminished transport function of OATP1B1 [134]. Reduced 
transport and diminished expression of OATP1B1 in European- and African- Americans has been 
associated with the several SNPs identified in SLCO1B1 [135]. Population with genetic variants 
of SLCO1B1 gene exhibited altered pravastatin (OATP1B1 substrate) kinetics [136]. Naturally 
occurring mutation in MRP1 resulted due to amino acid substitution affected the transporter 
capacity of MRP1 and resulted in 2-fold decreased transport of LTC4 via MRP1 [136]. It is not 
necessary that all the genetic polymorphisms associated with transporter gene will yield beneficial 
or harmful effects. Example, genetic polymorphism associated with MRP6 demonstrated no 
effects on transport activity of MRP6 [137, 138]. Dubin-Johnson syndrome has been associated 
with polymorphisms leading to non-functional activity of MRP2 which ultimately results in 
hyperbilirubinemic condition [139]. Liver biopsies of patients suffering Dubin-Johnson syndrome 
confirms the absence of MRP2 protein [140]. Impaired maturation and/or trafficking/localization 
of the protein or compromised ATP-hydrolysis has been attributed to different mutations in the 
MRP2 gene [141-143]. In recent years, revelation of genetic polymorphisms in hepatic transport 
genes, evaluation and examination of their functional significance, and development of assays to 
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identify patients exhibiting clinically significant polymorphisms have gained significant interest 
in the field of transporter based research [1]. 
Future Of Hepatobiliary Drug Transport Research 
This chapter highlights the highlights the major hepatic transport systems identified so far 
that mediate hepatic uptake, excretion, and/or interactions with xenobiotics, including therapeutic 
agents and their metabolites. Although our understanding of hepatic transport from a physiologic, 
pharmacological, and clinical perspective has amplified extensively during the past decade, we 
clearly lack complete knowledge about the complex processes involved in hepatobiliary drug 
disposition. Many vital questions still needs to be answered. Example, uptake/transport of 
xenobiotics through hepatocyte from the basolateral domain to metabolic sites, and from sites of 
metabolism to the basolateral or canalicular domains? Excretion of some drug molecules into bile 
whereas translocation of other molecules across the basolateral membrane into sinusoidal blood? 
Important concerns which governs the hepatic transport processes in normal and diseased liver 
still needs proper understanding. Current research focused on the transporter mediated hepatic 
uptake of substrates will enhance our current understanding of hepatobiliary drug transport by 
identifying the transporter proteins responsible for uptake of drugs into hepatocytes prior to 
metabolism and biliary excretion. This knowledge will provided an extra edge in the process of 
drug development by representing a new and exciting aspect of the discipline. Also, research area 
is focused towards identifying new chemical entities that are substrates for specific hepatic 
transport systems by a moderate/high-throughput screening methods. These methods will help in 
generating data which in turn will provide systematic characterization of structure-transport 
relationships for both animal and human hepatic transport proteins. Various in vitro assays to 
evaluate and examine hepatic drug transport will provide more in depth knowledge regarding 
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hepatobiliary drug disposition in humans. By elucidating the transporters responsible for uptake 
of compounds into the hepatic tissue prior to metabolism and biliary excretion will not only 
provided information about pharmacokinetics of the substrate molecule but will also provide 
information about potential transporter based drug interactions. This information or knowledge 
will act as a prerequisite in drug development process in order to achieve desirable clinical 
outcomes [1]. 
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CHAPTER 2 
ROLE OF OATP-1B1 AND/OR OATP-1B3 IN HEPATIC DISPOSITION OF TYROSINE 
KINASE INHIBITORS 
Rationale 
Hepatic uptake of drugs is mediated via various members of membrane transporter 
families. Membrane transporters localized on the basolateral side of hepatic tissue are known to 
play an important role in the uptake of therapeutic agents/metabolites from blood into the 
hepatocytes. This uptake process is recognized as the first step in hepatocellular elimination and 
plays a vital role in hepatic drug disposition. Organic anion transporting polypeptides (OATPs) 
appear to play a critical role in bioavailability, distribution and excretion of numerous exogenous 
amphipathic organic anionic compounds including anionic oligopeptides, steroid conjugates, 
organic dyes, bile salts, thyroid hormones and many drugs such as pravastatin, rifampicin etc.[144-
147]. 
Tyrosine kinase inhibitors (TKIs) target intracellular tyrosine kinase domain of various 
tyrosine kinase receptors which are often over expressed in cancer tissues. Human genome 
sequence data have indicated that deregulation of protein kinase pathway is one of the main 
mechanisms underlying tumor growth. Over the past few years, attention has been focused towards 
the discovery of a targeted therapy which will act against defining characteristics of cancer 
resulting from abnormal function of protein kinases [148, 149]. In the past decade, U.S. Food and 
Drug Administration (FDA) has approved several TKIs. Many of these compounds have been 
associated with low patient response along with unwanted effects of toxicity, which is unexpected 
and largely unexplained. Comprehensive data from Phase I studies of these TKIs establishes the 
optimized dose for Phase II. Even though TKIs offer theoretical advantages (selectively target/kill 
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the cancer precursor cells and protect normal tissues) over traditional anti-cancer agents, these 
agents are still associated with unpredictable clinical effects because of inter-individual 
pharmacokinetic variability and narrow therapeutic window [148, 150]. Substantial inter-
individual differences in the concentration-time profiles of TKIs range from 32-118% and is 
mostly unexplained. Many TKIs exhibit limited efficacy with significant degree of unexpected and 
unexplained toxicity [151]. Inter-individual pharmacokinetic variation in TKIs can have both 
genetic and non-genetic origins. This pharmacokinetic variation can be due to many plausible 
sources, including inter-individual differences in absorption, distribution, metabolism and 
excretion (ADME). TKIs are primarily metabolized in liver by CYP enzymes (mainly CYP3A4) 
and are eliminated via biliary excretion route into feces as unchanged drug or metabolites [151]. 
Hepatic uptake of TKIs can be attributed as a major source of pharmacokinetic variability, which 
is also recognized as one of the most crucial and complex steps in drug disposition [148]. 
Currently, various OATP family transporters such as OATP-1B1, -1B3 and -2B1 have been 
identified and characterized on sinusoidal membrane of hepatic tissue [144]. However the 
mechanisms responsible for hepatocellular accumulation of TKIs prior to metabolism and biliary 
secretion are still largely unexplained. Previous investigations have reported that organic anion 
transporting polypeptide transporters (OATPs) namely OATP-1B1 and -1B3 are responsible for 
uptake of TKIs into human liver cells [148]. Uptake of TKIs such as axitinib, lapatinib and 
sorafenib into human hepatocytes is regulated by OATP-1B1 and/or -1B3. Also, some of the TKIs, 
namely, pazopanib and lapatinib are known to inhibit the functional capacity of OATP-1B1 and/or 
-1B3 transporter proteins [148]. However, there is still a need for systematic approach to delineate 
the mechanism involved in hepatic uptake of these TKIs. Since, hepatic system possesses many 
transporters (both influx and efflux), it is difficult to delineate the affinity of individual transporters 
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towards these TKIs. Hence, it is of utmost importance to estimate the relative contribution of 
OATP-1B1 and -1B3 in hepatic uptake of TKIs [144]. In the present study, we evaluated the 
interaction of the TKIs (pazopanib, erlotinib, canertinib, nilotinib and vandetanib) with the human 
OATPs expressed on sinusoidal membrane of liver by employing in vitro model system with wild 
type and transfected Chinese hamster ovary (CHO) cells. 
Materials And Methods 
Chemicals 
Pazopanib, erlotinib, canertinib, nilotinib and vandetanib were purchased from LC 
Laboratories (Woburn, MA). All other chemicals used were of high performance liquid 
chromatography grade and were obtained from either Sigma Aldrich or Fisher Scientific. 
 In Vitro Studies 
Cell Lines 
Chinese hamster ovary (CHO) cells (passage number 17-50) were selected for all in vitro 
experiments. Wild-type (WT), OATP-1B1 and -1B3 CHO transfected cells were a gift from Dr. 
Bruno Stieger (Department of Clinical Pharmacology and Toxicology, University Hospital Zürich, 
Switzerland). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM), 
supplemented with 10% heat inactivated fetal bovine serum (FBS), L-proline (50μg/mL), HEPES, 
penicillin (100μg/ml), streptomycin (100μg/ml), and maintained at 37°C with 5% CO2 under 
humidifying conditions. For OATP-1B1 and -1B3 expressing CHO cells, the medium was also 
supplemented with geneticin (100μg/mL). 
 In Vitro Cellular Accumulation Studies 
Cellular accumulation studies were conducted in 24 well polystyrene plates (Costar 
Corning, NY). CHO cells (WT and transfected) were plated at a seeding density of 3 × 105 
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cells/well. The medium was changed every alternate day. Cells formed confluent monolayers in 
3–4 days. Twenty-four hours before any experiment, the cells were exposed to 10mM sodium 
butyrate to induce higher expression of the transfected transporter. On the day of experiment, 
medium was aspirated and cells were rinsed three times with cell assay buffer (116.4 mM NaCl, 
5.3 mM KCl, 1 mM NaH2PO4, 0.8 mM MgSO4, 5.5 mM D-glucose and 20 mM Hepes/Tris; pH 
7.4) pre-warmed at 37ºC. The uptake experiment was initiated by adding 0.5 mL of fresh serum 
free medium containing 0.25 and 0.5μM of TKIs (pazopanib, erlotinib, canertinib, nilotinib and 
vandetanib) in WT as well as OATP-1B type transfected cells. After incubating cells for 10 
minutes with TKIs, uptake solution was aspirated and the cells were washed twice with 2 mL of 
ice-cold uptake buffer. This resulted in removal of the non-specifically bound substrate from the 
membrane as well as arrested further cellular accumulation. Finally, 0.5 mL of fresh DMEM was 
added to each well and cell lysis was carried out by storing the culture plates overnight at −80°C. 
On the following day, intracellular drug concentration was quantified using liquid chromatography 
tandem mass spectrometry (LC/MS–MS) as described in previous publications from our group as 
well as others [152-156]. Based on the time points for uptake the minimum concentration observed 
were well beyond the detection limit. The amount of TKIs accumulated was normalized to the 
protein content in each well with Bradford’s reagent (Bio-Rad, California). All stock solutions 
were prepared in dimethyl sulfoxide (DMSO) and diluted using medium such that the final DMSO 
concentration did not exceed 0.5% (v/v). 
Estimation Of Michaelis-Menten Kinetics 
To determine the kinetic basis for the differential uptake of OATP-1B1 and -1B3 
transporter proteins, concentration dependent uptake of TKIs were carried out. Using a 
concentrated stock solution of the TKIs, several working concentrations were prepared ranging 
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from (0.01μM - 50μM) in serum free fresh medium. Uptake was carried out at different 
concentration of TKIs in WT, OATP-1B1 and -1B3 transfected CHO cells. 
Data Analysis 
Kinetic parameters of TKIs uptake via hepatic OATP-1B1 and -1B3 were calculated with 
a nonlinear least squares regression analysis program KaleidaGraph version 3.5. The data was 
plotted and fitted to Michaelis-Menten equation (1) and the maximum transport rate (Vmax) and 
Michaelis-Menten constant (Km) were calculated. 
     𝒗 =
𝑽𝒎𝒂𝒙[𝑪]
𝑲𝒎 + [𝑪]
                                                                                                            𝐄𝐪. 𝟏 
v is the initial uptake rate, Vmax is the maximal velocity, Km is Michaelis–Menten constant, and C 
is the total concentration of TKIs. 
Cytotoxicity Studies 
Cell Titer 96® Aqueous Non-Radioactive Cell Proliferation Assay Kit (Promega, Madison, 
WI) was employed to carry out cytotoxicity assay. WT, OATP-1B1 and -1B3 transfected CHO 
cells were cultured in 96-well plate. Sterile drug solutions of highest concentration (50µM) of 
TKIs are prepared in the culture medium using 0.22µm nylon sterile membrane filters. Aliquots of 
TKIs having a volume of 100µL (previously made in culture medium) were added to each well 
and incubated for 24h. Cell proliferation of the cells in the presence of TKIs was compared with a 
negative control (medium without TKIs) and a positive control (Triton X). Twenty microliters of 
dye solution was added to each well after 24h of incubation with TKIs. Cells were then incubated 
for 4h in order to complete the reaction of cells with dye. UV absorbance of purple formazan 
formed was quantified at a wavelength of 590nm with a 96-well micro titer plate reader 
(SpectraFluor Plus, Tecan, Maennedorf, Switzerland). Toxicity of TKIs in WT and OATP-1B type 
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transfected CHO cells was estimated by the amount of formazan formed, which is directly 
proportional to the viable cells. 
Statistical Analysis 
All the experiments were conducted at least in quadruplicate (n=4) and the outcomes were 
expressed as mean±standard deviation (SD). To calculate statistical significance, student’s t test 
was performed. Any difference between mean values is considered statistically significant for P 
value ≤0.05. 
Results 
In Vitro Cellular Accumulation Of Tyrosine Kinase Inhibitors 
 Initial in vitro uptake experiments were carried out to determine cellular accumulation of 
TKIs in WT, OATP-1B1 and -1B3 transfected CHO cells. Cellular accumulation was measured 
by exposing the WT and OATP-1B1 transfected CHO cells to two different concentrations (0.25 
and 0.5µM) of TKIs. In previously reported results, concentration ranges from 0.1 to 10µM has 
been shown to be non-saturating for OATP-1B1 and -1B3 mediated transport [157]. We performed 
our studies within these linear non-saturable ranges and also at concentration which were well 
within our detection limit. Also, while studying transporter mediated uptakes, we always aim to 
use as low a concentration as possible so as to limit any toxicity. Hence, based on these 
considerations we chose 0.25 and 0.5 µM as our concentration ranges. Out of the selected TKIs, 
nilotinib and vandetanib showed significantly enhanced cellular accumulation in OATP-1B1 
transfected cells relative to WT cells. The remaining 3 TKIs (canertinib, pazopanib and erlotinib) 
did not show any significant enhanced cellular accumulation in OATP-1B1 transfected cells 
compared to WT cells. Vandetanib (0.25 and 0.5µM) showed the highest uptake, about 1.3 fold 
(p<0.01) in OATP-1B1 transfected cells compared to WT cells. Nilotinib (0.25 and 0.5µM) also 
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showed higher uptake about ~1.3 (p<0.01) and 1.2 (p<0.05) fold respectively in transfected cells 
relative to WT cells (Fig 2.1). It has been reported previously that OATP-1B3 shares 80% amino 
acid identity with OATP-1B1. Also, both the OATP isoforms share multiple overlapping 
substrates, such as rifampicin pravastatin, pitvastatin and docetaxel [158, 159].   
  
 
Fig.2.1: Cellular accumulation of TKIs at two concentrations (0.25 and 0.5µM) by OATP-1B1 
transporter. TKIs were incubated with WT and CHO-OATP-1B1 transfected CHO cells for 10 
minutes. Intracellular drug concentration was quantified using liquid chromatography tandem 
mass spectrometry (LC/MS–MS). Data represent the mean±SD, n=4 (*p<0.05, **p<0.01). 
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 In this study, we have also determined the cellular uptake of TKIs at two different 
concentrations (0.25 and 0.5µM) in WT and OATP-1B3 transfected cells. Canertinib, nilotinib and 
vandetanib at both concentrations showed significantly enhanced cellular accumulation in OATP-
1B3 transfected cells compared to WT cells (p<0.01). No difference was observed in cellular 
accumulation of pazopanib and erlotinib in OATP-1B3 transfected cells compared to WT cells 
(Fig 2.2). Highest uptake of canertinib (0.25 and 0.5µM) was observed, about 2 (p<0.01) and ~5 
(p<0.01) times respectively, in OATP-1B3 transfected cells than the WT cells. A significantly 
higher uptake of vandetanib and nilotinib was also evident in OATP-1B3 cells than WT (Fig 2.2). 
No statistically significant changes in cellular accumulation of pazopanib and erlotinib were found 
between WT and OATP-1B3 transfected cells (Fig.2.2). Nilotinib and vandetanib showed 
overlapping substrate specificity towards OATP-1B1 and -1B3 while canertinib only showed 
affinity towards OATP-1B3. 
 
Fig 2.2: Cellular accumulation of TKIs at two concentrations (0.25 and 0.5µM) by OATP-1B3 
transporter. TKIs were incubated with WT and OATP-1B3 transfected CHO cells for 10 minutes. 
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Intracellular drug concentration was quantified using liquid chromatography tandem mass 
spectrometry (LC/MS–MS). Data represent the mean±SD, n=4 (*p<0.05, **p<0.01). 
Estimation Of Michaelis-Menten (MM) Kinetics 
For estimation of MM kinetics, WT, OATP-1B1 and -1B3 transfected CHO cells were 
incubated with various concentration (0.01μM - 50μM) of TKIs. Previous studies have shown 
time-dependent uptake on similar cell lines to be linear up to 15 minutes [160-162]. We incubated 
our cells for 10 minutes as it falls within the linear range of uptake as well as gives us 
concentrations that lie well within the detectable range. Figs 2.3 and 2.4 clearly demonstrate that 
carrier mediated uptake of TKIs via OATP-1B1 and OATP-1B3 is concentration-dependent and 
saturable at higher concentrations. This is the first study where Michaelis-Menten kinetic 
parameters of OATP-1B1 and OATP-1B3 have been evaluated for selected TKIs (canertinib, 
pazopanib, nilotinib, vandetanib and erlotinib). The values obtained for kinetic parameters have 
been summarized in Table 2.1. Despite no significant changes in cellular accumulation of 
canertinib and nilotinib at lower concentration (0.01-0.075μM), these drugs showed greater 
accumulation at higher concentrations (0.1-50 μM) in OATP-1B1 and/or -1B3 cells in comparison 
to CHO-WT cells. For vandetanib, kinetic parameter were evaluated in the concentration range of 
0.01μM - 50μM. Intracellular accumulation of nilotinib and vandetanib was mediated via OATP-
1B1 transporter protein. Km value of 2.72 ± 0.25µM for vandetanib showed higher affinity towards 
OATP-1B1 transporter than nilotinib (Km = 10.14 ± 1.91µM).  
Three TKIs (vandetanib, nilotinib and canertinib) appeared to have affinity towards OATP-
1B3. Affinity of these TKIs towards OATP-1B3 transporter was in following order: 
vandetanib>nilotinib>canertinib (Km = 4.37 ± 0.79, 7.84 ± 1.43 and 19.87 ± 2.20µM, respectively). 
Also, vandetanib showed greater affinity towards OATP-1B1 than OATP-1B3 transporter protein 
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whereas nilotinib showed higher affinity for OATP-1B3 than OATP-1B1. Canertinib exhibited its 
affinity only towards OATP-1B3. Vmax values of both the hepatic uptake transporters for TKIs 
were calculated and summarized in Table 2.1.  
No statistically significant cellular accumulation was observed for pazopanib and erlotinib in 
OATP-1B1 and -1B3 transfected cells in comparison to WT cells.  
 
 
Fig 2.3.1: Concentration dependent uptake of nilotinib in OATP-1B1 transfected CHO cells. 
OATP-1B1 mediated nilotinib transport determined as the difference in uptake in OATP-1B1 and 
WT CHO cells at each substrate concentration. Each data point is expressed as mean±SD, n=4. 
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Fig 2.3.2: Concentration dependent uptake of vandetanib in OATP-1B1 transfected CHO cells. 
OATP-1B1 mediated vandetanib transport determined as the difference in uptake in OATP-1B1 
and WT CHO cells at each substrate concentration. Each data point is expressed as mean±SD, n=4. 
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Fig 2.3.3: Concentration dependent uptake of canertinib in WT and OATP-1B1 transfected CHO 
cells. Each data point is expressed as mean±SD, n=4. 
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Fig 2.3.4: Concentration dependent uptake of pazopanib in WT and OATP-1B1 transfected CHO 
cells. Each data point is expressed as mean±SD, n=4. 
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Fig 2.3.5. Concentration dependent uptake of erlotinib in WT and OATP-1B1 transfected CHO 
cells. Each data point is expressed as mean±SD, n=4. 
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Fig 2.4.1: Concentration dependent uptake of canertinib in OATP-1B3 transfected CHO cells. 
OATP-1B3 mediated canertinib transport determined as the difference in uptake in OATP-1B3 
and WT CHO cells at each substrate concentration. Each data point is expressed as mean±SD, n=4. 
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Fig 2.4.2: Concentration dependent uptake of nilotinib in OATP-1B3 transfected CHO cells. 
OATP-1B3 mediated nilotinib transport determined as the difference in uptake in OATP-1B3 and 
WT CHO cells at each substrate concentration. Each data point is expressed as mean±SD, n=4. 
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Fig 2.4.3: Concentration dependent uptake of vandetanib in OATP-1B3 transfected CHO cells. 
OATP-1B3 mediated vandetanib transport determined as the difference in uptake in OATP-1B3 
and WT CHO cells at each substrate concentration. Each data point is expressed as mean±SD, n=4. 
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Fig 2.4.4: Concentration dependent uptake of pazopanib in WT and OATP-1B3 transfected CHO 
cells. Each data point is expressed as mean±SD, n=4. 
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Fig 2.4.5: Concentration dependent uptake of erlotinib in WT and OATP-1B3 transfected CHO 
cells. Each data point is expressed as mean±SD, n=4. 
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Table 2.1: Michaelis–Menten kinetic parameters (Vmax and Km) and catalytic efficiency (Vmax/Km) 
estimated for tested TKIs for OATP-1B1 and/or OATP-1B3 transporter proteins. Units of Km: 
micromolar (µM), Vmax: nmoles/mg protein/min and Vmax/Km: ml/mg protein/min 
TKIs OATP-1B1 OATP-1B3 
Km Vmax Vmax/Km Km Vmax Vmax/Km 
Canertinib - - - 12.18 ± 3.32 
 
15.34 ± 1.59 1.25 
Nilotinib 10.14 ± 1.91 
 
6.95 ± 0.47 0.68 7.84 ± 1.43 6.75 ± 0.42 0.86 
Vandetanib 2.72 ± 0.25 75.95 ± 1.99 27.92 4.37 ± 0.79 193.64 ± 10.58 44.31 
Erlotinib - - - - - - 
Pazopanib - - - - - - 
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Cytotoxicity Studies 
To evaluate the cytotoxic effect of the selected TKIs, a cell proliferation assay was 
performed on cell monolayers of WT and transfected CHO cells for a period of 24h. No cytotoxic 
effects of pazopanib, erlotinib, canertinib, vandetanib and nilotinib at a concentration of 50µM were 
observed with WT and transfected cells in comparison to positive control (Triton X). The findings 
from this study clearly demonstrate that the selected TKIs are non-cytotoxic at a concentration of 
50µM (Fig 2.5). 
 
 
Fig 2.5: Cytotoxicity in the presence of TKIs at highest studied concentration (50µM) on CHO-
WT, OATP-1B1 and -1B3 transfected cells. Data represent the mean±SD, n=4. 
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Discussion 
 In the present study, we investigated the role of OATP family transporters in the hepatic 
uptake process of TKIs. This work also estimated the contribution of OATP-1B1 and -1B3 in 
hepatocellular accumulation of TKIs with in vitro model based systems. For uptake transporter 
analysis, we utilized CHO cells, WT as well as transfected with specifically expressing OATP 
transport protein. CHO cells were originally selected for the transfection because of the lack of 
expression of these family of proteins in the parent cell line resulting in minimal background 
activity. Also, these cells can be maintained in culture for sustained periods and can be ready for 
use in a specific experiment within few days. Our findings are in partial agreement with the study 
done by Zimmerman et al.[148], where the authors reported the uptake of nilotinib (only at 0.1µM) 
in HEK293 cells expressing OATP-1B1 and -1B3 and uptake of vandetanib (only at 0.1µM) via 
OATP-1B3 transporter. Similar results were observed in the in vitro cellular accumulation studies 
performed, demonstrating the uptake of nilotinib and vandetanib via OATP-1B1 and -1B3 
transporter proteins. Zimmermann et al. [148] also reported the uptake of pazopanib in cells 
expressing OATP-1B1 and -1B3 at a concentration of 0.1µM and no statistically significant uptake 
of vandetanib (0.1µM) in cells expressing OATP-1B1 transporter protein. Conversely, our findings 
demonstrate that there is no active involvement of OATP-1B1 and -1B3 in intracellular 
accumulation of pazopanib while uptake of vandetanib in hepatic tissue is mediated via OATP-
1B1 and -1B3. These contrasting results suggests that utilization of different concentration of TKIs 
and in vitro model based systems may affect the cellular accumulation of TKIs via OATP and can 
lead to misinterpretation of the role of OATPs in cellular accumulation of TKIs. The current 
concentrations used in this manuscript (0.25 and 0.5 µM) were selected based on previously 
published results for in vitro uptake studies of TKIs and their toxicity for CHO cells. The 
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concentration ranges used were close to clinically observed Cmax values but may not exactly mimic 
tissue concentration in clinic. These studies act as a proof of concept but further studies may be 
needed to make the data more clinically relevant.   
 It has been already reported that the tyrosine kinase inhibitors are substrate of efflux 
transporter proteins such as P-gp, MRPs and BCRP [152, 153, 163-166]. These efflux transporters 
are also expressed in the bile canalicular membrane and are responsible for excretion of drug and 
their metabolites from blood into bile. The membrane transporters (OATPs) along with efflux 
transporters and metabolizing enzymes play a vital role in hepatic disposition of drugs. Seithel et 
al. reported that coadministration of pravastatin together with macrolides (clarithromycin and 
roxithromycin) results in increased plasma concentration of pravastatin. It is a substrate for OATP-
1B1, -1B3 and CYP3A4 whereas clarithromycin and roxithromycin are inhibitors of OATP-1B1, 
-1B3 and CYP3A4. Since pravastatin is not extensively metabolized and is excreted almost 
unchanged into bile and urine, this DDI studies suggests the major involvement of hepatic uptake 
transporters than metabolizing enzymes for macrolide-induced altered plasma concentration of 
pravastatin [167]. Similarly, Backman et al. demonstrated that co-administration of cerivastatin 
and simvastatin (OATP-1B1 and CYP2C8 substrate) together with gemifibrozil resulted in a 6-
fold rise in the cerivastatin and simvastatin exposure. Such increase in plasma concentration of 
cerivastatin and simvastatin was due to the inhibitory potency of gemifibrozil on OATP-1B1 [168, 
169].  Uptake of drugs mediated via OATP can be considered as an important additional 
mechanism essential for DDIs [170]. Unlike statins, information on the role of hepatic uptake 
transporters (OATP-1B1 and -1B3) for TKIs is very sparse. Thus, it is of utmost importance to 
understand the role of OATPs in hepatocellular accumulation of TKIs. The results obtained from 
in vitro cellular accumulation studies, suggests for the very first time the involvement of OATP-
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1B1 and/or OATP-1B3 in hepatocellular accumulation of TKIs (canertinib, nilotinib and 
vandetanib).   This article is the first to report the affinity of selected TKIs for OATP-1B1 and/or 
-1B3 by estimating the MM kinetic parameters. These findings suggest that OATP-1B1 exhibits 
greater affinity towards vandetanib than nilotinib. The ratio of these kinetic parameters (Vmax/Km) 
provides an estimate of the catalytic efficiency of OATP-1B1 transporter. The transport efficiency 
(Vmax/Km) of OATP-1B1 transporter was observed for nilotinib and vandetanib as 0.68 and 27.92 
ml/mg protein/min, respectively. While comparing the efficiency values, OATP-1B1 transport 
efficiency was found to be higher for vandetanib than nilotinib. No significant changes in uptake 
of canertinib, pazopanib and erlotinib were observed in WT and OATP-1B1 transfected cells. 
Similarly, for OATP-1B3 transporter protein, the ratio of Vmax/Km provides an estimate of the 
catalytic efficiency of OATP-1B3 transporter. Such transport efficiency (Vmax/Km) of OATP-1B3 
transporter observed for canertinib, nilotinib and vandetanib was 1.25, 0.86 and 44.31 ml/mg 
protein/min, respectively. OATP-1B3 transporter exhibits highest transport rate for vandetanib 
than nilotinib and canertinib. In pazopanib and erlotinib, no significant difference was observed in 
uptake values of WT and OATP-1B3 suggesting that OATP-1B3 transporter does not play in major 
role in their hepatic accumulation. On comparing the Km values of OATP-1B1 and -1B3 transporter 
for nilotinib, it is apparent that nilotinib exerts higher affinity towards OATP-1B3 relative to 
OATP-1B1, whereas, Vmax values of OATP-1B1 and -1B3 are comparable to nilotinib. These MM 
kinetic parameters play an important role in determining differential transport efficiency of OATP-
1B1 and -1B3 in hepatic uptake of nilotinib. A distinction in Km values of OATP-1B1 and -1B3 
for nilotinib can be attributed as the primary driving force in determining its transport efficiency, 
since no difference was observed in Vmax values of both the OATP-1B type transporters. The 
difference in the transport efficiencies (Vmax/Km) of OATP-1B1 and -1B3 was not very large 
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suggesting equal involvement of both the OATPs in the hepatic uptake of nilotinib. On comparing 
Km values, vandetanib exhibits higher affinity towards OATP-1B1 than -1B3. Higher Vmax values 
were observed for OATP-1B3 (~2.6 fold) than -1B1. Large differences in Vmax has a significant 
contribution in determining the substrate specificity of vandetanib for OATP-1B1 and -1B3. 
Transport efficiency (Vmax/Km) of OATP-1B3 for vandetanib showed ~2 fold difference than -
1B1, showing greater contribution of OATP-1B3 than -1B1 in hepatic uptake of vandetanib. 
Therefore, hepatic uptake of vandetanib and nilotinib is tightly regulated by OATP-1B1 and -1B3 
which act as two gatekeepers localized on liver. Hence, OATP-1B1 and -1B3 can be considered 
as important factors in determining pharmacokinetics or DDIs of vandetanib and nilotinib. For 
canertinib, only OATP-1B3 was observed to be responsible for its hepatic uptake and it can act as 
key determinants in bioavailability of canertinib. These results though act mainly as a proof of 
concept and the actual rate constants in humans may vary based on various physiological and 
pathological conditions resulting in altered expression of these transporters within the liver. 
Inter-individual pharmacokinetic variability can arise at many stages of ADME. For 
individual therapy, dosing strategies can be based on pharmacokinetic properties. Decisive 
tailoring of individual dosing to a patient necessitates minimizing these inter-individual 
pharmacokinetic differences and reducing the risks of both toxicity and subtherapeutic dosing 
[150]. Till now most of the studies performed with TKIs have not considered affinity of hepatic 
uptake transporters as a determinant of pharmacokinetic profiles of TKIs. Inter-individual 
pharmacokinetic variability has been associated with OATP1B1 and -1B3 genetic polymorphisms 
in patients taking statins and irinotecan [162, 171]. Expression and involvement of these OATP-
1B type isoforms in liver has important implications for better understanding of the factors 
governing ADME of TKIs. Any compromise in the activity of OATP-1B type transporter proteins 
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will result in suboptimal treatment or high toxicity considering the wide inter-individual 
pharmacokinetic variability of the tested TKIs. Since vandetanib and nilotinib exhibit substrate 
specificity towards OATP-1B1 and -1B3, these results led us to the hypothesis that an inactive 
phenotypic variant of OATP-1B type transporter may determine the clinical pharmacokinetics of 
these TKIs.  
Previously published reports have only considered the role of efflux transporters and 
metabolizing enzymes in determining the pharmacokinetic profile of TKIs [152, 153, 158, 172-
175]. In this study we have observed that a carrier mediated uptake process via OATP-1B1 
transporter is involved in cellular accumulation of nilotinib and vandetanib in hepatic tissue. Also, 
OATP-1B3 is responsible for hepatocellular accumulation of canertinib, vandetanib and nilotinib. 
OATP-1B1 and/or -1B3 regulate the initial step of hepatic elimination of TKIs by carrying out the 
uptake of selected TKIs into the hepatic tissue exposing the molecules to CYP enzyme mediated 
metabolism and elimination via biliary secretion. These OATPs expressed on basolateral 
membrane of hepatocytes will induce uptake of TKIs and can be regarded as one of the 
determinants of overall metabolic rate of TKIs in liver [176]. An efficient directional movement 
of therapeutic agents across hepatic tissues requires the manifestation and synchronized activity of 
hepatic uptake, metabolizing enzymes and efflux transporters [177]. Duckett D.R. et al. [178] 
reported that coadministration of ketoconazole (CYP3A4 and P-gp inhibitor) with nilotinib 
resulted in 3-fold increase in the plasma concentration of nilotinib. Ketoconazole is also a well-
known inhibitor of OATP-1B type transporters [179] and we have shown that OATP-1B1 and -
1B3 transporters are responsible for hepatic uptake of nilotinib. Therefore, the 3-fold increase in 
the plasma concentration of nilotinib may not be just due to the inhibition of efflux transporter and 
metabolizing enzyme but also could be due to inhibition of OATP-1B type transporter. OATP-
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1B1 and -1B3 transporters also play a vital role in hepatic uptake of nilotinib making it vulnerable 
to metabolism by CYP3A4 and ultimately causing its elimination by biliary secretion via P-gp. 
Since a major fraction of nilotinib is eliminated into feces in unchanged form suggesting that the 
transmembrane localization of nilotinib by OATPs in liver has a major impact on its 
pharmacokinetics than metabolization. Similarly, Minocha et al. reported that the coadministration 
vandetanib and everolimus resulted in increased plasma concentration of vandetanib. Everolimus 
increases plasma concentration of vandetanib by inhibiting efflux transporters (P-gp and BCRP) 
which are also localized on the bile canalicular membrane. Everolimus is also a well-known 
inhibitor for OATP-1B1 and -1B3 transporters which are responsible for hepatocellular 
accumulation of therapeutic agents. In this article we have reported the involvement of OATP-1B1 
and -1B3 in hepatic uptake of vandetanib. Taken together, it is reasonable to assume that elevation 
in plasma concentration of vandetanib is not only due to the inhibition of P-gp and BCRP but also 
due to inhibition of OATP-1B1 and -1B3 by everolimus. Complex interplay of OATPs (localized 
on basloateral membrane of hepatic tissues) and efflux transporters (expressed on bile canalicular 
membrane) may be responsible for the hepatobiliary excretion of TKIs. Inhibition of TKIs uptake 
via hepatic OATPs by coadministration of drugs that are also substrate or inhibitor of these hepatic 
uptake transporters is a plausible explanation of several in vivo observed DDIs. Inhibition of 
metabolizing enzymes and/or efflux transporter could not be the only cause of the experimental 
effects. Drug induced alteration of OATP-1B1 and -1B3 transporter function is, therefore, an 
essential auxiliary mechanism underlying DDIs [170].  
OATPs mediated DDIs have the potential to completely influence drug efficacy and 
toxicity. Therefore, coadministration of canertinib, vandetanib and nilotinib (OATP-1B1 and/or -
1B3 substrates) along with other hepatic OATP substrates/inhibitors (paclitaxel, cyclosporine, 
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protease inhibitors, rifampicin, statins, telmisartan, valsartan, mTOR inhibitors, antibiotics etc.) 
may result in altered pharmacokinetics and pharmacodynamics of TKIs. On the other hand, 
induction of the expression of hepatic OATPs can also result in increased detoxification and 
elimination of numerous OATP-1B1 and -1B3 substrates from the body [158, 180-182]. 
Pharmacokinetic profile of TKIs is likely to be modified in subjects with hepatic impairment, since 
TKIs are primarily eliminated via hepatic metabolism and biliary excretion. Down-regulation of 
OATP-1B type transporter protein in liver disease has been reported by Oswald M et al. and Kietel 
V et al. [183, 184]. Also, reduced expression of OATP-1B1 and -1B3 in liver cancer compared to 
non-cancerous liver tissues has been reported by various investigators [185-187]. For hepatically 
impaired population, dose reduction of nilotinib has been proposed along with recommendation of 
lower starting dose and monitoring of any liver function abnormalities [188, 189]. Also, dose of 
vandetanib in patients with moderate and severe hepatic impairment has not been recommended 
as its safety and efficacy has not been established [188, 189]. In vitro accumulation studies along 
with estimation of MM kinetic profiles confirms the role of OATP-1B1 and -1B3 in hepatic uptake 
of nilotinib and vandetanib. On the basis of our findings along with already published reports 
mentioned above, we can hypothesize that higher plasma concentration of nilotinib or other TKIs 
in patients with hepatic impairment can be attributed to compromised/downregulated expression 
of OATP-1B1 and -1B3 transporter which can be responsible for any alteration in the 
pharmacokinetic profile of nilotinib or other TKIs. Similar findings have been reported by Baker 
SD et al., showing the involvement of OATP-1B1 and-1B3 in hepatic elimination of sorafenib and 
longer systemic accumulation due to compromised activity of OATP-1B type transporter protein 
[148].  
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Conclusion 
 In conclusion, we have shown OATP-1B1 and OATP-1B3 are responsible for 
hepatocellular accumulation of nilotinib and vandetanib whereas only OATP-1B3 is responsible 
for the carrier mediated uptake of canertinib in hepatic tissue. These findings delineate the 
involvement of OATP-1B1 and/or -1B3 in hepatic uptake of tested TKIs and confirms the affinity 
of these hepatic uptake transporters as a determinant of the pharmacokinetic profile of TKIs. Since 
co-administration of TKIs with other therapeutic agents is becoming common in multi-drug 
therapy, hepatic uptake transporters OATP-1B1 and -1B3 can be regarded as important molecular 
targets for potential DDIs. Thus, hepatic uptake mediated by OATP-1B1 and -1B3 for selected 
TKIs should be dynamically scrutinized in order to circumvent DDIs. These transporters in 
conjunction with the efflux proteins may eventually decide on the overall flux of the TKIs within 
the hepatic tissue. These studies act as a proof of concept substantiating the need for further clinical 
studies investigating the OATP based DDI potential of TKIs. Further in vivo studies are required 
for better understanding of the contribution of OATP-1B1 and/or -1B3 transporter proteins in the 
hepatic disposition of TKIs and for predicting any adverse drug reactions associated with DDIs 
[190]. 
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CHAPTER 3 
INHIBITION OF OATP-1B1 AND OATP-1B3 BY TYROSINE KINASE INHIBITORS 
Rationale 
Role of membrane transporters in drug disposition, safety and efficacy i.e., particularly 
concerning drug-drug interactions (DDIs) has been extensively investigated [191]. Giacomini KM 
et al recently emphasized drug development information on in vitro studies of drug-transporter 
interactions can be extrapolated to clinical studies of transporter based DDIs. Such transporter 
mediated DDIs can occur by (i) inhibition of membrane transporter resulting in potential DDI, 
and/or (ii) interacting drug may be a substrate for the transporter. Attention has been drawn towards 
various approaches and algorithms for predicting transporter mediated DDIs. In vitro and 
preclinical transport studies are pre-requisites for drug development. Recent progress in clinical 
translation of these results may impact on regulatory matters for delineation of transport mediated 
DDIs [122]. In order to predict whether a potential DDI may occur, in vitro studies were performed 
to compare concentration of an inhibitor (I, the maximum unbound plasma concentration) and it’s 
half maximal inhibitory concentration (IC50) for a transporter. Lower IC50 of the drug relative to it 
unbound plasma concentration is a strong indicator of a potential clinical DDIs. An I/IC50 value ≥ 
0.1 has been advocated as a measure to evaluate clinical transporter-based DDIs [122]. 
Tyrosine kinase inhibitors (TKIs) are the new class of anticancer drugs that specifically 
targets tyrosine kinases which are fused, mutated and over expressed in cancer [191, 192]. Many 
of these compounds have been associated with low patient response along with unwanted toxicity, 
which is unexpected and also largely unexplained. Even though TKIs offer theoretical advantages 
(selectively target/kill the cancer precursor cells and protect normal tissues) over traditional anti-
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cancer agents, these agents are still associated with unpredictable toxicity [150, 157]. Many TKIs 
exhibit limited efficacy with a high degree of unexpected and unexplained toxicity [151]. Most 
common side effects associated with TKIs are diarrhea, hypertension, nausea, anorexia and 
vomiting. The most common treatment-emergent laboratory abnormalities noticed were elevation 
of total bilirubin, liver transaminases and alanine aminotransferases. Hepatotoxicity is the most 
frequently reported toxicity among the TKIs with mandatory black box warnings [193]. There is a 
possibility that treatment associated elevation in liver enzymes with TKIs reveal over-lapping on-
target and off-target class effects, however, exact mechanism needs to be clarified [191, 194, 195]. 
These hepatic abnormalities associated with TKIs may lead to treatment interruption, 
compromising the potential treatment benefit to the patient. A clear understanding of the exact 
mechanism responsible for hepatic abnormalities, will give a better chance to interpret and manage 
these adverse effects which will ultimately benefit patients from continued chemotherapeutic 
treatment [194].  
Despite their frequent use as a chemotherapeutic agent, limited studies have been 
performed to examine the interactions of these TKIs with hepatic uptake transporters such as 
organic anion transporting polypeptide (OATP) transporters. Most studies examining interaction 
of TKIs with these transporters have focused on substrate specificity instead of inhibition 
interactions [153, 157, 172, 191, 196, 197]. Also, several TKIs have higher molecular weight, 
polar surface area and lipophilicity, which are essential for OATP inhibition and therefore have 
potential to inhibit OATPs including OATP-1B1 and OATP-1B3 [198]. Several in vitro and in 
vivo studies have indicated that drugs inhibiting these OATPs are responsible for clinically relevant 
drug-drug interactions. In such cases, inhibition of OATPs can lead to unexpected toxicity, causing 
marked increase in plasma concentration and area under the plasma concentration time curve 
 66 
 
(AUC) for compounds which are substrates of these hepatic transporters. DDIs caused by the 
inhibition of these transporters represent a large number of drugs which act as substrate or inhibitor 
of OATP-1B1 and/or -1B3 [199]. Hence, it is of utmost importance to estimate the inhibitory 
potential of TKIs on OATP-1B1 and -1B3. In the present study, we have evaluated the interaction 
of TKIs (pazopanib, erlotinib, canertinib, nilotinib and vandetanib) with human OATPs expressed 
on sinusoidal membrane of liver by employing in vitro model system with transfected Chinese 
hamster ovary (CHO) cells. In vitro studies were designed to compare the inhibitory potential of 
TKIs on the transport of [3H] estrone sulfate (substrate for OATP-1B1) and cholecystokinin 
octapeptide (CCK-8, substrate for OATP-1B3) in OATP-1B1 and -1B3 transfected CHO cells. 
Materials And Methods 
 Chemicals 
Pazopanib, erlotinib, canertinib, nilotinib and vandetanib were purchased from LC 
Laboratories (Woburn, MA). Rifampicin was purchased from TCI America, PA. [3H] Estrone 
sulfate ([3H] ES, specific activity 40-60 Ci/mmol) and [3H] cholecystokinin octapeptide ([3H] 
CCK-8, specific activity 60-100 Ci/mmol) was procured from Perkin Elmer (Boston, MA, USA). 
All other chemicals used were of high performance liquid chromatography grade and were 
obtained from either Sigma Aldrich or Fisher Scientific. Cell culture medium and other ingredients 
were purchased from Life Sciences. Fetal bovine serum was received from Atlanta Biologicals. 
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 In Vitro Studies 
 Cell Lines 
Chinese hamster ovary (CHO) cells (passage number 17-50) were selected for all in vitro 
experiments. OATP-1B1 and -1B3 CHO transfected cells were obtained as a gift from Dr. Bruno 
Stieger (Department of Clinical Pharmacology and Toxicology, University Hospital Zürich, 
Switzerland). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM), 
supplemented with 10% heat inactivated fetal bovine serum (FBS), L-proline (50μg/mL), HEPES, 
penicillin (100μg/ml), streptomycin (100μg/ml), geneticin (100μg/mL). Cell cultures were 
maintained at 37°C with 5% CO2 under humidifying conditions.  
In Vitro Cellular Accumulation Studies 
Confluent CHO OATP-1B1 and -1B3 cells were utilized for uptake experiments. 
Following medium removal, cells were rinsed thrice for 5 min each with 1–2 ml of Dulbecco’s 
phosphate-buffered saline (DPBS) containing 130 mM NaCl, 0.03 mM KCl, 7.5 mM Na2HPO4, 
1.5 mM KH2PO4, 1 mM CaCl2, 0.5 mM MgSO4, 20 mM HEPES, and 5 mM glucose maintained 
at pH 7.4. Uptake studies were initiated by adding 250μl of solution containing 0.25 μCi/ml of 
[3H] ES (for OATP-1B1) or [3H] CCK-8 (for OATP-1B3) in the presence of two different 
concentrations of (25 and 50µM) of TKIs and rifampicin (positive control). Following incubation, 
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the solution was removed and uptake was terminated with 2 ml of ice-cold stop solution containing 
200 mM KCl and 2 mM HEPES. The cell monolayer was washed thrice, 5 min each and 1ml of 
lysis buffer (0.1% Triton-X solution in 0.3% NaOH) was added to each well and plates were stored 
overnight at room temperature. Subsequently, cell lysate (400μl) from each well was transferred 
to scintillation vials containing 3 ml of scintillation cocktail (Universal ES from MP Biomedicals). 
Samples were analyzed by measuring the radioactivity in a liquid scintillation counter (Beckman 
Instruments Inc., Fullerton, CA, USA, model LS-6500). Protein content of each sample was 
estimated by BioRad Protein Estimation Kit (BioRad Protein Estimation Kit, Hercules, CA, USA). 
Estimation Of Half Maximal Inhibitory Concentration (IC50) 
To determine the half maximal inhibitory concentration (IC50) of TKIs for the differential 
uptake of OATP-1B1 and -1B3 transporter proteins, intracellular accumulation of the probe 
substrates (ES and CCK-8) in the presence of increasing concentrations (0.1-100µm) of TKIs was 
measured.  Using a concentrated stock solution of the TKIs, several working concentrations were 
prepared ranging from (0.1μM - 100μM) in fresh DPBS buffer spiked with [3H] ES (0.25μCi/ml) 
or [3H] CCK-8 (0.25μCi/ml). Uptake was carried out at different concentration of TKIs in OATP-
1B1 and -1B3 transfected CHO cells. The data was fitted to equation as shown in section 2.3 and 
the IC50 values were calculated according to nonlinear least squares regression analysis program; 
GraphPad Prism version 5. 
 Data Analysis 
IC50 values of TKIs on intracellular accumulation of the probe substrates uptake via hepatic 
OATP-1B1 and -1B3 were calculated with a nonlinear least squares regression analysis program 
GraphPad Prism version 5. The data was plotted and fitted to (Eq.1) and the half maximal 
inhibitory concentration (IC50) were calculated. 
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𝒀 = 𝒎𝒊𝒏 +
𝒎𝒂𝒙 − 𝒎𝒊𝒏
𝟏 + 𝟏𝟎(𝑳𝒐𝒈𝑰𝑪𝟓𝟎−𝒙)∗𝑯
                              𝐄𝐪. 𝟏 
x denotes the log conc. of the inhibitors, Y is the cellular accumulation of the probe substrate (ES 
or CCK-8), IC50 represents the TKIs conc. where the influx of the substrate is inhibited by 50% 
and H is the Hill constant. Y starts at a min value and then plateaus at a max value resulting in a 
sigmoidal plot. 
Cytotoxicity Studies 
Cell Titer 96® Aqueous Non-Radioactive Cell Proliferation Assay Kit (Promega, Madison, 
WI) was employed to carry out cytotoxicity assay. OATP-1B1 and -1B3 transfected CHO cells 
were cultured in 96-well plate. Sterile drug solutions of highest concentration (100µM) of TKIs 
are prepared in the culture medium using 0.22µm nylon sterile membrane filters. Aliquots of TKIs 
having a volume of 100µL (previously made in culture medium) were added to each well and 
incubated for 24h. Cell proliferation in the presence of TKIs was measured and compared with a 
negative control (medium without TKIs) and a positive control (Triton X). Twenty microliters of 
dye solution was added to each well after 24h of incubation with TKIs. Cells were then incubated 
for 4h in order to complete the reaction with dye. UV absorbance of purple formazan product was 
measured at a wavelength of 590nm with a 96-well micro titer plate reader (SpectraFluor Plus, 
Tecan, Maennedorf, Switzerland). Toxicity of TKIs in OATP-1B type transfected CHO cells was 
estimated by the amount of formazan formed, which is directly proportional to viable cells. 
Statistical Analysis 
All the experiments were conducted at least in quadruplicate (n=4) and the outcomes were 
expressed as mean±standard deviation (SD). To calculate statistical significance, student’s t-test 
was performed. Any difference between mean values is considered statistically significant for P 
value ≤0.05. 
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 Results 
 In Vitro Inhibitory Activity Of Tyrosine Kinase Inhibitors 
 Initial in vitro uptake experiments were carried out to determine inhibitory activity of 
TKIs for OATP-1B1 and -1B3 transfected CHO cells utilizing radiolabelled substrates. [3H] ES 
(5nM) and [3H] CCK-8 (3.1 nM) were employed as radiolabelled probe substrate for OATP-1B1 
and -1B3 transporter proteins, respectively. Cellular accumulation of [3H] ES was measured by 
exposing OATP-1B1 transfected CHO cells to two different concentrations (25 and 50µM) of 
TKIs and rifampicin (positive control). Out of the selected TKIs, pazopanib and nilotinib showed 
significant inhibition on cellular accumulation of [3H] ES in OATP-1B1 transfected cells. The 
remaining 3 TKIs (canertinib, vandetanib and erlotinib) did not show any significant inhibitory 
activity on cellular accumulation of [3H] ES in OATP-1B1 transfected cells. Pazopanib and 
nilotinib (25 and 50µM) diminish the uptake of [3H] ES by ~90% (p<0.05) in OATP-1B1 
transfected cells. Rifampicin reduced uptake of [3H] ES by ~50% and 70% at 25 and 50µM, 
respectively (Fig.3.1).  
Fig.3.1: Influence of 5 different TKIs and rifampicin at two different concentrations (25 and 
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50µM) on the activity of OATP-1B1, expressed in CHO cells, as determined by the intracellular 
accumulation of [3H] estrone sulfate ([3H] ES, 10 min incubation). Data are shown as mean±S.D. 
n=4. S.D. means standard derivation. (*p<0.05) 
 It has been reported previously that OATP-1B3 shares 80% amino acid homolog with 
OATP-1B1. Also, both the OATP isoforms share multiple overlapping substrates, such as 
rifampicin pravastatin, pitvastatin and docetaxel [158, 159].  In this study, we have also determined 
the inhibitory activity of TKIs and rifampicin (positive control) at two different concentrations (25 
and 50µM) on cellular accumulation of [3H] CCK-8 in OATP-1B3 transfected cells. Only 
vandetanib showed significant inhibition on cellular accumulation of [3H] CCK-8 in OATP-1B3 
transfected cells. Pazopanib, nilotinib, canertinib and erlotinib at both concentrations did not 
showed any significant effect on the cellular accumulation of [3H] CCK-8 in OATP-1B3 
transfected cells. Reduced uptake of [3H] CCK-8 was aslo observed in the presence of rifampicin 
in OATP-1B3 transfected cells. Uptake of [3H] CCK-8 in OATP-1B3 transfected cells was reduced 
to ~10% to 20% and ~5% to 10% in the presence of vandetanib and rifampicin (25 and 50µM), 
respectively (Fig.3.2). Pazopanib and nilotinib showed inhibitory activity towards OATP-1B1 
while vandetanib only indicated inhibitory potential towards OATP-1B3. 
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Fig.3.2: Influence of 5 different TKIs and rifampicin at two different concentrations (25 and 
50µM) on the activity of OATP-1B3, expressed in CHO cells, as determined by the intracellular 
accumulation of [3H] cholecystokinin octapeptide ([3H] CCK-8, 10 min incubation). Data are 
shown as mean±S.D. n=4. (*p<0.05) 
 
 
 Estimation Of Half Maximal Inhibitory Concentration (IC50) 
To determine the half maximal inhibitory concentration (IC50) concentrations of TKIs to 
inhibit OATP-1B1 and -1B3 functional activity, cellular accumulation experiments were 
conducted using probe substrates, ([3H] ES for OATP-1B1 and [3H] CCK-8 for OATP-1B3) in the 
presence of increasing concentrations (0.1-100µM) of TKIs and rifampicin. Previous studies have 
shown time-dependent uptake on similar cell lines to be linear up to 15 minutes [160-162, 200]. 
We incubated cells for 10 minutes as it remains within the linear range of uptake as well as gives 
us concentrations well within the detectable range. A modified log [dose]-response curve was 
applied to fit the data (Eq. 1) in order to obtain IC50 values. Diminished net uptake rate of probe 
substrate ([3H] ES) in the presence of increasing concentrations of the TKIs was observed in 
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OATP-1B1 cells. IC50 values for rifampicin, pazopanib and nilotinib towards OATP-1B1 
transporter inhibition were 10.46±1.15, 3.89±1.21 and 2.78±1.13 µM respectively (Figs.3.3, 3.4, 
3.5 and Table 3.1). Nilotinib appeared to be more potent inhibitor of OATP-1B1 than pazopanib. 
Vandetanib, canertinib and erlotinib did not cause any concentration dependent inhibition on 
cellular accumulation of probe substrate ([3H] ES) via OATP-1B1 transporter (Figs.3.6, 3.7 and 
3.8). Also, reduced intracellular accumulation of [3H] CCK-8 was observed in OATP-1B3 
transfected cells in a concentration dependent manner in the presence of vandetanib. IC50 values 
for rifampicin and vandetanib for OATP-1B3 transporter inhibition were 3.67±1.20 and 
18.13±1.21 µM respectively (Figs.3.9, 3.10 and Table 3.1). Likewise, no significant inhibition in 
net uptake rate of probe substrate ([3H] CCK-8) was observed in OATP-1B3 cells in presence of 
pazopanib, nilotinib, canertinib and erlotinib (Figs.3.11, 3.12, 3.13 and 3.14). 
 
 
Cytotoxicity Studies 
To evaluate the cytotoxic effect of the selected TKIs, a cell proliferation assay was 
performed on cell monolayers of transfected CHO cells for a period of 24h. No cytotoxic effects 
of pazopanib, erlotinib, canertinib, vandetanib and nilotinib at a concentration of 100µM were 
observed in OATP-1B1 and -1B3 transfected cells in relative to positive control (Triton X). The 
findings from this study clearly demonstrate that the selected TKIs are non-cytotoxic even at a 
concentration of 100µM (Fig.3.15). 
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Fig.3.3: Inhibitory potency of rifampicin towards OATP-1B1. Intracellular accumulation of 
OATP-1B1 substrate [3H] ES in the presence of increasing concentrations of rifampicin (0.1-
100µM). Data is shown as mean±S.D. n=4. 
 
Fig.3.4: Inhibitory potency of pazopanib towards OATP-1B1. Intracellular accumulation of 
OATP-1B1 substrate [3H] ES in the presence of increasing concentrations of pazopanib (0.1-
100µM). Data is shown as mean±S.D. n=4. 
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Fig.3.5: Inhibitory potency of nilotinib towards OATP-1B1. Intracellular accumulation of OATP-
1B1 substrate [3H] ES in the presence of increasing concentrations of nilotinib (0.1-100µM). Data 
is shown as mean±S.D. n=4. 
 
Fig.3.6: Inhibitory potency of vandetanib towards OATP-1B1. Intracellular accumulation of 
OATP-1B1 substrate [3H] ES in the presence of increasing concentrations of vandetanib (0.1-
100µM). Data is shown as mean±S.D. n=4. 
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Fig.3.7: Inhibitory potency of canertinib towards OATP-1B1. Intracellular accumulation of 
OATP-1B1 substrate [3H] ES in the presence of increasing concentrations of canertinib (0.1-
100µM). Data is shown as mean±S.D. n=4. 
 
Fig.3.8: Inhibitory potency of erlotinib towards OATP-1B1. Intracellular accumulation of OATP-
1B1 substrate [3H] ES in the presence of increasing concentrations of erlotinib (0.1-100µM). Data 
is shown as mean±S.D. n=4. 
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Fig.3.9: Inhibitory potency of rifampicin towards OATP-1B3. Intracellular accumulation of 
OATP-1B3 substrate [3H] CCK-8 in the presence of increasing concentrations of rifampicin (0.1-
100µM). Data is shown as mean±S.D. n=4. 
 
Fig.3.10: Inhibitory potency of vandetanib towards OATP-1B3. Intracellular accumulation of 
OATP-1B3 substrate [3H] CCK-8 in the presence of increasing concentrations of vandetanib (0.1-
100µM). Data is shown as mean±S.D. n=4. 
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Fig.3.11: Inhibitory potency of pazopanib towards OATP-1B3. Intracellular accumulation of 
OATP-1B3 substrate [3H] CCK-8 in the presence of increasing concentrations of pazopanib (0.1-
100µM). Data is shown as mean±S.D. n=4. 
 
Fig.3.12: Inhibitory potency of nilotinib towards OATP-1B3. Intracellular accumulation of 
OATP-1B3 substrate [3H] CCK-8 in the presence of increasing concentrations of nilotinib (0.1-
100µM). Data is shown as mean±S.D. n=4. 
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Fig.3.13: Inhibitory potency of canertinib towards OATP-1B3. Intracellular accumulation of 
OATP-1B3 substrate [3H] CCK-8 in the presence of increasing concentrations of canertinib (0.1-
100µM). Data is shown as mean±S.D. n=4. 
 
Fig.3.14: Inhibitory potency of erlotinib towards OATP-1B3. Intracellular accumulation of 
OATP-1B3 substrate [3H] CCK-8 in the presence of increasing concentrations of erlotinib (0.1-
100µM). Data is shown as mean±S.D. n=4. 
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Fig.3.15: Cytotoxicity in the presence of TKIs at highest studied concentration (100µM) on 
OATP-1B1 and -1B3 transfected cells. Data represent the mean±SD, n=4. 
Discussion 
In the present study, we investigated the inhibitory potential of several TKIs on OATP 
family transporters. This study also estimated the half maximal inhibitory concentration (IC50) of 
TKIs for OATP-1B1 and -1B3. CHO cells were originally selected for the transfection because of 
the lack of expression of these family of proteins in the parent cell line resulting in minimal 
background activity. Also, these cells can be maintained in culture for sustained periods and can 
be ready for use in a specific experiment within a few days. Our findings are in partial agreement 
with the study done by Hu S et al [200], where the authors reported the inhibitory potency of 
nilotinib and pazopanib (only at 10µM) in Flp-In T-Rex293 cells expressing OATP-1B1. Similar 
results were observed in studies evaluating in vitro inhibitory activity of TKIs, demonstrating 
inhibition of OATP-1B1 transporter protein by nilotinib and pazopanib. S Hu et al. [148, 200][1] 
also reported the inhibitory activity of erlotinib and vandetanib in Flp-In T-Rex293 cells 
expressing OATP-1B1 at a concentration of 10µM. Conversely, our findings demonstrate that 
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there is no active involvement of erlotinib and vandetanib in the inhibition of OATP-1B1 
transporter proteins. These contrasting results suggest that utilization of different radiolabelled 
probe substrate and in vitro model based systems may affect the inhibitory action of TKIs on 
cellular accumulation of probe substrate via OATP and can lead to misinterpretation of the role of 
TKIs causing inhibition of OATPs. 
Expression of OATP-1B1 and -1B3 have been exclusively reported on liver, suggesting 
their vital role in hepatic uptake of many drugs. Moreover expression of OATP-1B3 has also been 
reported on cancer tissues [90, 145, 199, 201-203]. Several substrates of OATP like statins, 
paclitaxel, and docetaxel are taken and metabolized by liver. Rate of hepatic transporter mediated 
uptake is considered as one of the important parameter of total metabolic rate [199, 204-207]. 
Hence, plasma concentration of drugs which undergo hepatic metabolism may be altered by 
inhibition of hepatic uptake transporters (OATPs). Cyclosporin A (CsA) is a well-known inhibitor 
of OATP-1B1, CYP3A4 and MDR1. It is a more potent inhibitor of OATP-1B1 (IC50: 0.2µM) 
than CYP3A4 (IC50: >0.3µM). Coadministration of pravastatin, rosuvastatin and atorvastatin 
together with CsA resulted in increased AUC by 9.93, 7.08 and 8.69 fold, espectively [199, 208, 
209]. Considering this result, concentration of CsA in systemic circulation was not high enough 
from oral administration to inhibit hepatic CYP3A4 function. Thus, increase in AUC of statins on 
coadministring CsA was due to inhibition of OATP-1B1. Similarly, gemfibrozil is also a more 
potent inhibitor of OATP-1B1 than metabolic enzymes, i.e., CYP1A2, 2C8, 2C9 and 2C19. 
Coadministration of pravastatin, rosuvastatin and atorvastatin together with CsA results in higher 
AUC by 2.01, 1.88 and 1.35 fold, respectively [199, 210-212]. Since, these statins are primarily 
excreted from the liver in an unchanged form, magnitude of increase can be attributed as a result 
of inhibition of OATP-1B1. Hence inhibition of hepatic uptake transporters (OATPs) can result in 
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many clinically relevant DDIs. Unlike statins, information on the inhibitory potency of TKIs on 
hepatic uptake transporters (OATP-1B1 and -1B3) is very sparse. Thus, it is of utmost importance 
to understand clinically relevant DDIs which may arise due to inhibitory action of TKIs on OATP-
1B1 and -1B3.  
 The results obtained from our studies evaluating in vitro inhibitory activity of TKIs reveals 
inhibition of OATP-1B1 and/or-1B3 by selected TKIs.  In this article, we have reported inhibitory 
potential of TKIs for OATP-1B1 and/or -1B3 by estimating half maximal inhibitory concentration 
(IC50). Our findings suggest that nilotinib is a more potent inhibitor of OATP-1B1 than pazopanib. 
No significant inhibition in uptake of radiolabelled probe substrates were observed in OATP-1B1 
transfected cells with vandetanib, canertinib and erlotinib indicating that all tested TKIs do not act 
as inhibitor for OATP-1B1. Similarly for OATP-1B3 transporter protein, while vandetanib showed 
its inhibitory action on the probe radiolabelled substrate intracellular accumulation, pazopanib, 
nilotinib, canertinib and erlotinib did not produce any inhibitory effect on OATP-1B3. Hence, 
OATP-1B1 and/or -1B3 can be considered as important factors in determining pharmacokinetics 
or DDIs of pazopanib, nilotinib and vandetanib. These results though act mainly as a proof of 
concept and the actual inhibitory potency/activity in humans may vary based on various 
physiological and pathological conditions resulting in altered expression of these transporters in 
liver. 
Although TKIs share similar structural backbone but minor changes in the structure can lead to 
drastic changes in binding affinities to OATP-1B1 and-1B3 transporter and hence, it might be a 
reason for the large disparity in the inhibition potential among the various drugs for the hepatic 
uptake transporters. Additionally, a single radioactive substrate was used to determine the 
inhibition efficiency of the drugs for respective transporters. Since there can be multiple binding 
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sites on a single transporter for various substrates as previously reported [213, 214] the positive 
inhibitors might only inhibit the specific substrate-transporter site interaction. It might happen that 
if a different substrate that binds to a different binding site is used, then we might see the other 
non-positive inhibitors to become active for OATP-1B1 and-1B3. 
 Currently, OATP-1B1 and -1B3 related DDIs involving clinical as well as pre-clinical 
interactions has been published in many reports. These DDIs are considered as vital components 
in discovery and development of drugs with safer profiles since these DDIs may lead to elevated 
risk of drug induced adverse effects, even resulting in withdrawal from the market. Many 
therapeutic agents are substrates or inhibitors of OATP-1B1 and/or -1B3. Alteration in the hepatic 
uptake of these compounds via OATPs may result in clinically relevant DDIs. Expression and 
involvement of these OATP-1B type isoforms in liver needs to be delineated for better 
understanding of the factors governing absorption, distribution, metabolism and elimination 
(ADME) of therapeutic agents. Any change in the activity of OATP-1B type transporter proteins 
will result in suboptimal treatment or high toxicity. Thus it is necessary to investigate the role of 
these transporters in order to avoid DDIs [199]. 
 Previously published articles have focused on TKIs as substrates and not on the inhibition 
potential of these agents with OATPs [153, 157, 172, 191, 196, 197]. In this study we have 
observed concentration dependent inhibition of OATP-1B1 transporter by pazopanib and nilotinib 
in in vitro model system. Also, concentration dependent inhibition of OATP-1B3 in presence of 
vandetanib.  
 OATP-1B1 and/or -1B3 are responsible for regulating the initial step of hepatic elimination 
of therapeutic agents (substrates of OATPs) by carrying out the uptake of selected agents into the 
hepatic tissue exposing the molecules to CYP enzyme mediated metabolism followed by 
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elimination via biliary secretion. These OATPs expressed on basolateral membrane of hepatocytes 
may induce drug uptake and can be regarded as one of the determinants of overall metabolic rate 
in liver [147]. An efficient directional movement of therapeutic agents across hepatic tissues 
requires synchronized activity of hepatic uptake, metabolizing enzymes and efflux transporters 
[177]. Tan AR et al, reported that coadministration of pazopanib (weak CYP3A4 and CYP2C8 
inhibitor) with paclitaxel resulted in 14% lower paclitaxel clearance and a 31% higher 
concentration [215]. We have shown that pazopanib inhibits OATP-1B1 transporter which is 
responsible for hepatic uptake of paclitaxel. Therefore, 31% higher plasma concentration of 
paclitaxel may not be just due to the inhibition of metabolizing enzymes but also may be due to 
inhibition of OATP-1B1 transporter. This hypothesis of OATP inhibition by TKIs resulting in 
increased plasma taxol concentration (docetaxel) has also been reported by Hu S et al [200]. 
OATP-1B1 plays a vital role in hepatic uptake of paclitaxel making it vulnerable to metabolism 
by CYP3A4 and ultimately accelerating elimination by biliary secretion via P-gp [216, 217].  
 Coadministration of vandetanib has been warranted with digoxin. Vandetanib is a weak 
inhibitor of the efflux pump P-glycoprotein (P-gp). Coadministration of vandetanib and digoxin 
(substrate of P-glycoprotein, P-gp) may result in increased plasma concentrations of digoxin 
(caprelsa, product monograph). Also, digoxin is a well know substrate of OATP-1B3 as well [122]. 
We have shown that vandetanib inhibits OATP-1B3 transporter which is responsible for hepatic 
uptake of digoxin. Hence, enhanced plasma concentration of digoxin will not be just because of 
the inhibition of P-gp but also may be due to inhibition of OATP-1B3 transporter by vandetanib. 
Inhibition of OATPs (localized on basloateral membrane of hepatic tissues), metabolizing 
enzymes and efflux transporters (expressed on bile canalicular membrane) may be responsible for 
enhance plasma concentration of OATP substrates.  
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 OATPs mediated DDIs have the potential to influence drug efficacy and toxicity. 
Therefore, coadministration of pazopanib, nilotinib and vandetanib (OATP-1B1 and/or -1B3 
inhibitors) along with other hepatic OATP substrates (paclitaxel, docetaxel, cyclosporine, protease 
inhibitors, rifampicin, statins, telmisartan, valsartan, mTOR inhibitors, antibiotics etc.) may result 
in altered pharmacokinetics and pharmacodynamics of OATP substrates. Inhibition of hepatic 
uptake of OATP substrates by coadministration of OATPs inhibitor is a plausible explanation of 
several clinically observed DDIs. Inhibition of metabolizing enzymes and/or efflux transporter 
may not be the only cause of DDI induced effects. Drug induced alteration of OATP-1B1 and -
1B3 transporter function is an essential auxiliary mechanism underlying DDIs [170]. 
 Several TKIs are associated with drug induced hepatotoxicity. Rise in serum transaminase 
levels and bilirubin were the common adverse effects associated with TKIs therapeutic regimen. 
Xu CF et al [194], reported that higher bilirubin levels in plasma or hyperbilirubinemia is 
associated with the inhibition of both OATP-1B1 and enzyme uridine diphosphate 
glucuronosyltransferase 1A1 (UGT1A1). OATP-1B1 is responsible for hepatic uptake of bilirubin 
whereas UGT1A1 is responsible for bilirubin metabolism prior to its elimination. Hence, 
pazopanib induced hyperbilirubinemia may result due to inhibition of both OATP-1B1 and 
UGT1A1. We have also here reported the inhibitory potency of pazopanib for OATP-1B1. This 
result is consistent with the observation that pazopanib induced inhibition of OATP-1B1 may 
cause diminished hepatic uptake of bilirubin resulting in hyperbilirubinemia. Similarly, we have 
reported inhibitory activity of nilotinib towards OATP-1B1 transporter proteins. Singer JB et al 
[218], reported that inhibition of UGT1A1 activity by nilotinib and genetic polymorphism can be 
attributed as the cause of increased rate of hyperbilirubinemia. On the basis of our findings along 
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with published reports, we postulate that nilotinib induced hyperbilirubinemia may be the result of 
inhibition of both OATP-1B1 and UGT1A1. 
Conclusion 
 In conclusion, we have shown that selected TKIs may cause inhibition of OATP-1B1 and 
OATP-1B3. Pazopanib and nilotinib exhibit concentration dependent inhibitory activity against 
OATP-1B1 whereas vandetanib generates inhibitory action with OATP-1B3. These findings 
delineate the involvement of TKIs in inhibiting hepatic uptake of OATP-1B1 and -1B3 substrate. 
These findings also confirm that inhibitory activity of TKIs towards hepatic uptake transporters 
and can be utilized as a vital determinant of the pharmacokinetic profile of coadministered 
therapeutic agents. Since co-administration of TKIs with other drugs is fairly common in multi-
drug therapy, hepatic uptake transporters OATP-1B1 and -1B3 can be regarded as important 
molecular targets for potential DDIs. Thus, hepatic uptake mediated by OATP-1B1 and -1B3 for 
selected TKIs should be dynamically scrutinized in order to circumvent DDIs. These transporters 
in conjunction with the metabolizing enzymes and efflux proteins may eventually decide on the 
overall flux/loss of the therapeutic agents within the hepatic tissue. These studies act as a proof of 
concept substantiating the need for further clinical studies investigating the OATP based DDI 
potential of TKIs. Further in vivo studies are required for better understanding of the contribution 
of OATP-1B1 and/or -1B3 transporter proteins in the hepatic disposition of drugs coadministered 
with TKIs and for predicting any adverse drug reactions associated with these hepatic transporter 
mediated DDIs [219]. 
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CHAPTER 4 
THE ROLE OF TRANSPORTERS AND EFFLUX SYSTEM IN DRUG DELIVERY 
Rationale 
The transporters are membrane proteins and integral part of cell membrane. These proteins 
are broadly involved in selective absorption of endogenous substances (substances such as anions 
and cations, vitamins, sugars, nucleosides, amino acids, peptides, etc) and elimination of toxic 
substances. In fact, transporters direct the influx of essential nutrients and ions and the efflux of 
cellular metabolites and xenobiotics. These proteins also play a pivotal role in drug absorption, 
distribution, elimination, and drug-drug interactions. Although the occurrence of multidrug 
resistance of bacteria was noticed more than fifty years ago, the discovery of P-glycoprotein (P-
gp), a major factor for efflux of xenobiotics out of cell took twenty years, It is clear now that apart 
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from intestinal absorption barrier and blood brain barrier, different tumor cells express P-gp which 
contributes a major role to the drug resistance in chemotherapy.  In fact, these transporters take 
part a considerable role in the process of drug absorption, distribution, metabolism and elimination 
(ADME) of drugs.  Almost 2000 genes have been identified for transporters or transporter-related 
proteins [220]. Approximately 400 membrane transporters, in two superfamilies, have been 
identified and characterized for specific tissue localization, and a number of these transporters 
have been cloned [122]. From pharmacological point of view two major superfamilies, ABC (ATP 
binding cassette) and SLC (solute carrier) transporters, are focused.  The ABC, as active 
transporters, operates by ATP hydrolysis to expel their substrate out of cells across lipid bilayer. 
The ABC proteins are encoded by 49 genes and are categorized into seven subclasses [221] P-
glycoprotein (P-gp) is the most well documented transporter in the ABC superfamily and encoded 
by the MDR1 (ABCB1) gene. The SLC superfamily consists of forty three families [221] which 
participate in drug absorption. There are many well-known SLC transporters include serotonin 
(SLC6A4) and dopamine (SLC6A3) transporters. Besides carrying nutrients or extruding cellular 
waste or, toxins, the wide-ranging role of membrane transporters is drug absorption, distribution 
and elimination. These transporters also participate in drug-drug interactions. The role of these 
transporters in multidrug resistance has been well recognized. In addition to drug delivery service, 
some of these transporter proteins also provide as a protective barrier to particular organ such as 
the brain. For example, P-gp in the blood-brain-barrier (BBB) or blood-retinal barrier protects the 
brain and eyes respectively from toxic influx of a variety of structurally diverse molecules through 
efflux pump. The ABC transporters also work in concert with drug metabolizing enzymes by 
eliminating drugs and their metabolites. Molecular cloning of transporter genes reveals the 
association of multiple genes encoding subtypes with similar function with different tissue 
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distribution and specificity towards drugs. Studying these subtypes (eg. glucose transporters, 
GLUT 1-4) can unravel the structure-activity correlation for drug transport which may allow 
modulation of its activity when considered necessary.  Sometimes transporters can be present in 
the form of multiple alleles with functional defects resulting in defective drug binding or transport. 
Although the importance of drug transporters in the process of ADME and drug-drug interactions 
is well documented, our knowledge in this area is still emerging. The US Food and Drug 
Administration (FDA) and International Transporter Consortium (ITC) recently selected few 
transporters: organic anion transporter (OAT), organic anion transporting polypeptide (OATP), 
organic cation transporter (OCT), peptide transporter (PEPT), P-gp, multidrug resistance 
associated protein (MRP) and breast cancer resistance protein (BCRP) which are decisive to 
xenobiotics absorption, and  drug-drug interactions. From pharmacokinetic point of view, 
localization and function of these transporters in the intestine, liver and kidney receives major 
attention. However, current evidence suggests that some of these transporters, particularly ABC 
transporters in the BBB also have drawn interest for delivering drugs to the brain.  In this chapter, 
we will discuss mainly those transporters as well as vitamin transporters which appear to be 
significant for drug delivery. 
ABC Transporters 
ABC Proteins 
ATP binding cassette (ABC) family is a superfamily of membrane proteins responsible for 
translocation of various substances comprising sugars, amino acids, sterols, peptides, proteins, 
antibiotics, toxins and xenobiotics. These proteins utilize the energy derived from hydrolysis of 
ATP for translocations various substances across a concentration gradient. Forty eight different 
ABC transporters have been in human genome. The ABC transporter genes stand for the largest 
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family of transmembrane proteins. Based on sequence homology and domain structure, they are 
categorized into seven different classes (ABCA-ABCG).  So far, thirteen different transporters 
have been identified from classes A, B, C and G. These transporters play a significant role in the 
development of multidrug resistance (MDR) [222, 223]. First,  Biedler and Riehm (1970) reported 
that Chinese hamster ovary (CHO) cells identified for resistance to Actinomycin D also 
demonstrated cross-resistance to many other drugs such as duramycin, democoline, mithramycin, 
mytomycin C, puromycin, vinblastin and vincristine [224-227]. It is also accountable for the efflux 
of HIV-protease inhibitors, anti-cancer agents and many others drugs. It appeared that after 
selection of a single cytotoxic drug, mammalian cells simultaneously developed cross-resistant to 
a variety of therapeutic agents with different chemical structures and functions. This phenomenon 
was referred to multidrug resistance. While it was believed that this drug resistance was due to 
permeation alteration of cell membrane, Juliano and Ling (1976) revealed that drug resistance in 
CHO cells was due to the presence of P-glycoprotein [225]. Why so many efflux transporters 
present in life forms? Many toxins are present in the nature, and clinicians administer many toxins 
to treat life threatening diseases (cancer, HIV, diabetes, etc). The amphiphilic drug molecules are 
hydrophobic enough to diffuse through lipid bilayer, but hydrophilic enough to reach the target. 
Once inside cells, these drugs can be inactivated by oxidation or conjugation to become more 
hydrophilic and get trapped inside the cells. These efflux transporters help them get out.  While P-
gp become warrior in effluxing wide range of therapeutic agents, MRP family deserves credit in 
extruding drugs conjugated to GSH, glucuronate, or sulfate and many other organic anions such 
as methotrexate.   
These ABC transporters always function unidirectional as opposed to several others 
transporters which function bidirectional [228]. All these ABC proteins show a minimal 
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requirement of two transmembrane domains (TMDs) and two nucleotide binding domains 
(NBDs). This structural requirement can be assured by a single polypeptide chain or gathered from 
two homo-dimeric (equal) to hetero-dimeric (unequal) chains [229, 230]. All ABC transporters 
include a conserved sequence in NBD for binding ATP. The hydrolysis of ATP is required as a 
standard power for translocation by these transporters [231].  All the ABC transporters 
demonstrate 25 % homology. The conserved regions of sequence motifs consist of (i) Walker A 
region, (ii) Walker B region, (iii) signature C motif (90-120 amino acids linker between Walker A 
and B regions) (iv) glutamine loop (Q-loop) (v) histidine loop (H-loop) and (vi) D-loop [232-234]. 
The Walker A and B regions play a vital role in nucleotide binding. The signature motif is 
considered as a hallmark of ABC transporters which aids in communicating TMDs and also ATP 
hydrolysis [235].  The glutamate and histidine loops assist in ATP hydrolysis [236, 237]. The other 
trademark of ABC transporters is the D-loop which contributes a vital function in communicating 
the catalytic sites [238]. Three important ABC transporters: P-gp, MRP and BCRP will be 
discussed further from drug delivery point of view. 
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Fig.4.1: Localization of selected transporters in 4 tissues involved in ADME of drugs. Adapted 
from Giacomini et al., 2010 [122] 
Efflux transporters 
The efflux transporter proteins belong to ATP-binding cassette family.  In particular, we 
are interested in the efflux transporters that are expressed at physiological barriers (e.g. intestinal 
absorption barrier, BBB, placental barrier, corneal and retinal barriers), in the liver, cancer cells, 
and other tissues responsible for drug clearance or excretion of xenobiotics. In this chapter, we 
will focus on three efflux transporters: P-gp, MRP and BCRP. These transporters significantly 
influence ADME of a number of drugs and their metabolites and cause drug resistance for many 
therapeutic agents. The tissue distribution of these transporters (Table 4.1) and their localizations 
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in various tissues are illustrated in Fig. 4.1. These proteins along with primary metabolizing 
enzyme cytochrome P450 (CYP) together constitute a highly efficient barrier for oral drug 
absorption. P-gp is the most extensively studied efflux transporter which functions as a biological 
barrier by extruding toxins and xenobiotics into extracellular fluid. MRP belongs to the same ABC 
super family. Human MRP-1, MRP-2 and MRP-3 are known to be involved in efflux of anti-HIV 
agents and their conjugated metabolites [239-243]. Substrate specificity and tissue localization of 
MDR protein differs from MRP. As a consequence of efflux, drug absorption is reduced and 
bioavailability of xenobiotics diminishes at the target organs [244, 245]. In recent reviews we have 
elaborately discussed the role of these efflux transporters in drug-drug and drug-herbal interactions 
[246, 247].  
Table 4.1: Tissue Distribution of P-gp, MRP and BCRP [221, 246, 247] 
 
Tissue P-gp MRP-1 MRP-2 BCRP 
Small intestine Epithelium, apical side 
of lumen 
Basolateral 
membrane of 
lumen 
Epical 
membrane 
of the lumen 
Apical side 
of lumen 
Colon Epithelium, apical side 
of lumen 
Not present Apical 
membrane 
of the lumen 
Apical side 
of lumen 
Liver Bile canalicular face of 
hepatocytes 
Basolateral 
membrane of 
hepatocytes 
Apical bile 
canalicular 
Bile 
canalicular 
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Kidney Brush border surface of 
proximal tubules 
(apical) 
Basolateral 
membrane of 
tubules 
Apical 
proximal 
tubules 
Not present 
Placenta Trophoblasts Trophoblasts Trophoblasts Trophoblasts 
(facing 
maternal 
blood) 
BBB Luminal side of brain 
endothelium 
Luminal side of 
brain endothelial 
cells 
Luminal 
side of brain 
endothelial 
cells 
Brain 
endothelial 
cells 
Ocular Rabbit corneal 
epithelium, rabbit 
PCEC, human cornea, 
Human RPE, porcine 
RPE, D407, h1RPE, rat 
retinal vessels, TR-
iBRB 
Human corneal 
epithelium, 
Primary human 
RPE cells, ARPE-
19, porcine RPE 
Rabbit 
corneal 
epithelium, 
ARPE-19, 
D407, 
primary 
human RPE 
cells 
Human 
limbal 
epithelial 
cells, 
primary 
human 
limbal 
epithelial 
culture, 
human 
corneal 
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epithelium, 
Mouse 
retinal 
vessels, TR-
iBRB 
Other major 
organs 
Abundant on adrenal 
cortex. 
Basolateral 
membrane of 
sertoli cells 
None Breast 
lobules, 
apical; stem 
cells 
 
P-glycoprotein 
  P-gp, a product of MDR gene, was first characterized as the ATP-dependent transporter, 
responsible for the efflux of therapeutic agents from resistant cancer cells. In early seventies, 
Juliano and Ling demonstrated a 170 kDa protein in Chinese hamster ovary cells resistant to 
colchicines [225] and that protein was absent in drug-sensitive cells. The word ‘P’ stands for 
permeability because this transporter caused marked alteration in the permeation of several drugs 
across cell membranes. P-gp is an integral membrane protein having two homologous halves, each 
consisting of one hydrophobic domain with six transmembrane segments and one hydrophilic 
nucleotide-binding domain. Two halves are connected by a short flexible polypeptide linker to 
form the functionally active 1280 amino acid protein. P-gp encoding genes have been identified in 
hamster, mice, human and other species. It is a transporter protein, encoded by a small multi gene 
family, described by MDR Ι, ΙΙ, ΙΙΙ. P-gp from all three classes are present in rodents, while human 
cells express P-gp belonging to class Ι and ΙΙΙ. It is the first ATP-dependent transporter found in 
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the liver and it represents the most studied member of the ATP binding cassette family of 
transporters.  MDR proteins in humans and other species play a central role in protecting the cells 
against cytotoxic agents [248]. These efflux proteins exhibit a broad range of substrate specificity, 
such as digoxin, loperamide, doxorubicin, vinblastine, paclitaxel, fexofenadine cyclosporine-A, 
taxol, dexamethasone, lidocaine, erythromycin, ketoconazole, rifampicin, protease inhibitors and 
many anti-cancer agents [249-255]. Several P-gp substrates (including anticancer drugs, protease 
inhibitors and a variety of other therapeutic agents from different classes) and its inhibitors are 
given in the Table 4.2. 
Table 4.2: P-gp Substrates and Inhibitors [256] 
Substrates Inhibitors 
Acebutolol, Acetaminophen, Actinomycin D, 
h-Acetyldigoxin, Amitriptyline, Amprenavir, 
Apafant, Asimadoline, Atenolol, Atorvastatin, 
Azidopine, Azidoprocainamide methoiodide, 
Azithromycin, Benzo(a)pyrene, 
Betamethasone, Bisantrene, Bromocriptine, 
Bunitrolol, Calcein-AM, Camptothecin, 
Carbamazepine, Carvedilol, Celiprolol, 
Cepharanthin, Cerivastatin, Chloroquine, 
Chlorpromazine, Chlorothiazide, 
Clarithromycin, Colchicine, Corticosterone, 
Cortisol, Cyclosporin A, Daunorubicin 
(Daunomycin), Debrisoquine, 
Amiodarone, Amitriptyline, Amlodipine, 
Astemizole, Atemoyacin-B, Atorvastatin, 
Aureobasidin A, Azelastine, Barnidipine, 
Benidipine, Bepridil, Bergamottin, Bergapten, 
Bergaptol, Biochanin A, Biricodar (VX-710), 
Bromocriptine, Buspirone, Caffeine, Carvedilol, 
Celiprolol, Cepharanthin, Chlorpyrifos, 
Cholesterol, Cimetidine, Clarithromycin, 
Clofazimine, Clomipramine, Clotrimazole, 
Colchicine, Cortisol, Cremophor EL, Cyclosporin, 
Cytochalasin E, Daunorubicin (Daunomycin), 
Desethylamiodarone, Desipramine, Desloratadine, 
Desmethylazelastine, Dexamethasone, 
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Desoxycorticosterone, Dexamethasone, 
Digitoxin, Digoxin, Diltiazem, Dipyridamole, 
Docetaxel, Dolastatin 10, Domperidone, 
Doxorubicin (Adriamycin), Eletriptan, 
Emetine, Endosulfan, Erythromycin, h-
Estradiol, Estradiol-17h-d-glucuronide, 
Etoposide (VP-16), Fexofenadine, GF120918, 
Grepafloxacin, Hoechst 33342, 
Hydroxyrubicin, Imatinib, Indinavir, 
Ivermectin, Levofloxacin, Loperamide, 
Losartan, Lovastatin, Methadone, 
Methotrexate, Methylprednisolone, 
Metoprolol, Mitoxantrone, Monensin, 
Morphine, 99mTc-sestamibi, N-
desmethyltamoxifen, Nadolol, Nelfinavir, 
Nicardipine, Nifedipine, Nitrendipine, 
Norverapamil, Olanzapine, Omeprazole, PSC-
833 (Valspodar), Perphenazine, Prazosin, 
Prednisone, Pristinamycin IA, Puromycin, 
Quetiapine, Quinidine, Quinine, Ranitidine, 
Reserpine, Rhodamine 123, Risperidone, 
Ritonavir, Roxithromycin, Saquinavir, 
Sirolimus, Sparfloxacin, Sumatriptan, 
Dexniguldipine, Digoxin, 6V,7V-
Dihydroxybergamottin, Dihydrocytochalasin B, 
Diltiazem, Dipyridamole, Doxepin, Doxorubicin 
(Adriamycin), [d-Pen2, d-Pen5]-enkephalin, 
Efonidipine, Eletriptan, Emetine, Endosulfan, 
Epiabeodendroidin F, Ergometrine, Ergotamine, 
Erythromycin, Estramustine, Etoposide (VP-16), 
Fangchinoline, Felodipine, Fentanyl, Fluconazole, 
Fluoxetine, Fluphenazine, Fluvoxamine, 
Forskolin, Gallopamil, Genistein, GF120918, 
Haloperidol, Hydrocortisone, 1V-
Hydroxymidazolam, Indinavir, Itraconazole, 
Ivermectin, Ketoconazole, Lansoprazole, 
Loperamide, Loratadine, Lovastatin, Manidipine, 
Methadone, Metoprolol, Mibefradil, Miconazole, 
Midazolam, Morin, Morphine, Naringenin, 
Nefazodone, Nelfinavir, Nicardipine, Nifedipine, 
Nilvadipine, Nisoldipine, Nitrendipine, Nobiletin, 
Norverapamil, Omeprazole, Pafenolol, 
Pantoprazole, Phenylhexyl isothiocyanate, 
Pimozide, Piperine, Pluronic block copolymer, 
Pristinamycin IA, Progesterone, Promethazine, 
PSC-833 (Valspodar), Quercetin, Quinacrine, 
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Tacrolimus, Talinolol, Tamoxifen, 
Taxol(Paclitaxel), Telithromycin, Terfenadine, 
Timolol, Toremifene, 
Tributylmethylammonium, Trimethoprim, 
Valinomycin, Vecuronium, Verapamil, 
Vinblastine,Vincristine, Vindoline, 
Vinorelbine. 
 
Quinidine, Quinine, Ranitidine, Rapamycin, 
Reserpine, Ritonavir, Saquinavir, Silymarin, 
Simvastatin, Sirolimus, Mephenytoin, 
Spironolactone, Staurosporine, Sufentanil, 
Talinolol, Tamoxifen, Tangeretin, Taxol 
(Paclitaxel), Terfenadine, Tetrandine, 
Tetraphenylphosphonium, Trans-flupenthixol, 
Trifluoperazine, Triflupromazine, 
Trimethoxybenzoylyohimbine, Troleandomycin, 
Tween 80, Valinomycin, Verapamil, Vinblastine, 
Vincristine 
  
Multidrug Resistance Associated Proteins (MRPs) 
  MRP family consists of at least nine members: MRP-1 and its eight isoforms, known as 
MRP2-9. MRP-2has been recognized in the apical (luminal) membrane of rat brain capillary 
endothelium [257]. The transmembrane domains in this family vary among the members. MRP-4 
(ABCC4), MRP-5 (ABCC5), and MRP-7 (ABCC7) have 12 transmembrane domains and two 
NBD-binding sites. Other members of MRP family such as MRP-1 (ABCC1), MRP-2 (ABCC2), 
MRP-3 (ABCC3), and MRP-6 (ABCC6) have 17 transmembrane domains and two cytoplasmic 
NBD-binding sites. These membrane proteins (190kD) mediate ATP-dependent unidirectional 
efflux of glutathione, glucuronate, or sulfate conjugates of lipophilic drugs. In addition to many 
anionic conjugates, a number of unconjugated amphiphilic anions can serve as substrates for 
MRPs. There are numerous overlapping substrates between MRP, MATE (multidrug and toxin 
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extrusion transporters) and MOAT (multi-specific organic anion transporter) [122]. Gene symbol 
and other names used for human MRP family have been shown in Fig.4.2.  
 
Fig.4.2: Human MRP gene family 
Recent reports have identified MRP in the brain capillary endothelium. A recent report revealed 
that MRPs play a significant role in-vivo in the absorption of saquinavir across BBB [258]. Since 
MRP family is capable of exporting GHS complexes such as cisplatin, their importance in drug 
resistance are gaining attention. MRP4 and MRP5 can develop resistance to nucleotide analogues 
(PMEA) and purine base analogues (thioguanine and 6-mercaptopurine). Therefore, role of MRPs 
in drug resistance cannot be ignored. A wide range of MRP substrates and inhibitors is provided 
in the Table 4.3. 
 
 
Table 4.3: Substrates and Inhibitors for MRP2  [256] 
Substrates Inhibitors 
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N-Acetyl leukotriene E4, p-Aminohippurate, Arsenic, 
Azithromycin, Benzbromarone, Bilirubin 
bisglucuronide, Bilirubin monoglucuronide, 
Cadmium, Calcein, 5-Carboxyfluorescein, 
Cefodizime, Cisplatin, Copper, S-Decyl-glutathione, 
Dibromosulfophtalein, 2,4-Dinitrophenyl-S-
glutathione (DNP-SG), Epicatechin-3-gallate, 
Epigallocatechin-3-gallate, Estradiol-17h-d-
glucuronide, Etoposide (VP-16), N-Ethylmaleimide-
glutathione, Ethinylestradiol-3-O-glucuronide, 
Ethinylestradiol-3-O-sulfate, Fluo-3, Glutathione, 
Glutathione-bimane, Glutathion-methylfluorescein, 
Glycyrrhizin, Grepafloxacin, Grepafloxacin 
glucuronide, Indinavir, Irinotecan, Leucovorin, 
Leukotriene C4, Leukotriene D4, Leukotriene E4, 
Methotrexate, 4_-OMethyl-epigallocatechin gallate, 
Ochratoxin A, Oxidized glutathione, Pravastatin, 
Probenecid, Ritonavir, Saquinavir, SN-38 
carboxylate, SN-38 glucuronide 
Benzbromarone, Bergamottin, 
Bilirubin bisglucuronide, Bilirubin 
monoglucuronide, Cyclosporin, 
Daunorubicin, Etoposide (VP-16), 
6V,7V-Dihydroxybergamottin, 
Furosemide, GF120918, 
Glibenclamide, Glutathione, 
LY335979, Leukotriene C4, MK571, 
Ochratoxin A, Oxidized glutathione, 
Pravastatin, Probenecid, 
Sulfinpyrazone, Tangeretin, 
Vincristine. 
 
 
 
Breast Cancer Resistant Protein (BCRP) 
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  BCRP belongs to a novel branch, subfamily G, of the large ABC transporter super family. 
The founding member of ABCG subfamily, ABCG1 has been implicated in the regulation of 
cellular lipid homeostasis in macrophages through facilitating efflux of cellular lipids including 
cholesterol and phospholipids. It is also known as mitoxantrone-resistance protein. BCRP is a 72 
kD protein, described as a half transporter which contains only six transmembrane domains and 
one NBD-binding site. Predicted secondary structures of these drug efflux transporters of the ATP-
binding cassette family are illustrated in the Fig.4.3. 
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Fig.4.3. Predicted secondary structures of drug efflux transporters of the ATP-binding cassette 
family: four classes are distinguished here, based on predicted structure and amino acid sequence 
homology. (1) P-glycoprotein consists of two transmembrane domains, each containing 6 
transmembrane segments, and two nucleotide binding domains (NBDs). It is N-glycosylated 
(branches) at the first extracellular loop; (2) MRP1, 2 and 3 have an additional amino terminal 
extension containing 5 transmembrane segments and they are N-glycosylated near the N-terminus 
and at the sixth extracellular loop; (3) MRP4 and 5 lack the amino terminal extension of MRP1–
3, and are N-glycosylated at the fourth extracellular loop; (4) BCRP is a ‘half transporter’ 
consisting of one NBD and 6 transmembrane segments, and it is most likely N-glycosylated at the 
third extracellular loop. Note that, in contrast to the other transporters, the NBD of BCRP is at the 
amino terminal end of the polypeptide. BCRP almost certainly functions as a homodimer. N and 
C denote amino- and carboxy-terminal ends of the proteins, respectively. Cytoplasmic (IN) and 
extracellular (OUT) orientation indicated for BCRP applies to all transporters drawn here. 
(Reproduce with permission from Schinkel, A.H. and Jonker, J.W., (2003) [259]) 
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Two features that distinguish the subfamily G members from other ABC transporters are 
their unique domain organization. Functional characterization has demonstrated that BCRP can 
transport a wide range of substrates ranging from chemotherapeutic agents to organic anion 
conjugates. P-gp substrates have a tendency to overlap BCRP but the later includes acids or drug 
conjugates (mitoxantrone, methotrexate, topotecan, imatinib, irinotecan, statins, sulphate 
conjugates, porphyrins, etc).  More evidence is emerging to suggest that BCRP plays a significant 
role in drug disposition. Hence, it is important to examine its effect on pharmacokinetics and drug-
drug interactions of therapeutic agents [260-266]. Information regarding various substrates and 
inhibitors of BCRP has been depicted in the Table 4.4. 
Table 4.4: Substrates and Inhibitors for BCRP [256] 
Substrates Inhibitors 
Actinomycin D, 9-Aminocamptothecin, 2-Amino-1-
methyl-6-phenylimidazole [4,5-b]pyridine (PhIP), 
Azidodeoxythymidine, Bodipy-FLPrazosin, C6-NBD-
phosphatidylcholine, C6-NBD-phosphatidylserine, 
Cholesterol, Cimetidine, Daunorubicin, 
Dehydroepiandrosterone sulfate, Doxorubicin, 
Epirubicin, 17h-Estradiol, 17h-Estradiol-glucuronide, 
17h-Estradiol-3-sulfate, Estrone, Estrone-3-sulfate 
Acacetin, Apigenin, 
Beclomethasone, Biochanin A, 
Chrysin, Corticosterone, 
Cyclosporin A, Daidzein, 
Dehydroepiandrostrone sulfate, 
Diethylstilbestrol, Digoxin, 
Dexamethasone, Doxorubicin 
 
Genetic Factors In Drug Response  
Growing evidence suggests that genetic factors influence inter-individual variation in drug 
response. Polymorphism has been indicated to vary with ethnicity. Mutations in genes may lead 
to genetic polymorphism. Several reports suggest that inter-individual variability in drug response 
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is linked to single nucleotide polymorphisms (SNP). Polymorphism in a number of genes encoding 
for drug metabolizing enzymes and transporters has been reported. So far 28 SNPs have been 
detected at 27 positions on MDR1 gene [267]. Mutations at exon 26 (C3435T) and 21(G2677T/A) 
of MDR are responsible for duodenal expression of P-gp. A significantly reduced duodenal P-gp 
expression in homozygous (3435TT) individuals has been linked to higher plasma digoxin level 
[241].  Also C3435T has been reported to be a risk factor for HIV infection [268].  Chowbay et 
al., have described ethnic variability among Chinese, Malays and Indians [269]. Pharmacogenetics 
of MDR1 in Asian populations is different from those in Caucasian and African populations. 
MDR1 is a well conserved gene. But current evidence indicates that its polymorphism affects 
substrate specificity. Three SNPs frequently arise at positions 1236C>T, 2677G>T and 3435C>T. 
In a recent review Fung and Gottesman have indicated that the frequency of synonymous 3435C>T 
polymorphism appears to vary significantly with ethnicity [270]. ABCB1 3435C>T genotype was 
also found to alter serum levels of cortisol and aldosterone during postmenstrual phase of a normal 
cycle [271]. Common haplotype plays a significant role in drug response and efficacy. An evidence 
of high CYP3A4 expression in MDR1 2677T carriers was found in human intestine [272]. The 
influence of MDR1 genotype on CYP3A4 expression adds additional complexity in drug-drug 
interaction.  
Substrate Recognition By P-Glycoprotein 
P-gp actively exports wide range chemically diverse compounds out of cells.  TMDs 5-6 
and 11-12 play a critical role in recognizing and binding its substrates. Seelig has reported a general 
pattern for substrate recognition by P-gp by analyzing more than a hundred diverse compounds 
[273]. A well-defined two or three electron donor groups (recognition elements) are required for a 
substrate to bind P-gp. These recognition elements are classified into two groups:  Type I and Type 
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II. Type I units compose of two electron donor groups with a spatial separation of 2.5 ± 0.3 Ǻ 
whereas type II units either consist of two or three electron donor groups with a spatial separation 
of 4.6 ± 0.6 Ǻ. Accordingly, if  a compound contains at least type I or type II unit is expected to 
be recognized by P-gp. On the basis of the type and number of recognition elements, various 
compounds can be classified as non-substrate, weak substrate or strong substrate.  The structural 
elements responsible for a substrate-P-gp interaction reside in specific hydrogen bonding acceptor 
units.  P-gp-substrate binding and its over-expression  enhance with the number and strength of 
hydrogen bonding acceptor units [273]. 
Substrate And Inhibitor Selectivity 
P-gp mediated efflux of substrates or therapeutic agents plays a major role in drug 
disposition across biological barrier. Apart from cancer cells, P-gp is expressed in many organs 
such as the intestine, liver, kidney, eye and brain [274]. It has been proven that the oral absorption 
and brain penetration of P-gp substrates are significantly enhanced in mdr1 knockout mice 
compared to normal mice [275]. The oral bioavailability and brain permeability of P-gp substrates 
can be significantly enhanced by co-administration of P-gp modulators [276, 277]. Both biliary 
excretion and renal clearance are significantly reduced in the presence of P-gp inhibitors [278, 
279]. Now it is well accepted that appropriate P-gp inhibitors should be co-administrated with P-
gp substrates for therapeutic effectiveness. The activity of P-gp mediated efflux is a saturable 
process. This is a complex area of drug-drug or drug-inhibitor interactions. Such interactions can 
give rise to competitive inhibition, noncompetitive inhibition, and cooperative simulation [224]. 
These interactions can take place either at the P-gp binding site or at ATP binding domains. There 
is more than one P-gp binding locations. The exact numbers of P-gp binding locations are yet to 
be confirmed. However, P-gp substrates and inhibitors can bind at different locations. In general, 
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the substrate binding site and the two ATP-binding domains act together to operate efflux pump. 
Therefore, inhibition of P-gp mediated drug efflux could potentially take place either due to the 
contest of P-gp-binding site and ATP-binding domains or due to blockage of ATP hydrolysis. 
Strategies To Overcome Active Efflux  
  As we mentioned that MDR mediated efflux poses a major impediment for successful drug 
delivery. Hence strategies to overcome efflux proteins are warranted. We have briefly discussed 
the recent developments and research strategies to circumvent MDR mediated efflux.  
Pharmacological Inhibition Of Efflux Proteins  
Co-administration of chemical agents that can inhibit the activity of efflux proteins by 
either competitive or non-competitive binding appears to be an attractive strategy to avoid drug 
efflux. An ideal efflux modulator can inhibit the activity of efflux pumps at the apical membrane 
and subsequently enhance permeability of drug molecule in desired tissues. A schematic of this 
mechanism is depicted in Fig.4.4  
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Fig.4.4: Combination Therapy Approach 
First -Generation MDR Modulators  
Clinically approved Ca2+ channel blocker Verapamil restored the cellular accumulation of 
vincristine in P-gp overexpressing cell lines. This finding stimulated to develop several P-gp 
inhibitors [280, 281]. Antimalarial drugs quinine, quinidine and immunosuppressant cyclosporine 
A emerged as other first-generation inhibitors and approved for the therapeutic use in clinic [282-
284]. Although these first-generation inhibitors were potent in vitro, but very high doses required 
to block MDR mediated efflux in humans, leading to potential life threatening toxicity [285].  
Second-Generation MDR Modulators  
Due to high toxicity with the first-generation modulators, the development of new MDR 
modulators with lower inherent toxicities was essential. Structural analogues of verapamil, 
including dexverapamil and an analogue of Cyclosporin A, PSC-833 (Valspodar) were thus 
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developed as second-generation modulators [286, 287]. However, these compounds appeared to 
alter the pharmacokinetic properties of co-administered anticancer drugs, such as paclitaxel, and 
doxorubicin, producing dose dependent haematological side effects [288, 289]. This altered 
pharmacokinetic profile of co-administered drugs, and caused nonspecific interactions with CYP 
enzymes [290]. As a consequence, the dose adjustment of anticancer drugs appeared imminent to 
prevent adverse outcome of the therapy.  
Third Generation MDR Modulators 
These agents were designed to overcome the limitations of these previous modulators. 
These new set of efflux modulators are highly specific for MDR efflux pumps sparing any 
interaction with drug metabolizing (CYP-450) enzymes and do not alter pharmacokinetic 
interaction with other therapeutic agents. For example, zosuquidar [291], tariquidar [292]and 
elacridar [293]are the MDR inhibitors that have shown promise in pre-clinical mouse model and 
more recently in the clinic. Zosuquidar and tariquidar are specific inhibitors of P-gp. A non-
competitive inhibitory mechanism has been suggested since these are neither substrates for P-gp 
and nor be transported by the ABC transporter [294]. Preclinical studies using such inhibitors with 
anticancer drugs showed significantly prolonged survival and reduction of MDR-bearing human 
tumours engrafted in mice [294]. No alterations in pharmacokinetic parameters of anticancer drugs 
such as doxorubicin, etoposide, daunorubicin, vincristine and paclitaxel have been demonstrated 
upon such co-administrations. Various Phase1 and phase II studies have been conducted upon co-
administration of zosuquidar with docetaxel and Daunorubicin and doxorubicin for the treatment 
of breast cancer, leukaemia and non-Hodgkin’s lymphoma [295-298]. Elacridar is a dual inhibitor 
of P-gp and BCRP. Co-administration of elacridar has been reported to increase the oral 
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bioavailability of topotecan in patients [299]. Pre-clinical studies suggest effective reversal of 
chemo-resistance upon co-administration of elacridar [300]. 
Herbal Modulation Of MDR Efflux Proteins 
Flavonoids such as chalcones, flavonols, flavones, procyanidins, flavan-3-ols (catechins), 
flavanones, and isoflavones are the major constituents among numerous other constituents of many 
naturally occurring herbal products in the market. There have been well documented reports in the 
literature suggesting their interactions with efflux transporters particularly P-gp [247]. To name a 
few, St.john’s wort, garlic, ginseng and grapefruit juice are well known as over the counter herbal 
products as dietary supplements, and medications. Both in preclinical and clinical settings these 
products have been shown to interact with drugs that are substrates for P-gp. These herbal 
ingredients can either inhibit the ATPase activity of efflux pumps or act as competitive inhibitors 
for other drug molecules. Patel et al demonstrated that P-gp mediated efflux of ritonavir was 
greatly reduced by quercetin in Caco-2 cells and MDCKII-MDR1 cells [301]. Similarly, 
intracellular accumulation of daunomycin was greatly enhanced in P-gp over-expressing K562 
cells, with co-administration of various flavonoids [302]. Similar interactions of herbal products 
with other efflux transporters such as MRP2 and BCRP have also been reported in the literature. 
Flavonols such as myricetin and robinetin were shown to inhibit MRP2 mediated efflux of calcein 
in MRP2-over expressing MDCKII cells [303]. Zhang et al. showed that chrysin, biochanin A and 
7,8-benzoflavone, were the most potent flavonoids for inhibiting the efflux of mitoxantrone among 
25 naturally occurring flavonoids tested in MCF-7 cells overexpressing BCRP [304, 305]. 
Likewise, genistein and naringenin were shown to reverse BCRP-mediated resistance [306]. 
Although exact mechanism of P-gp-mediated drug-drug interaction during co-
administration of modulators and substrates yet to be comprehended, it appears that substrate 
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bioavailability does not follow simple kinetics. The competitive inhibition indicates two substrates 
operate at the same binding site of P-gp where only one can bind on any one occasion, whereas 
non-competitive inhibition suggests that two substrates are competent to translocate 
simultaneously at two distinct P-gp binding sites and may function independently. The situation 
may change when allosteric effects are engaged during interaction between substrate and 
modulator.   
When single drug is substrate for more than one efflux transporters, one specific inhibitor 
may not alter pharmacokinetics profile. For example vincristine is substrate for both P-gp and 
MRP2. In that case coadministration of vincristine with either quinidine (inhibitor of P-gp) or 
MK571 (inhibitor of MRP) may not significantly change its brain absorption of vincristine. 
Because when one transporter is inhibited, other transporter overworks for pumping that drug out 
of the brain. In that case selection of a duel inhibitor is critical. Recently we have shown that brain 
uptake of vandetanib (trade name Caprelsa), an anti-cancer drug was significantly enhanced in the 
presence of either GF120918 (elacridar) or everolimus (m-TOR inhibitor) compared to either 
Ko143 or, LY335979. Vandetanib is a substrate for both P-gp and BCRP. While Ko143 and 
LY335979 are inhibitors of P-gp and BCRP respectively, GF120918 (elacridar) or everolimus can 
inhibit both P-gp and BCRP mediated efflux of vandetanib in mouse brain [197]. 
Pharmaceutical Excipients As Inhibitors Of MDR Efflux Proteins 
Drug delivery system using novel Pluronic block copolymers becomes popular to 
overcome efflux pump to overcome multidrug-resistant cancers. Improved oral drug absorption of 
topotecan, a model BCRP substrate was observed after pre-tretament of wild type mice with 
Pluronic 85 (P85) and tween 20 [307]. In a separate study, the cellular accumulation of digoxin 
was increased by 3-fold in LLC-PK1 cells and by 5-fold in the LLC-PK1-MDR1- transfected cells 
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following addition of P85. Similar effects were observed for rhodamine-123 [308]. The co-
administration of 1% P85 with radiolabeled digoxin in wild-type mice increased its brain 
permeation by 3-fold [308]. These data indicate that excipients such as P85 and tween 20 can 
enhance the delivery of drug substrates through the inhibition of the P-gp and BCRP mediated 
efflux mechanism. 
Prodrug Strategy  
Besides efflux transporters, such as P-gp, MRP2 and BCRP, a number of nutrient (influx) 
transporters are also expressed on the cellular membranes. These nutrient transporters are 
responsible for the influx of various nutrients and drugs into various epithelial (enterocytes) 
and endothelial cells (e.g. blood–brain barrier). Recently, transporter targeted prodrug 
derivatization has received great attention amongst drug delivery scientists. Prodrugs have been 
designed such that the modified compounds become substrates of nutrient transporters leading to 
enhanced absorption of these compounds across various physiological barriers, which upon 
crossing the membrane get bio-transformed to parent drug and the pro-moiety (Fig 4.5). This 
strategy not only circumvents efflux pumps but can also reduce the toxic effects of the P-gp 
modulators. Jain et.al reported evasion of P-gp mediated cellular efflux and enhanced permeability 
of HIV protease inhibitor saquinavir upon prodrug modification. Di-peptide prodrugs namely 
valine-valine-saquinavir and glycine-valine-saquinavir showed enhanced absorption with reduced 
efflux  relative to unmodified saquinavir across MDCKII-MDR1 cells [309]. In a similar study, 
parallel results were reported for evasion of P-gp mediated efflux of lopinavir [310] and quinidine 
[311] upon peptide prodrug modifications.  
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Fig 4.5: Transporter targeted prodrug strategy: improved permeability could be achieved by 
overcoming MDR efflux transporters upon chemical modification of parent drug molecule. 
Nanotechnology  
Nanotechnology provides an alternative strategy to circumvent MDR by offering a means 
to encapsulate drugs to lipids, gelatine and polymers producing nanoparticles which are resistant 
to drug efflux. These nanoparticles take advantage of the endocytosis process simultaneously 
evading MDR proteins on cell membranes. Moreover, these nanoparticles can be surface- 
decorated with folic acid, biotin etc for receptor mediated targeted delivery. Fig 4.6 demonstrates 
the mechanism of efflux evasion via endocytosis following encapsulation of the drug molecules in 
nanoparticles. Inclusion of targeting ligands on the surface of nanoparticles has the potential of 
tumor-specific drug delivery and retention, thus minimizing systemic toxicity [312].  
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Fig 4.6: Evasion of MDR efflux proteins by surface-decorated nanoparticles: substrate drug 
molecules encapsulated in the nanoparticles can evade MDR proteins upon endocytosis Acharya, 
S. and Sahoo, S.K., 2011[313]. 
Recently, numerous reports have been published showing encapsulation of 
chemotherapeutic agents such as doxorubicin and paclitaxel in liposomes or micelles. These 
encapsulated drugs exhibited high intracellular accumulations and  5-10 fold lower IC50 values in 
P-gp overexpressing cell lines in comparison to the free drugs [314] . Furthermore, accumulation 
DOX in the xenograft was approximately 20 fold higher when doxorubicin loaded micelles with 
folate in their surface was administered in mice [269]. 
Antibodies Specific To MDR1 Protein 
To avoid the clinical side effects associated with pharmacological chemosensitizer, 
monoclonal antibodies recognizing P-gp have been explored as potential inhibitors of P-gp.. The 
studies using MRK-16, one of the P-gp monoclonal antibodies, suggested that their use, together 
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with MDR-related cytotoxic drugs with or without chemosensitizer, may have a potential effect as 
an anti-MDR therapy [315, 316]. Besides MRK-16, another monoclonal antibody UIC2 that 
targets extracellular domain of P-gp has been characterized [252]. However, an effective delivery 
of these large molecular weight monoclonal antibodies is a challenging task. To overcome this 
issue recombinant DNA technology can be exercised to isolate new recombinant scFv antibodies 
which have much smaller molecular weight with desired specificity and affinity directed toward a 
large array of antigens such as MDR1 protein. Haus-Cohen et al. isolated and characterized such 
recombinant scFv fragment capable of disrupting P-gp efflux activity thereby reversing the MDR 
phenotype of drug-resistant human tumor cell lines [317]. 
Influx Transporters 
Influx transporters are integral plasma membrane proteins that control the influx of 
essential nutrients and ions. The presence of these transporters has been reported on various tissues 
and cell lines. These proteins play an important role in drug delivery. These influx transporters 
belong to SLC (solute carrier) transporter family. These include carriers for peptides, vitamins, 
organic anions, organic cations, glucose and other nutrients. These transporters are involved in 
pharmacokinetic and pharmacodynamic pathways of drug molecule. A number of drug molecules 
are modified chemically in order to achieve desired lipophilicity and solubility which will 
ultimately improve drug bioavailability. Designing a transporter targeted drug can be considered 
as a rational approach for improving drug bioavailability. These modified drugs are often called 
‘prodrugs’ that are designed to target influx transporters. In this part, we will be discussing about 
the influx transporters that can be exploited as molecular targets for tissue-selective drug delivery 
which may reduce systemic toxicity [318, 319] 
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Peptide Transporters 
The cellular intake of dipeptides and tripeptides along with other peptidomimetics is 
mediated by peptide transporters. In mammals two peptide transporters have been identified, 
peptide transporter 1 (PEPT1, SLC15A1) and peptide transporter 2 (PEPT2, SLC15A2).  PEPT1 
and PEPT2 share similar topology and consist of 708 and 709 amino acid residues, respectively. 
Apart from the intestine PEPT is present in many tissues such colon, kidney, liver, lung, mammary 
gland, pancreas, eye and CNS (Table 4.5). Various drugs and prodrugs are substrates for peptide 
transporters like β – lactam antibiotics (cefadroxil, cefime, cefadrine, cycleacilin and ceftibuten), 
angiotensin converting enzyme (ACE) inhibitors (captopril, enalapril and fosinopril), 
aminopeptidase inhibitors (bestatin), and prodrugs & non – peptidic compounds (L- DOPA and 
valacyclovir) (Table 4.6) [320].  Drug molecules can be chemically modified by introducing 
structural fragments (valyl, leucyl, isoleucyl or glycine residues) for the recognition by peptide 
transporters. Such strategy has been successfully employed to nucleoside drugs such as acyclovir 
[321-323], ganciclovir [321, 324], azidothymidine [321, 325], floxuridine [321, 326], HIV 
protease inhibitors [310, 321] and L-DOPA [321, 327, 328] resulting in a significant improvement 
of oral absorption of these drugs by making use of the peptide transporter pathways [321]. In order 
to exert their pharmacological activity, these peptide prodrugs are metabolized by peptidase to 
release the free active drugs required for desired therapeutic effects. 
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Table 4.5: Distribution of peptide transporters in tissues, cells and sub-cellular compartments. 
Modified from Rubio-Aliaga, I. and Daniel, H., (2002) [320] 
Transporters Tissue Localization References 
PEPT1 
 
 
 
 
 
 
Small Intestine Brush border membrane of 
enterocytes 
[320, 
329] 
Kidney Brush border membrane of 
epithelial cells of the proximal 
tubule S1 segment 
[320, 
330] 
Bile Duct Apical membrane of 
cholangiocytes 
[320, 331] 
Pancreas Lysosomes of acinar cells 
[320, 
332] 
Cornea Apical membrane 
[333] 
PEPT2 
 
 
 
 
 
 
 
 
Kidney Brush border membrane of 
epithelial cells of the proximal 
tubule (S2 and S3 segment) 
[320, 330] 
Central Nervous 
System 
Epithelial cells of the choroid 
plexus, ependymal cells and 
astrocytes 
[320, 
334] 
Peripheral Nervous 
System 
Membrane and cytoplasm of glial 
cells 
[320, 
335] 
Lung Apical membrane of bronchial 
and tracheal epithelial cells, 
membrane and cytoplasm 
pneumocytes type II 
[320, 
336] 
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PEPT2 
Mammary gland Epithelial cells of the glands and 
ducts 
[320, 
337] 
Cornea Apical membrane 
[333] 
Iris ciliary body - 
[333] 
Retina/Choroid Basolateral Membrane 
[333] 
 
Dipeptides, tripeptides, β-lactams, angiotensin-converting enzyme (ACE) inhibitors and several 
prodrugs are taken up into cells by peptide transporter 1 (PEPT1) and PEPT2, against a 
concentration gradient. The acidic pH of the intestine generated by the brush-border Na+/H+ 
exchanger serves as driving force for intestinal absorption of dipeptides and tripeptides and 
peptidomimetic drugs. The velocity of transport is determined by membrane voltage. By and large, 
the proton gradient is generated and maintained by NHE-3, the apical Na+ -H+ antiporter with 
intracellular Na+ removed by Na+-K+ ATPase in the basolateral membrane. Whereas dipeptides 
and tripeptides undergo rapid intracellular hydrolysis and free amino acids leave cells via 
basolateral transporters. Hydrolysis-resistant substrates, such as most peptidomimetics, are 
released into the circulation by a basolateral peptide transporter that is yet to be identified and/or 
by other drug transporting systems. A list of clinically relevant drugs or inhibitors of peptide 
transporter is presented in the Table 4.6. 
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Fig. 4.7: Model of peptide transport in epithelial cells from intestine and kidney. (Reproduced with 
permission from Rubio-Aliaga, I. and Daniel, H., (2002) [320]) 
Table 4.6: Example of various drugs/prodrugs acting as substrates/ competitive inhibitors of 
peptide transporters 
Drug Substrates/Competitive 
inhibitors  of 
    PEPT1                    PEPT2 
Reference 
β-lactam antibiotics 
Cephalexin 
Ceftibuten 
Cefadroxil 
Ciclacillin 
Cefixime 
 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
 
[327, 338, 339] 
[327, 340] 
[327, 341, 342] 
[327, 343, 344] 
[327, 340, 345] 
Photosensitizing agents 
5-Aminolevulinic acid 
 
+ 
 
+ 
 
[327, 346] 
Antitumour agents 
Bestatin 
 
+ 
 
+ 
 
[327, 347] 
 119 
 
Floxuridine (prolyl- and lysil- 
prodrugs) 
+ n.d. [327, 348] 
Hypotensives 
Midodrine 
 
+ 
 
n.d. 
 
[327, 349] 
Antivirals 
Acyclovir 
Zidovudine 
 
+ 
+ 
 
+ 
n.d. 
 
[324, 327, 350] 
[327, 350] 
Dopamine receptor interactors 
Sulpiride 
Amino ester derivatives of L-DOPA  
 
+ 
+ 
 
n.d. 
n.d. 
 
[327, 351] 
[327, 328] 
Angiotensin-converting enzymes 
(ACE) inhibitors 
Fosinopril 
Captopril 
Enalapril 
 
 
+ 
+ 
+ 
 
 
+ 
+ 
+ 
 
 
[327, 352] 
[327, 353] 
[327, 353] 
                                                                                             +: Confirmed; n.d.: Not determined 
Organic Anion Transporting Polypeptide (OATP) 
OATP are the members of the solute carrier organic anion transporter family (SLCO) 
classified within the solute carrier class (SLC) superfamily. OATP protein encodes for 643-722 
amino acids and has 9-12 transmembrane domains with intracellular amino and carboxy termini 
[7]. So far, 11 human isoforms (Table 4.7) and 14 rat isoforms have been identified in the OATP 
family. The OATP superfamily has been divided according to amino acid sequence identity i.e. 
families (≥ 40% amino acid sequence identity) and subfamilies (≥ 60% amino acid sequence 
identity). OATP1B1, -1B3 and -2B1 are involved in the hepatic uptake of bulky and relatively 
hydrophobic organic anions. Several other OATPs are expressed in many tissues, such as the 
choroids plexus, brain, placenta, heart, intestine, lungs, kidneys and testes [354]. Substrates for 
OATP include bile acids, eicosanoids, steroids, thyroid hormones, and their conjugates as well as 
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xenobiotics such as anionic oligopeptides, organic dyes, several toxins and numerous drugs (Table 
7) [7, 355]. OATPs are ubiquitously expressed in human body and mediate the Na+-independent 
uptake of wide range of amphipathic molecules (molecular weight >300kDa). The substrates of 
OATP are not limited to anions; they also transport cationic and neutral compounds. Altered 
expression levels of OATPs have been reported in different types of cancers (Table 4.8) [356]. 
Table 4.7: Characteristics and selective substrates of human OATP family members 
Protein  
name 
Amino  
acids 
Tissue 
distribution 
Substrates Kinetic 
Parameter 
(Km) 
Reference 
OATP1A2 670 Brain, kidney, 
Rat RPE, retinal 
vessels 
Bromosulfophthalein  
Estrone-3-sulfate 
Rosuvastatin 
Saquinavir 
Fexofenadine 
20µM 
16µM 
3µM 
36µM 
6µM 
[357-361] 
OATP1B1 
 
 
 
691 
 
 
Liver 
 
 
 
Atorvastatin 
Bilirubin 
Estrone-3-sulfate 
Valsartan 
Enalapril 
10µM 
0.01µM 
0.5µM 
1.4µM 
262µM 
[362-366] 
OATP1B3 702 Liver Amanitin 
Estradiol-17β-
glucuronide 
Methotrexate 
Paciltaxel 
Rifampicin 
4µM 
5-25µM 
 
25-39µM 
7µM 
2µM 
[202, 204, 
366-370] 
OATP1C1 712 Brain, testis, 
retinal vessels 
Reverse 
triiodothyronine 
Thyroxine 
0.12µM 
0.09µM 
[371] 
OATP2A1 643 Ubiquitous Latanoprost 5.4µM [372] 
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OATP2B1 709 Ubiquitous Fluvastatin 
Bosentan 
Taurocholate 
0.7µM 
202µM 
72µM 
[373-375] 
OATP3A1 710 Ubiquitous Prostaglandin E1 
 
Prostagalndin E2 
0.05-0.1µM 
 
0.06-0.2µM 
[376, 377] 
OATP4A1 722 Ubiquitous, rat 
corneal 
epithelium, RPE 
cells 
Taurocholate 
Triiodothyronine  
15µM 
1µM 
[13] 
OATP4C1 724 Kidney Digoxin 
Oubain 
8µM 
0.4µM 
[378] 
 
OATP5A1 848 - - - - 
OATP6A1 719 Testis - - - 
 
Table 4.8: Expression of OATP in various cancer tissues 
OATP Cancer tissue expression 
Increased                       Reduced 
Reference 
OATP1A2 In breast carcinoma 
cells and malignant 
breast tissue 
In colon polyps and 
cancer 
[379-381] 
OATP1B1 - In hepatocellular 
carcinoma 
[187, 382] 
OATP1B3 - In hepatocellular 
carcinoma 
[186] 
OATP2A1 In malignant breast 
tissue and liver 
cancer 
In tumors of bowel, 
stomach, ovary, lung 
and kidney 
[383-385] 
OATP2B1 In bone cysts - [386] 
 
Organic Anion Transporter (OAT) 
OATs are another family of multispecific transporters, the major facilitator superfamily 
(MFS) and are encoded by the SLC22/Slc22 gene superfamily. OATs differ in their composition 
of amino acids. Human OAT1 and OAT3 consist of 563 and 542 amino acids, respectively. They 
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have 12 α-helical transmembrane domains (TMDs) with intracellular amino and carboxy-termini 
[387, 388]. Main function of these transporters is to act as transmembrane uniporters, symporters, 
and antiporters, and translocate a diverse range of xenobiotics (drugs and toxins), endogenous 
metabolites (amino acids, sugars, neurotransmitters, etc.) and hydrophilic and amphiphilic 
substrates including inorganic ions (Na+, Cl−, HCO3
−, etc.). They are responsible for the uptake of 
a wide range of low molecular weight substrates including steroid hormone conjugates, biogenic 
amines, various drugs and toxins (Table 4.9) [387-391]. Due to their expression on liver and 
kidneys, they might play a substantial role in maintaining endogenous homeostasis. They are 
capable of translocating a number of prescribed pharmaceuticals, such as loop and thiazide 
diuretics, methotrexate, angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-
inflammatory drugs and β-lactam antibiotics [392]. The presence of OATs on olfactory mucosa, 
choroid plexus, and retina corroborates their involvement in secretory processes [393]. OAT 
family majorly represents the classic renal organic anion transport system. So far, eight isoforms 
(OAT 1-7 and URAT 1) of OAT have been identified (Table 4.9). Members of OAT belong to 
SLC22A gene family and are structurally similar to organic cation transporters (OCTs) [354]. It is 
of clinical importance to understand the transport mechanism of OATs for critical elucidation 
related to drug handling and nephrotoxicity. 
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Table 4.9: Tissue expression and prototypical substrates of OAT family members 
OAT Tissue expression 
Apical                       Basolateral 
Substrates Inhibitors Reference 
OAT1 Mouse 
and rat 
choroid 
plexus 
Renal proximal 
tubules and plasma 
membrane of 
skeletal muscles 
p-
Aminohippurate 
Probenecid, 
novobiocin 
[122, 387, 
394-400] 
OAT2 - Renal proximal 
tubules and 
hepatocytes 
(rodents) 
p-
Aminohippurate 
Bumetanide, 
Chlorothiazide, 
Cyclothiazide 
[387, 401, 
402] 
OAT3 - Renal proximal 
tubules 
Estrone 3-
sulfate 
Probenecid, 
novobiocin 
[122, 387, 
403] 
OAT4 Renal 
proximal 
tubules 
Syncytiotrophoblasts 
in placenta 
Estrone 3-
sulfate 
Olmesartan, 
telmisartan 
[25, 387, 401, 
404, 405] 
OAT5 - - Ochratoxin A Bumetanide, 
furosemide 
[387, 401, 
406] 
OAT6 - - Estrone 3-
sulfate 
Benzylpenicillin, 
Carbenicillin 
[18, 387, 401] 
OAT7 - Hepatocytes Estrone 3-
sulfate 
- [387, 407] 
URAT1 Renal 
proximal 
tubules 
- Urate Losartan, 
telmisartan, 
furosemide 
[387, 401, 
408] 
 
Organic Cation Transporter (OCT) 
OCTs are also members of SLC22A family of solute carrier (SLC) transporters including 
novel organic cation transporters OCTN1 and OCTN2 (encoded by genes SLC22A4 and 
SLC22A5 respectively). They are responsible for the uptake of a wide range of low-molecular-
weight, relatively hydrophilic organic cations such as prototypical cation TEA, neurotoxin MPP+, 
and endogenous compound N-methylnicotinamide (NMN) (Table 4.10) [409-411]. OCT consists 
of 543-557 amino acids. They have 12 transmembrane domains (TMDs) with intracellular amino 
and carboxy-termini. Facilitated diffusion driven by the inside-negative membrane potential is the 
 124 
 
mechanism of uptake of organic cations via OCT [387, 409, 412-417].  The substrates of the OCTs 
are mostly cations with rare exception for anionic or neutral compounds at physiological pH. Three 
isoforms of OCTs (OCT 1-3) has been cloned from human, rabbits, rats and mice. The paralogs of 
OCT1 and OCT2 share about 68–69% sequence homology for humans, rats, and mice, and 71% 
for rabbits [418]. Substrate specificity for orthologous OCT may vary due to difference in species. 
For example, the transport of tetrapropylammonium (TPA) or tetrabutylammonium (TBA) is 
mediated by human and rabbit OCT1 but not by rat and mouse Oct1. This example acts as a 
supporting statement for differences in recognition of OCT substrates across species [419]. Both 
the tissue expression and localization of OCTs (Table 4.10) show that these transporters play a 
governing role in the excretion of toxic xenobiotic and endogenous organic cations. Their crucial 
involvement in drug disposition or drug response depicts tissue expression, substrate and inhibitors 
specificity of OCT family.  
Table 4.10: Tissue expression and substrates of OCT family members 
OCT Tissue expression 
    Apical                       
Basolateral 
Substrates Inhibitors Reference 
OCT1 Lung epithelial 
cells 
Hepatocytes
, Rodents 
enterocytes 
and 
proximal 
tubule 
epithelial 
cells 
(rodents) 
Acyclovir, 
famotidine, 
metformin 
etc. 
 
 
Quinine, 
quinidine, 
disopyramide 
[122, 387, 
409, 420-
423] 
OCT2 Lung epithelial 
cells 
Distal 
convoluted 
tubules 
Cimetidin, 
dopamine, 
metformin 
etc. 
Cimetidine, 
pilsicainide, 
cetirizine, 
testosterone, 
quinidine 
[122, 387, 
410, 411, 
420, 422, 
424] 
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OCT3 Lung epithelial 
cells and 
enterocytes 
Hepatocytes
, and 
trophoblasts 
Cimetidine
, 
histamine, 
serotonin 
etc. 
β-Estradiol, 
Corticosterone, 
Deoxycorticostero
ne, Progesterone  
[387, 410, 
411, 422, 
425-428] 
OCTN
1 
Renal epithelial 
cells (rodents), 
intestinal epithelial 
cells and lung 
epithelial cells 
- - - [30, 387] 
OCTN
2 
Renal proximal 
tubules, 
syncytiotrophoblast
s in placenta and 
lung epithelial cells 
- - - [31, 387, 
429] 
  
Sodium Dependent Multivitamin Transporter (SMVT)  
SMVT is an important plasma membrane protein which facilitates the cellular uptake of 
vitamins and other essential cofactors such as biotin, pantothenic acid and lipoic acid. SMVT 
primarily facilitates the cellular uptake of biotin (vitamin B7) and is a highly sodium dependent 
specific vitamin carrier system. It has been referred as sodium dependent multivitamin transporter 
because of its sodium and substrate specificity. SMVT protein encodes for 635 amino acids and 
has 12 transmembrane domains. The expression of SMVT has been reported in various tissues 
such as placenta, intestine, brain, liver, lung, kidney, cornea, retina and heart. Biotin has been 
utilized in drug delivery by covalently attaching or by surface modification of various therapeutic 
molecules [430]. Russel-Jones et al. reported enhanced tumor accumulation of biotinylated 
fluorescently-labelled N-(2-hydroxypropyl) methacrylamide (HPMA) polymers following 
intravenous administration in mice [431]. Biotin has also been employed as a target moiety to 
deliver large peptides orally by varying the absorptive transport pathways and improving intestinal 
permeability. Ramanathan et al. demonstrated enhanced cellular accumulation of biotinylated 
PEG-based conjugates of Tat9 via SMVT in Caco-2 and transfected CHO cells. The 29 kDa 
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peptide-loaded bioconjugate [PEG:(R.I-Cys-K(biotin)-Tat9)8] and biotin-PEG-3400 interact with 
human SMVT to enhance the cellular accumulation of these large molecules. This strategy of 
conjugating high molecular weight compounds with targeting moiety enhances the intestinal 
absorption and oral bioavailability of macromolecules [430, 432]. Biotin-ganciclovir (B-GCV) 
uptake mediated by SMVT was substantially higher compared to ganciclovir in both ARPE-19 
cells and rabbit retina [433]. This study secularizes the intravitreal pharmacokinetics of GCV and 
B-GCV by an ocular microdialysis technique. The AUC of Biotin-GCV (17.5 ± 1.38 mg*min*mL–
1) was significantly higher than GCV (10.6 ± 1.27 mg*min*mL–1) and no statistically significant 
difference was observed between half-lives of GCV and B-GCV [434]. The tissue distribution and 
kinetic parameters of SMVT are presented in the Table 4.11. 
Table 4.11: An overview of tissue distribution and kinetic parameters of SMVT on cellular 
accumulation 
Cells/ Tissue Michaelis – Menten Kinetic Parameters 
     Km                                                    Vmax 
Reference  
Bovine brain microvessel 
endothelial cells (BMEC) 
49.1 μM 313.2 pmoles/mg protein/min [435] 
Human colonic epithelial 
cells (NCM460) 
19.7 μM 38.8 pmoles/mg protein/3min [436] 
Human derived prostate 
cancer cells (PC-3) 
19 μM 23 pmoles/min/mg protein [437] 
Human corneal Epithelial 
(HCE) cells 
296.23 μM 77.23 pmol/mgprotein/min [438] 
Human retinal pigmented 
epithelial cells (ARPE-19 
and D407) 
138.25 μM 
(ARPE-19) 
and 
863.81 μM 
(D407) 
38.85 pmoles/mg protein/min 
(ARPE-19) and  
308.26 pmol/mgprotein/min 
(D407) 
[434, 438] 
Canine kidney cells 
(MDCK-MDR1) transfected 
with human MDR1 gene  
13 μM 21.5 pmoles/mg protein/min [439] 
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Human retinoblastoma cells 
(Y-79) 
8.53 μM 14.12 pmoles/mg protein/min [440] 
Human placental brush 
border membrane 
21 μM 4.5 nmoles/mg protein/min [441] 
Rabbit corneal epithelial 
cells (rPCEC) 
32.52 μM 10.43 pmoles/mg protein/min [433] 
Rat retinal capillary 
endothelial cells (TR-
iBRB2) 
146 μM 0.223 nmoles/mg protein/min [442] 
Human proximal tubular 
epithelial cells (HK-2) 
12.16 μM 14.4 pmoles/mg protein/7 min [443] 
Human intestinal cells  
(Caco-2) 
9.5 μM 520 pmoles/mg protein/min [444] 
Human kidney cortex brush 
border membrane 
31 μM 82 nmoles/mg protein/30 sec [445] 
Human liver basolateral 
membrane vesicles 
1.22 μM 4.76 pmoles/mg protein/10 sec [446] 
Human intestinal brush 
border membrane (BBM) 
5.26 μM 13.47 pmoles/mg protein/20 
sec 
[447] 
Human rat kidney cortex 
brush-border membrane 
vesicles 
55 μM 217 pmoles/mg protein/sec [448] 
 
Sodium-dependent vitamin C transporters (SVCT1 and SVCT2) 
Ascorbic acid (AA or, vitamin C) is an essential nutrient required for cellular function, 
wound healing and immunity. Sodium-dependent vitamin C transporters (SVCT1 and SVCT2) 
have been cloned recently from human and rat DNA libraries [449-451].  Both isoforms have 
similar function and can mediate L-AA transport. This transporter is present in many tissues such 
as intestine [452, 453], kidney [454, 455], brain [456, 457], eye [458, 459], bone [460], and skin 
[461]. Luo et al. [462] reported the presence of SVCT1 and SVCT2 in MDCK cells. While SVCT1 
expresses mainly on the apical membrane, SVCT2 is present on both the apical and basolateral 
membrane. Uptake of ascorbic acid in MDCK-MDR1 cells appears to be saturable and 
concentration dependent process in a range with Km of 83.2 μM and 7.27 μM for SVCT1 and 
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SVCT2 respectively. Analysis of deduced primary amino acid sequence of hSVCT1 and hSVCT2 
suggests the presence of five putative PKC phosphorylation sites while SVCT1 possess an 
additional PKA site [463].Various inter and intra cellular stimuli (hormones, paracrine factors, 
signaling molecules, etc.) are engaged in the expression of SVCT [464].  
Conclusion 
Complex nature of disease and presence of barrier in ocular and cancerous tissues provides 
a significant challenge for the treatment of ocular and other diseases. Identification and 
characterization of novel influx transporters and exploring them in terms of drug delivery helps in 
partially meeting these challenges in drug delivery to ocular or various tissues. Lower side effects 
with significant improvement in bioavailability are the major advantages provided by targeting 
specific transporters in specific tissues. Drug delivery has been revolutionized by development of 
non-invasive or less invasive drug delivery techniques. New polymers and polymeric drug delivery 
systems have been examined and evaluated for the purpose of controlled and sustained delivery 
for treating vision-threatening diseases and cancer. Progress in nanotechnology, influx transporter 
and non-invasive drug delivery techniques will lead the race for development of new and novel 
drug delivery systems. 
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CHAPTER 5 
NOVEL PENTABLOCK COPOLYMER BASED NANOPARTICLES CONTAINING 
PAZOPANIB: A POTENTIAL THERAPY FOR OCULAR NEOVASCULARIZATION 
 
Rationale 
Several pathologic conditions such as infection, trauma, and loss of the limbal stem cells 
result in invasion of vessels from the limbal arcade to normally avascular cornea leading to corneal 
neovascularization (CNV) [465-467]. It leads to loss of ocular immunity due to induction of allo-
immunity which ultimately leads to penetrating keratoplasty [465, 468-471]. Furthermore, graft 
rejection is also triggered due to ingrowth of neovessels into avascular recipient tissue following 
corneal surgery [465, 472]. Apart from CNV, one of the most common cause of vision loss is 
choroidal neovascularization (ChNV). It is mostly associated with age-related macular 
degeneration (AMD) leading to pathological myopia, ocular histoplasmosis, angioid streaks, and 
several other diseases. Limited information is available regarding the pathogenesis of 
neovascularization (NV). However understanding the role of vascular endothelial growth factor 
(VEGF) in development of neovessels is considered to be major advancement [473, 474]. 
Intraocular injections of ranibizumab, an anti-VEGF agent that binds with all isoforms of VEGF-
A demonstrated substantial vision improvement in 34% to 40% of patients with ChNV [475, 476]. 
Also, bevacizumab (anti-VEGF agent that binds with all isoforms of VEGF-A) has shown positive 
indication in patients with ChNV from AMD [477-483]. Reduction in subretinal and intraretinal 
fluid accompanied by improvement in visual acuity was observed following administrations of 
ranibizumab and bevacizumab (antagonists of VEGF-A). However, monthly injections of 
ranibizumab only halted growth of ChNV and did not cause any significant effect on the regression 
of existing ChNV, possibly due to the involvement of factors other than VEGF-A [475]. These 
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factors are responsible for endothelial cell survival and once the levels of ranibizumab reaches 
below the critical level, onset of vascular leakage and growth of CNV is noted. Apart from VEGF 
family members, several factors such as pericytes, are platelet derived growth factor B (PDGF-B) 
are also responsible for survival of endothelial cells [484]. 
As mentioned above, neovascularization is triggered by a cascade of cellular and molecular 
events [485-487]. Development of neovessels is mainly triggered by VEGF such as VEGF-A, B, 
C and D [488]. Retinal pigmented epithelial cells, vascular endothelial cells, macrophages, 
fibroblasts and corneal epithelial cells are the main source of VEGF in cornea and retina 
respectively [489]. Expression of VEGF is highly upregulated in inflamed and vascularized 
cornea. Accelerated growth, migration, and survival of the endothelial cells are attributed to 
VEGF-triggered effects mediated via tyrosine kinase receptors (VEGFR1, 2, 3) [490, 491]. 
Tyrosine kinases selectively phosphorylate tyrosine residues by binding to extracellular domain of 
receptors that induce receptor dimerization of VEGF and VEGFR. This induction leads to tyrosine 
kinase activation and transcription of VEGF. Blockage of VEGF not only inhibits CNV but also 
promotes corneal graft survival [492-494]. VEGF transcription is also stimulated by PDGF via 
tyrosine kinase PDGF receptors (α and β) which play a vital role in recruitment of pericytes to 
neovessels. Growth of pericyte and endothelial cells are interdependent. Pericyte recruitment can 
be disrupted by inhibition of PDGF signaling pathways. PDGF is secreted by endothelial cells. 
Pericytes express PDGFR-β and the resulting signal stmulates pericyte growth. By inhibiting 
PDGF signaling pathways, endothelial cells undergo apoptosis because of lack of pericyte support 
and absence of VEGF signaling [484, 494-500].  From this information, it can be postulated that 
modulation of VEGF and PDGF may provide better therapeutic outcome in ocular NV [501]. 
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Pazopanib, a small molecule tyrosine kinase inhibitor, not only inhibits VEGF but also 
targets PDGF receptors inhibiting angiogenesis [502, 503]. It has been approved by U.S. FDA for 
the treatment of renal cell carcinoma and soft tissue sarcoma [195, 504]. In preclinical studies, 
pazopanib exhibited proven beneficial effect in ocular complications. Following oral 
administration, pazopanib induced inhibition of VEGF and PDGF pathways leading to lowering 
of laser induced ChNV [505]. In rats, topical eye drops of pazopanib causes inhibition of laser 
induced ChNV, diabetic retinal vascular leukostasis, and leakage [506, 507]. 
Recently, Csaky G et al have reported that in phase 2B clinical trial no statistically 
significant differences were observed between pazopanib eye drops and monthly ranibizumab with 
regard to optical coherence tomography (OCT) parameter, including retinal morphology and CNV 
lesion size (abstract presented at Annual meeting of the American Academy of Ophthalmology, 
Louisiana, 2013). Expression of efflux transports on corneal epithelium and blood-retina barrier 
(i.e. retinal capillaries and retinal pigment epithelium (RPE) has been reported. These efflux 
transporters play a significant role in ocular pharmacokinetics and drug disposition [508].  
Pazopanib is a substrate of efflux transporters which can limit uptake into the target tissue [152, 
153, 509]. Thus by inhibiting or bypassing the efflux transporters, pazoapanib tissue penetration 
can be improved. However, inhibitors or specific efflux modulators may lead to systemic toxicity 
at doses required to modulate efflux activity. Hence, we have developed pazopanib encapsulated 
nanoparticles (NP) which not only eliminates efflux inhibitor related toxicity but also enhances 
tissue penetration of pazopanib along with controlled drug release. In this study, we have examined 
a novel pentablock copolymer (PB) composed of FDA approved polymer blocks such as PEG, 
PCL, and PLA/PGA. We have prepared a PB copolymer with block arrangements of PLA3000-
PCL7000-PEG2000-PCL7000-PLA3000. This polymer was utilized to prepare pazopanib loaded NP for 
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the treatment of ocular neovascularization. Characterization of PB polymer has been carried out 
with NMR, GPC, X-ray diffraction, cytotoxicity and biocompatibility studies. Also, several NP 
parameters such as entrapment efficiency, drug loading, in vitro drug release and effect of 
pazopanib NP in evading efflux transporters were studied. 
Material And Methods 
Materials 
PEG (2 kDa), stannous octoate, ε-caprolactone, poly (vinyl alcohol) (PVA), 
lipopolysaccharide were procured from Sigma-Aldarich (St. Louis, MO; USA). L-lactide was 
purchased from Acros organics (Morris Plains, NJ; USA). Mouse TNF-α, IL-6 and IL-1β (Ready-
Set-Go) ELISA kits were obtained from eBioscience Inc. Lactate dehydrogenase estimation kit 
and CellTiter 96® AQueous non-radioactive cell proliferation assay (MTS) kit were obtained from 
Takara Bio Inc. and Promega Corp., respectively. [3H] Digoxin (specific activity 35.4 Ci/mmol) 
and [3H] Abacavir (specific activity 0.1 Ci/mmol) were procured from Perkin Elmer (Boston, MA, 
USA). All other reagents utilized in this study were of analytical grade. Human conjunctival (CCL 
20.2) and mouse leukaemic monocyte macrophage cells (RAW-264.7) were procured from 
American Type Culture Collection (ATCC). Human corneal epithelial (HCEC) and human retinal 
pigmental cells (D407) were generous gifts from Dr. Araki-Sasaki (Kinki Central Hospital, Japan) 
and Dr. Richard Hunt (University or South Carolina, Columbia, SC, USA), respectively. 
Synthesis Of TB And PB Copolymers 
Triblock (TB) and pentablock (PB) copolymers were synthesized by ring-opening bulk 
copolymerization [510]. Briefly, PCL-PEG-PCL copolymers (TB) were synthesized by 
copolymerization of ε-caprolactone on the hydroxyl ends of PEG (2kDa). In this reaction, PEG 
was used as a macro-initiator and stannous octoate (0.5wt%) as catalyst. To synthesize PCL-PEG-
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PCL, pre-determined amount of PEG was vacuum-dried for 4 h followed by addition of ε-
caprolactone and catalyst. The reaction was carried out in close vessel under nitrogen environment, 
at 130°C for 36 h. The reaction mixture was solubilized in DCM followed by precipitation in ice-
cold diethyl ether. Precipitated polymer was vacuum-dried to remove any residual solvent and 
characterized to evaluate the reaction yield. Structure and molecular weight of TB copolymers 
were confirmed by 1H-NMR and GPC. 
In order to synthesize PB copolymers, predetermined amount of TB copolymer was 
employed as a macro-initiator and stannous octoate (0.5wt%) as catalyst. For the synthesis of PB, 
L-lactide was polymerized on the hydroxyl ends of TB copolymer. Reaction was carried out at 
130°C for 36 h. In order to remove catalyst and unreacted monomers. The reaction mixture was 
dissolved in DCM and precipitated by addition of ice-cold diethyl ether. Polymers were vacuum-
dried and characterized for structure and polydispersity by employing 1H-NMR and GPC as 
analytical techniques. Purified polymers were stored at -20 °C until further use. Reaction scheme 
for the synthesis of TB and PB are described in Fig.5.1 
Characterization Of Polymers 
1H-NMR and GPC analysis were performed to characterize polymers for purity, molecular 
weight and polydispersity. Further, XRD studies were performed to understand the crystalline 
nature of polymers. 
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Fig.5.1: Synthesis scheme for triblock (TB) and pentablock (PB) copolymers 
1H-NMR 
For 1H-NMR spectroscopy, polymeric material was dissolved in deuterated chloroform 
(CDCl3) and analyzed via Varian-400 NMR spectrometer. Using 
1H-NMR, purity and molecular 
weight (Mn) of the polymers were confirmed. 
Gel Permeation Chromatography (GPC) Analysis  
Purity of polymer is further confirmed by analyzing molecular weight and 
polydispersity.Five mg of polymeric material was dissolved in tetrahydrofuran (THF). It was 
utilized as eluting solvent at the flow rate of 1 mL/min whereas separation was performed on 
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Styragel HR-3 column. Polystyrene samples with narrow molecular weight distribution were 
employed as standards. 
X-Ray Diffraction (XRD) Analysis Of Copolymers 
Diffraction patterns of samples were analyzed in order to understand the effects of polymer 
composition (TB vs PB) on the crystallinity of copolymers. MiniFlex automated X-ray 
diffractometer (Rigaku, The Woodlands, Texas) with Ni-filtered Cu-kα radiation (30 kV and 15 
mA) was employed to obtain diffraction patterns. XRD analysis was performed at room 
temperature. 
In Vitro Cytotoxicity Studies 
Cell Culture 
RAW-264.7 cells were cultured and maintained in Dubelcco's modified Eagle medium 
(DMEM) supplemented with 10% FBS, 100 mg/L of streptomycin and 100 U/L of penicillin. 
HCEC cells were cultured according to previously published protocol [511-513]. Cells of passage 
numbers between 25 and 30 were cultured at 37°C, humidified 5% CO2/95% air atmosphere in a 
DMEM/F-12 culture medium supplemented with 15% (v/v) FBS (heat inactivated), 15 mM 
HEPES, 22 mM NaHCO3, 100 mg of penicillin and streptomycin each, 5 μg/ml insulin, and 10 
ng/ml of human epidermal growth factor. D407 cells (passage numbers between 75 and 80) were 
grown at 37°C, humidified 5% CO2/95% air atmosphere in a DMEM culture medium 
supplemented with 10% (v/v) FBS (heat inactivated), 29 mM NaHCO3, 20 mM HEPES, 100 mg 
of penicillin and streptomycin each, and 1% nonessential amino acids at pH 7.4 [514, 515]. Chang's 
conjunctival cell line (CCL 20.2) were grown at 37°C, humidified 5% CO2/95% air atmosphere in 
a Medium 199 containing Earle's BSS supplemented with 10% (v/v) FBS (heat inactivated), 29 
 136 
 
mM NaHCO3, 20 mM HEPES, 100 mg of penicillin and streptomycin each, and 1% nonessential 
amino acids at pH 7.4. 
Lactate Dehydrogenase (LDH) Assay 
Cytotoxicity of PB copolymer was evaluated according to previously published protocol 
with minor modifications [516]. Briefly, different concentrations (1-20 mg/mL) of PB copolymer 
were prepared in acetonitrile (ACN). A 100μL of solutions was aliquoted in each well of 96-well 
cell culture plates. In order to evaporate ACN and to sterilize block copolymers, cell culture plates 
were exposed overnight under UV light in a hood with laminar flow. Once the ACN is evaporated, 
1.0 x 104 of HCEC cells were seeded in each well on the film of PB polymer formed after 
evaporation of ACN and incubated for 48 h at 37°C and 5% CO2 in humidified atmosphere. After 
appropriate incubation time, LDH assay kit was utilized to analyze the supernatant for the levels 
of LDH. LDH assay was performed according to the supplier’s protocol. Samples were analyzed 
using 96-well plate reader at 450 nm. Amount of released LDH is directly proportional to 
cytotoxicity of the polymers. In this study, LDH release >10% was considered as cytotoxic. To 
evaluate toxicity of block copolymers on or retinal and conjunctival cells, similar experiment was 
performed with D407 and CCL 20.2 cells. LDH release (%) was calculated by utilizing following 
equation: 
     𝑳𝑫𝑯 𝒓𝒆𝒍𝒆𝒂𝒔𝒆 (%) =
𝑨𝒃𝒔. 𝒐𝒇 𝒔𝒂𝒎𝒑𝒍𝒆 − 𝑨𝒃𝒔. 𝒐𝒇 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆 𝒄𝒐𝒏𝒕𝒓𝒐𝒍
𝑨𝒃𝒔. 𝒐𝒇 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆 𝒄𝒐𝒏𝒕𝒓𝒐𝒍 −  𝑨𝒃𝒔. 𝒐𝒇 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆 𝒄𝒐𝒏𝒕𝒓𝒐𝒍
∗ 𝟏𝟎𝟎 
MTS Assay 
In vitro cell viability (MTS) assay was performed in order to confirm the safety of PB 
copolymer. MTS assay was carried out according to previously published protocol with minor 
modifications [517]. Four different concentrations of block copolymer solutions were prepared, 
aliquoted and sterilized according to the previously mentioned procedure. After sterilization, 
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HCEC cells at the density of 1.0 x 104 cells per well were seeded in 96-well plate. Cells were 
incubated for 48 h at 37°C and 5% CO2 in humidified atmosphere. After incubation, cell culture 
medium was replaced with 100μL of serum free medium containing 20μL of MTS solution. Cells 
were further incubated for 4h at 37°C and 5% CO2. Absorbance of each well was determined at 
450 nm. Polymer concentrations at which viability of cell is > 90% was observed, were considered 
as non-toxic. Percent cell viability was estimated by the following equation. The similar 
experiment was repeated with CCL 20.2 and D407 cells. 
     𝑪𝒆𝒍𝒍 𝒗𝒊𝒂𝒃𝒊𝒍𝒊𝒕𝒚 (%) =
𝑨𝒃𝒔. 𝒐𝒇 𝒔𝒂𝒎𝒑𝒍𝒆 − 𝑨𝒃𝒔. 𝒐𝒇 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆 𝒄𝒐𝒏𝒕𝒓𝒐𝒍
𝑨𝒃𝒔. 𝒐𝒇 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆 𝒄𝒐𝒏𝒕𝒓𝒐𝒍 −  𝑨𝒃𝒔. 𝒐𝒇 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆 𝒄𝒐𝒏𝒕𝒓𝒐𝒍
∗ 𝟏𝟎𝟎 
In Vitro Biocompatibility Studies 
Different concentrations (1-20 mg/mL) of block copolymer solutions were prepared in 
ACN and were added (200µl) in each well of 48-well cell culture plate. These plates were 
incubated overnight under UV light in a laminar flow hood for sterilization as well as for 
evaporation of ACN. After sterilization, RAW-264.7 cells were plated at the cell density of 5.0 x 
104 per well. Cells were exposed to polymer for 48 h at 37 °C and 5% CO2. After appropriate 
incubation time, cell supernatant was analyzed for the quantification of three different cytokines, 
i.e., TNF-α, IL-6 and IL-1β. ELISA method was employed to estimate the levels of cytokines. 
ELISA was performed according to the manufacturer’s instruction. Calibration curves for TNF-α, 
IL-6 and IL-1β were prepared in the range of 10-750 pg/mL, 5-500 pg/mL and 10-500 pg/mL, 
respectively. 
Preparation Of Nanoparticles 
Nanoparticles were prepared using PB copolymer. An earlier published process 
(spontaneous emulsion solvent diffusion method) was adopted with minor modifications for the 
preparation of nanoparticles [518]. Briefly, 1 mg of pazopanib and 5mg of PB copolymer (1:5) 
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was dissolved in 1 ml of DMSO. This solution was added drop wise from a syringe into 5 ml of 
1% poloxamer solution under constant stirring. Nanoparticles were formed instantaneously on 
mixing of both the solutions. Prepared nanoparticles were stirred for 1 hr followed by 
centrifugation. Finally, nanoparticles were washed two times with DDW to remove surface bound 
pazopanib, poloxamer, and DMSO. Several batches of nanoparticles were prepared with different 
ratios of pazopanib to PB copolymer (1:5 and 1:10). NPs were freeze-dried in 5% mannitol solution 
and stored at -20 °C until further characterization. NPs were prepared utilizing two different drug 
to polymer ratios i.e., 1:5 and 1:10. Freeze-dried NPs were characterized for particle size, 
entrapment efficiency (EE), drug loading (DL) and in vitro drug release behavior. This study was 
carried out in triplicate. Blank nanoparticles were also prepared by employing only polymer in 
similar amounts. 
Characterization Of NPs 
Particle size 
NPs (1 mg/mL) suspended in DDW were subjected to particle size analysis. NPs mean size 
was evaluated at room temperature and 90° scattering angel utilizing Zeta sizer (Zetasizer Nano 
ZS, Malvern Instruments Ltd, Worcestershire, UK). All the samples were analyzed in triplicate. 
The size analysis consisted of 30 measurements per sample, and the results are expressed as mean 
size ± SD.  
Entrapment efficiency (EE %) and drug loading (DL %) 
Pazopanib-loaded freeze-dried NPs were examined for the estimation of DL and EE. 
Supernatant collected during NP preparation were analyzed to evaluate EE utilizing Micro 
BCATM protein estimation kit. Two milligram equivalent of pazopanib-encapsulated NPs were 
dissolved in 200μL of DMSO in order to evaluate DL. Resulting solution was subjected for 
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estimation of pazopanib via UV absorbance spectroscopy at 275nm. Standard curve of pazopanib 
ranging from 0.97 to 1000μg/mL was prepared in DMSO. EE (%) and DL (%) were estimated as 
per to the following equations. 
     %𝑬𝑬 =
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝒅𝒓𝒖𝒈 − 𝑨𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝒅𝒓𝒖𝒈 𝒊𝒏 𝒔𝒖𝒑𝒆𝒓𝒏𝒂𝒕𝒂𝒏𝒕
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝒅𝒓𝒖𝒈
∗ 𝟏𝟎𝟎 
 
     %𝑫𝑳 =
𝑨𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝒅𝒓𝒖𝒈 𝒊𝒏 𝒏𝒂𝒏𝒐𝒑𝒂𝒓𝒕𝒊𝒄𝒍𝒆𝒔
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝒅𝒓𝒖𝒈 𝒂𝒏𝒅 𝒑𝒐𝒍𝒚𝒎𝒆𝒓
∗ 𝟏𝟎𝟎 
 
In Vitro Release Studies 
Dialysis Bag Method 
 A volume of 0.6 mL of NP formulation (1:5) was put in a dialysis bag (3.8 cm in length). 
Dialysis tubing consisted of regenerated cellulose, a material chemically and physically treated to 
increase its resistance (Avg. flat width 9 mm (0.35 in.), MWCO 2000, Sigma Aldrich, MO, USA). 
Both ends were tied. The dialysis bag was suspended in 10 mL of 0.1M phosphate buffer saline 
(pH - 7.4) at 37°C. The tube containing dialysis bag was placed in a shaker with water bath at 
37°C. At predetermined time intervals dialysis bag was exchanged into a tube containing 10 mL 
of fresh 0.1M phosphate buffer saline (pH - 7.4) at 37°C. Drug concentrations were quantified 
using NanoDrop 2000c UV-Vis Spectrophotometer at 275nm and all experiments were conducted 
in triplicate 
Release Kinetics 
Release data were fitted in various kinetic models described below for the investigation of release 
mechanism of pazopanib from PB NPs. 
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Korsmeyer-Peppas Equation 
     
𝑀𝑡
𝑀∞
= 𝑘𝑡𝑛                                                                                                         
Where k is the kinetic constant and n is the diffusion exponent describes release mechanism. 
Mt and M∞ represent the cumulative pazopanib release at time t and at the equilibrium, 
respectively. 
Higuchi Equation 
𝑄𝑡 = 𝐾𝑡1/2  
K denotes the Higuchi rate kinetic constant, Qt is the amount of released pazopanib at time t, and 
t is time (hour). 
Hixon-Crowell Equation 
𝐶01/3− 𝐶𝑡1/3 = 𝑘𝑡  
C0 and Ct represents the initial amount and remaining amount of pazopanib, respectively. k is the 
constant incorporating surface-volume relation and t is time in hour. 
First Order Equation 
𝐿𝑜𝑔𝐶=𝐿𝑜𝑔𝐶0− 𝐾𝑡/2.303  
K denotes the first order rate constant, C0 is the initial pazopanib concentration and t represents 
time in hour. 
Zero Order Equation 
𝐶= 𝐾0𝑡  
K0 is the zero-order rate constant and t is time in hour. 
In Vitro Cellular Accumulation Studies 
 Twelve well polyester plates (Coaster Corning, NY) were utilized to conduct cellular 
accumulation studies. Following media removal, MDCK-MDR1 cells were rinsed thrice for 5 min 
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each with 1–2 ml of Dulbecco’s phosphate-buffered saline (DPBS) containing 140 mM NaCl, 0.03 
mM KCl, 7.5 mM Na2HPO4, 1.5 mM KH2PO4, 1 mM CaCl2, 0.5 mM MgSO4, 20 mM HEPES, 
and 5 mM glucose maintained at pH 7.4. Uptake studies were initiated by adding 250μl of solution 
containing 0.25 μCi/ml of [3H] Digoxin (probe radiolabelled substrate for P-gp) in the absence and 
presence of GF 120918, pazopanib and pazopanib NPs. Following incubation, the solution was 
removed and uptake was terminated with 2 ml of ice-cold stop solution containing 200 mM KCl 
and 2 mM HEPES. The cell monolayer was washed thrice, 5 min each and 1ml of lysis buffer 
(0.1% Triton-X solution in 0.3% NaOH) was added to each well and plates were stored overnight 
at room temperature. Subsequently, the cell lysate (400μl) from each well was transferred to 
scintillation vials containing 3 ml of scintillation cocktail (Fisher Scientific, Fairlawn, NJ, USA). 
Samples were quantified by measuring the radioactivity using liquid scintillation 
spectrophotometer coulter (Beckman Instruments Inc., Fullerton, CA, USA, model LS-6500). 
Protein content of each sample was estimated by BioRad Protein Estimation Kit (BioRad Protein 
Estimation Kit, Hercules, CA, USA). Similarly, experiment was repeated in MDCK-Bcrp1 cells 
by utilizing 0.25 μCi/ml of [3H] Abacavir (probe radiolabelled substrate for Bcrp1). 
Results And Discussion 
 Inhibition of VEGFR and PDGFR tyrosine kinases has been explored as a new target for 
treatment of ocular neovascularization. In a recently concluded Phase 2b trial, pazopanib failed to 
demonstrate any significant effect on neovascularization lesion size over the control arm 
(ranibizumab) (abstract presented at Annual meeting of the American Academy of 
Ophthalmology, Louisiana, 2013). Expression and functional role of active efflux at the ocular 
tissues has been very well established [508]. Such efflux transporters may vary the ocular 
pharmacokinetics of the therapeutic agent. Higher affinity of efflux transporters (P-gp and BCRP) 
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toward this particular class of molecularly targeted agents has been reported before [152, 153, 
509]. Reason behind failure of pazopanib in the treatment of ocular neovascularization has not 
been clearly revealed so far.  
 In this study, we have prepared novel PB copolymers which are composed of FDA 
approved polymer blocks such as PEG, PCL, and PLA. Each block plays a vital role such as 
presence of Stability of NPs is improved by incorporating PEG which ultimately reduces NP 
aggregation and helps in escaping phagocytosis by macrophages resulting in improved half-life. 
Sustain drug release can be improved by incorporating PCL, which is a slow degrading semi-
crystalline polymer. Extremely slow degradation profile of polymer is not advantageous if the 
formulation is administered via intravitreal route. Synchronization of polymer degradation profile 
with the drug release profile is an important aspect to be considered by formulation scientists in 
order to avoid accumulation of empty formulation in limited vitreous cavity. As per previously 
published reports, reduction in the crystallinity of PCL may improve its hydrolytic and enzymatic 
degradation, since poor degradation of PCL has been attributed to its crystalline nature [519]. 
According to Huang et al, crystallinity of PCL can be significantly reduced by conjugation of PLA 
to PCL which will result in faster degradation of PCL [520]. The final formulation (pazopanib 
loaded NPs) will not only help in evading efflux transporters but will also exhibit sustain release 
of pazopanib from NPs. 
Synthesis And Characterization Of TB And PB Copolymers 
 We have synthesized various PB copolymers with different molecular weights of 
PEG/PCL. For this whole study we have only utilized the PB copolymer with highest PCL content 
out of the various PB copolymers. Since one of our main goal was to sustain release of pazopanib 
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from formulation, that’s the reason we utilized the PB copolymer having highest PCL content 
which imparts enhanced hydrophobicity to the polymer.  
Ring-opening bulk copolymerization of ε-caprolactone, and L-lactide leads to successful synthesis 
of TB and PB copolymers. First step involves synthesis of TB copolymers (PCL-PEG-PCL) with 
different molecular weight of PEG/PCL utilizing PEG (4kDa) as macroinitiator and stannous 
octoate as catalyst. Purified TB copolymer was employed as macroinitiator for the synthesis of PB 
copolymers. Molecular weight (Mn) and purity of TB and PB copolymers were confirmed by 1H-
NMR spectroscopy. As described in Fig.5.2, typical 1H-NMR characteristic peaks of PCL units 
were observed at 1.40, 1.65, 2.30 and 4.06 δ ppm representing methylene protons of -(CH2)3-, -
OCO-CH2-, and -CH2OOC-, respectively. A sharp proton peak observed at 3.65 δ ppm was 
attributed to methylene protons (-CH2CH2O-) of PEG. 
1H-NMR spectrograms of PB copolymers 
with PLA as terminals (PB-A, PB-B, PB-D and PB-E) exhibited two additional peaks at 1.50 (-
CH3) and 5.17 (-CH-) δ ppm (Fig.5.3). 
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Fig.5.2: 1H-NMR of TB in CDCl3 (PCL7000-PEG2000-PCL7000) 
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Fig.5.3: 1H-NMR of PB CDCl3 (PLA3000-PCL7000-PEG2000-PCL7000-PLA3000) 
  Molecular weight and purity of the TB and PB block copolymers were further 
confirmed by GPC analysis. Mono-distribution of molecular weight was exhibited by block 
copolymers along with absence of any other homopolymers such as PEG, PCL or PLA. Narrow 
distribution of molecular weights were observed since the calculated molecular weights were very 
close to the feed ratio and polydispersity of block copolymers. Table 5.1 represents theoretical 
molecular weights, calculated molecular weights (1H-NMR and GPC) and polydispersity. The Mn 
values obtained from GPC analysis were markedly lower relative to the Mn values observed from 
1H-NMR. Difference in hydrodynamic diameter of block copolymers in comparison to parent 
homopolymers can be attributed as a cause of difference in Mn values from GPC and 1H-NMR 
analysis. As reported in Table 5.1, observed molecular weights were very similar to theoretical 
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molecular weights. For the future reference in the text, theoretical molecular weights will be 
mentioned instead of calculated molecular weights.  
Table 5.1: Characterization of TB and PB copolymers 
Polymer Structure Total Mn
a
  
(theoretical) 
 
  
Total Mn
b
  
(calculated) 
 
  
Total Mn
c
  
(calculated) 
 
  
Mw
c
 
(GPC) 
 
  
PD
c 
  
PCL
7000
-PEG
2000
-PCL
7000
 16000 14654 12560 16520 1.31 
PL(L)A
3000
-PCL
7000
-PEG
2000
-
PCL
7000
-PL(L)A
3000
 
22000 20780 17250 24020 1.39 
 
a. Theoretical value, calculated according to the feed ratio  
b. Calculated from 1H-NMR results  
c. Determined by GPC analysis 
 Covalent conjugation between PLA and PCL, significantly reduces crystallinity of PCL 
[521-524]. In order to confirm this, we carried out XRD studies for TB and PB copolymers. PLA 
with L-lactide is a semi-crystalline in nature [520]. XRD patterns of TB and PB copolymer has 
been described in Fig.5.4. TB-A shows two strong characteristic crystalline peaks of PCL blocks 
at diffraction angle (2θ) 21.5° and 23.8° in Fig.5.4. Conjugation of PLA (L-lactide) significantly 
diminished the crystallinity of TB which is confirmed by demonstration of reduced intensity of 
PCL peaks in PB copolymer containing L-lactide.  
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In Vitro Cytotoxicity Studies 
LDH assay 
 On rupture of cell membrane, Lactate dehydrogenase (LDH) (a cytosolic enzyme) is 
screted in the culture medium. Measurement of LDH release is an ideal way to estimate the 
membrane damage and cytotoxicity of polymer as the cell membrane act as a potential site for 
polymer-cell interaction. As described in Fig.5.5 (D407, CCL 20.2 and HCEC cells), LDH release 
on exposure of  4 different concentration of PB copolymers was comparable with negative control 
and less than 10% at any given concentrations indicating negligible or no toxicity. 
 
Fig.5.4: XRD patterns of TB and PB copolymers 
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Fig.5.5: In vitro cytotoxicity (LDH) assay of PB copolymer at different concentrations were 
performed on D407, CCL 20.2 and HCEC cells 
MTS Assay 
 In order to further confirm the results observed in cytotoxicity (LDH assay) studies, 
cytotoxic nature of PB copolymer were further evaluated by MTS assay. On exposure to various 
concentrations ranging from 1-20 mg/mL PB copolymer exhibited greater than 90% cell viability 
(Fig.5.6). Moreover, results obtained were comparable to the negative control indicating lack of 
toxicity of PB copolymer. Results observed in LDH and MTS assays clearly indicated that PB 
block is safe for ocular application. 
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Fig.5.6: In vitro cytotoxicity (MTS) assay of PB copolymer at different concentrations were 
performed on D407, CCL 20.2 and HCEC cells 
In Vitro Biocompatibility Studies 
 It is also important to confirm that newly synthesized PB copolymer is not producing any 
inflammatory responses on administration via ocular route. A quick, cost effective and reliable 
technique to examine biocompatibility of polymers is via carrying out in vitro assessment for 
release of cytokines upon exposure to polymer. To study inflammatory responses of polymers 
intended for human applications RAW-264.7 cells (a well-established in vitro cell culture model) 
was employed. Negligible release of TNFα, IL-6 and IL-1β upon 24 h exposure to different 
concentrations of PB copolymer ranging from 1-20 mg/mL were observed in (Fig.5.7). Release of 
any cytokines from PB copolymer was not significantly different relative to negative control 
indicating excellent biocompatibility of PB copolymer for ocular applications. 
 150 
 
 
Fig.5.7: In vitro biocompatibility of PB copolymer were evaluated by estimating the levels of 
TNF-α, IL-6 and IL-1β in the supernatants of polymer treated RAW 264.7 cells 
Characterization Of NPs 
Particle Size 
 Pazopanib loaded PB NPs were prepared by spontaneous emulsion solvent diffusion 
method. As described in Table 5.2, size of NPs were between 420 nm to 515 nm. In order to 
understand the effect of drug to polymer ratio on particle size, we have prepared NPs with two 
distinct drug to polymer ratios i.e., 1:5 and 1:10. Interestingly, we observed significant increase in 
the size of nanoparticles, as we employed higher amounts of PB copolymer to prepare pazopanib 
NPs. These results suggest that particle size is highly influenced polymer:drug ratio. 
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Entrapment efficiency (EE) and drug loading (DL) 
 This work also studied the entrapment efficiency of pazopanib in two different batches of 
nanoparticles. We observed the higher entrapment of the pazopanib as we increased the amount of 
PB copolymer used in the preparation of nanoparticles. When the ratios of pazopanib to PB 
copolymer were 1:5 and 1:10, entrapment efficiencies of pazopanib in NPs were 85.6±9.05 and 
92.9±7.9% respectively (Table 5.2). It is possible that higher polymer content leads to enhanced 
hydrophobic interactions with pazopanib. This could be the explanation for higher entrapment of 
pazopanib in NPs with higher polymer content. The DL % was found to be 13.09±1.05 and 
8.36±0.58% for pazopanib loaded NP batches 1:5 and 1:10 respectively. 
Table 5.2: Characterization of pazopanib loaded PB copolymer NPs 
 
Ratio of 
 Drug:Polymer 
Entrapment 
Efficiency (%) 
Drug Loading (%) Particle Size (nm) 
1:5 85.6±9.05 13.09±1.05 423.5±15.9 
1:10 92.9±7.9 8.36±0.58 514.2±10.3 
 
In Vitro Release Studies 
 Finally, we studied the release of pazopanib from NPs (ratio of pazopanib:PB 1:5). NPs 
demonstrated bi-phasic release profile i.e., initial burst release phase followed by a phase of 
sustained release (Fig.5.8). Sustained release of pazopanib from nanoparticles was observed over 
~100 days with minimal burst effect (≈ 7% in first 2 days). Releases of a drug molecule from PB 
nanoparticles involve various phases. Burst effect was observed due to initial release of drug 
adsorbed on the surface of nanoparticles. After this phase, drug is released from NPs by following 
a slower diffusion phase. Due to different rate of diffusion of pazopanib from NPs, variation in 
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drug release was observed. Pazopanib demonstrates slow release rate from NPs because of 
hydrophobicity and low crystallinity of PB copolymer. Therefore, PB copolymer NPs are valuable 
relative to existing PLGA-based and other TB polymers which show very high burst release [520, 
525]. An advantage associated with this sustained release formulation (pazopanib loaded NPs) is 
higher residence time of drug molecule at the site of absorption. This sustained release profile of 
NPs will help in overcoming the flaws associated with current therapeutic regimen i.e. frequent 
intravitreal injection to maintain therapeutic levels at retina/choroid. Also, potential complications 
like endophthalmitis, retinal detachment, retinal hemorrhage, and patient non-compliance has been 
widely associated as adverse effects with frequent intravitreal injections. This approach will 
eventually eliminate the potential complications linked with current therapy and may lower cost 
of treatment. 
 153 
 
 
Fig.5.8: In vitro release of pazopanib from NPs prepared with PB copolymer 
Drug Release Kinetics 
 Diffusion/degradation or a combination of diffusion and degradation mediated release 
phenomena is usually followed by drug released from NPs [526]. On fitting the data in in five 
different release kinetic models i.e., Korsmeyer-Peppas, Higuchi, Hixon-Crowell, zero-order and 
first-order (Table 5.3), data was correlated well with Korsmeyer-Peppas with R2 value of 0.9945. 
Also, n values in Korsmeyer-Peppas model for release of pazopanib from PB NPs were below 0.45 
indicating controlled release diffussion (Fickian diffusion). These results suggests that drug release 
from PB NPs is controlled by diffusion of pazopanib from the NPs instead of degradation process 
of the PB copolymer.  
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Table 5.3: Coefficient of determination (R2) for various kinetic models for in vitro release of 
pazopanib from PB copolymer NPs 
 
 
Korsmeyer-
Peppas model 
Hixson-
Crowell 
model 
Higuchi 
Model 
Zero 
Order 
First 
order Best Fit Model 
 R
2
 n R
2
 R
2
 R
2
 R
2
  
1:5 0.9945 0.4482 0.9785 0.9643 0.9488 0.9842 Korsmeyer-Peppas model 
 
In Vitro Cellular Accumulation Studies 
 Intracellular accumulation of [3H] digoxin was studied in MDCK-MDR1 overexpressing 
cells. On incubating the MDCK-MDR1 cells with GF 102918 (2µM) and pazopanib (0.1µM), 
enhanced intracellular accumulation of [3H] digoxin by 2.1 and 1.5 fold respectively was observed. 
Further incubating the pazopanib NPs (containing pazopanib equivalent to 0.1µM), no effect on 
the intracellular accumulation of [3H] digoxin was observed (Fig.5.9). Similarly, intracellular 
accumulation of [3H] abacavir was studied in MDCK-Bcrp1 overexpressing cells. Increased 
intracellular accumulation of [3H] abacavir (5.2 and 3.5 fold) was observed on incubating the 
MDCK-Bcrp1 cells with GF 102918 (2µM) and pazopanib (0.1µM) respectively. On incubating 
the pazopanib NPs (containing pazopanib equivalent to 0.1µM), no effect on the intracellular 
accumulation of [3H] abacavir was observed (Fig.5.10). Presence of efflux transporters on corneal 
and retinal epithelial cells are known to limit the permeability fo drug across the ocular tissue 
[508]. These results confirms that pazopanib loaded polymeric PB copolymer NPs successfully 
prevent the P-gp and Bcrp1 mediated efflux of pazopanib. This evasion of drug efflux may help in 
achieving enhanced permeability and bioavailability of pazopanib across ocular tissue. The exact 
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mechanism by which these nanoparticles helps in evading efflux transporters needs to be fully 
explored. 
 
Fig.5.9: Intracellular accumulation of [3H] digoxin in absence and presence of GF 102918 (2µM), 
pazopanib (0.1µM) and pazopanib NPs (containing pazopanib equivalent to 0.1µM) in MDCK-
MDR1 cells. Results are expressed as mean±S.D. n = 4 (*p < 0.05) 
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Fig.5.10: Intracellular accumulation of [3H] abacavir in absence and presence of GF 102918 
(2µM), pazopanib (0.1µM) and pazopanib NPs (containing pazopanib equivalent to 0.1µM) in 
MDCK-Bcrp1 cells. Results are expressed as mean±S.D. n = 4 (*p < 0.05) 
Conclusion 
 We have successfully synthesized and characterized novel PB copolymer. These PB 
copolymers were studied for the development of pazopanib loaded NPs in the treatment of ocular 
neovascularization. Our results demonstrate that the synthesized PB polymers does not exhibit any 
cytotoxicity on ocular cell lines. Also, in vitro inflammatory studies confirmed that PB copolymer 
is an excellent biomaterial for the development of pazopanib loaded sustained delivery formulation 
for the treatment of ocular neovascularization. Pazopanib loaded PB NPs were successful in 
evading drug efflux. Nanoparticles prepared from PB copolymers had overcome the restrictions 
associated with existing PLGA or TB based copolymer NPs such as burst release effect and 
provided sustained release for longer duration. Novel PB copolymers are excellent biomaterials 
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and could serve as a vehicle not only for ocular drug delivery but also for other disorders where 
sustained levels of tyrosine kinase inhibitors is vital. 
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CHAPTER 6 
FUNCTIONAL CHARACTERIZATION AND MOLECULAR IDENTIFICATION OF 
VITAMIN C TRANSPORTER (SVCT2) IN HUMAN CORNEAL EPITHELIAL (HCEC) AND 
RETINAL PIGMENT EPITHELIAL (D407) CELLS 
Rationale 
Ascorbic acid (AA, vitamin C) is an essential water-soluble vitamin required for various 
physiological and metabolic functions. It is a potent reducing agent that effectively quenches 
various reactive oxygen species (ROS), absorbs ultraviolet (UV) radiation and protects cornea, 
lens and other intraocular tissues against light-induced damage [458, 527]. Levels of antioxidant 
AA in aqueous humor plays an important role in the prevention of cataract. Human ocular tissues 
contain considerably higher amounts of ascorbic acid (1.33mg/g wet weight in corneal epithelium, 
0.20mg/ml in aqueous humor, 23mg/100g in neural retina and 5mg/100mg in retinal pigment 
epithelium (RPE)/choroid) [458, 528]. Concentration of ascorbic acid in human tear fluid (23μM) 
is responsible for rapid wound healing and tear stability during ocular infections. Protective role 
of AA against various ocular infections and UV induced damage of ocular tissue suggests the need 
to scrutinize the mechanism of AA transport across ocular tissues (mainly, cornea and retina) 
[458].  
Human and other primates cannot synthesize AA thus making this vitamin an essential 
dietary requirement. Therefore, AA is usually obtained from exogenous sources through the 
dietary intake [462]. AA uptake has already been reported in intestine [453], brain [457], kidney 
[454], skin [461], eye [458, 459] and bone [460] via specific transporter system. Human SLC23 
family consists of two isoforms of sodium-dependent vitamin C transporters (SVCT) namely 
SVCT1 and SVCT2 [529]. Comparative analysis of two isoforms reveals that AA exhibits higher 
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affinity towards SVCT2 than SVCT1. Both SVCT1 and SVCT2 express close sequence homology 
and functional similarity but vary in distribution [458]. Structural and functional studies shows 
that transport of AA across various epithelial cells is mainly mediated via SVCT [458, 462].  
In recent years, transporter targeted drug delivery has been widely employed to improve 
the drug absorption across biological membranes. In order to enhance drug permeation and 
absorption, active agent is chemically modified with transporter targeted moieties. Interaction 
between targeting moiety and the transporter will facilitate transport of conjugated drug across the 
cell membrane [437].  Many investigators have exploited SVCT2 as an important target for drug 
delivery across various membranes. AA conjugated saquinavir shows higher absorptive 
permeability and metabolic stability compared to saquinavir alone [530]. Conjugation of nipecotic, 
kynurenic and diclophenamic acids with AA has been utilized as an important tool in studying the 
mechanism of AA prodrugs interactions with vitamin C transporters across RPE cells. This 
approach has provided a new perspective for transporter/receptor targeted prodrug delivery by 
means of SVCT2 transporter system [531]. 
Hence, SVCT targeted drug delivery can be utilized as a vital strategy for enhancing 
intracellular accumulation of drugs in ocular complications. The aim of this study is to investigate 
the presence of a specialized carrier mediated transport system (SVCT2) across human corneal 
(HCEC) and retinal (D407) cells.  
The presence of SVCT on rabbit cornea and Madin-Darby canine kidney cells has been 
previously reported from our laboratory [458, 462]. Variation in structural and biological 
properties between the rabbit and human eye suggest that the expression of transporters and 
receptors can highly differ. These anatomical and functional disparities among various species 
make it difficult to determine their impact on ocular drug absorption in human [438]. This 
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compelled us to study the practicality of human derived ocular cell lines as in vitro models for 
ocular drug absorption. 
In the present study, we evaluated the ascorbic acid uptake process, kinetics as well as the 
expression, relative contribution, and regulation of the SVCT2 in HCEC and D407 cells. No 
information currently exists with regard to a comprehensive study of AA carrier mediated uptake 
across HCEC and D407 cells. Results obtained from this study may indicate involvement of a 
specific and high affinity carrier transport system (SVCT2) for translocation of AA. 
Material And Methods 
Materials 
[14C] Ascorbic acid ([14C] AA specific activity 8.5 mCi/mM) was procured from Perkin 
Elmer (Boston, MA, USA). Unlabeled L-ascorbic acid, D-iso-ascorbic acid, dehydro-ascorbic acid 
(DHAA), glucose, para amino hippuric acid (PAHA), sodium azide, ouabain, 2,4-dinitrophenol, 
choline chloride, HEPES, bovine insulin, human epidermal growth factor, Triton X-100, phorbol-
12-myristate-13-acetate (PMA), bisindolylmaleimide I (BIS), 3-isobutyl-1-methylxanthine 
(IBMX), 4,4’-di-isothiocyanatostilbene- 2,2’-disulphonic acid (DIDS), 4-acetamido-4’- 
isothiocyanostilbene-2,2’-disulfonic acid (SITC), and D-glucose were purchased from Sigma 
Chemical Co (St. Louis, MO, USA). Dulbecco’s modified Eagle’s medium (DMEM) and 
Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) were purchased from 
Invitrogen (Carlsbad, CA, USA). Fetal bovine serum (FBS) was obtained from Atlanta biologicals 
(Lawrenceville, GA, USA). Culture flasks (75 cm2 growth area) and uptake plates (3.8 cm2 growth 
area) were obtained from Corning Costar Corp. (Cambridge, MA, USA). The buffers for cDNA 
synthesis and amplification (oligodT, dNTP, MgCl2, M-MLV reverse transcriptase and Taq 
polymerase) were procured from Promega Corporation (Madison, WI, USA). Light Cycler 480® 
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SYBR I green master mix was obtained from Roche Applied Science (Indianapolis, IN, USA). 
Qualitative and quantitative primers used in the study were custom-designed and obtained from 
Invitrogen Life Technologies (Carlsbad, CA, USA). All other chemicals were obtained from Fisher 
Scientific Co. (Fair Lawn, NJ, USA) and utilized without further purification. 
Cell Culture 
HCEC and D407 cells were generous gifts from Dr.Araki-Sasaki (Kinki Central Hospital, 
Japan) and Dr.Richard Hunt (University or South Carolina, Columbia, SC, USA), respectively. 
HCEC cells were cultured according to previously published protocol [511, 512] [513]. Cells of 
passage numbers between 25 and 30 were cultured at 37°C, humidified 5% CO2/95% air 
atmosphere in a DMEM/F-12 culture medium supplemented with 15% (v/v) FBS (heat 
inactivated), 15 mM HEPES, 22 mM NaHCO3, 100 mg of penicillin and streptomycin each, 5 
μg/ml insulin, and 10 ng/ml of human epidermal growth factor.   
D407 cells (passage numbers between 75 and 80) were grown at 37°C, humidified 5% 
CO2/95% air atmosphere in a DMEM culture medium supplemented with 10% (v/v) FBS (heat 
inactivated), 29 mM NaHCO3, 20 mM HEPES, 100 mg of penicillin and streptomycin each, and 
1% nonessential amino acids at pH 7.4 [514, 515]. The growth medium was changed every 
alternate day. Both HCEC and D407 cells were cultured in 75 cm2 flasks, harvested at 80–90% 
confluency with TrypLE™ Express (Invitrogen, Carlsbad, CA, USA). Cells were then plated in 
24-well uptake plates at a density of 300,000 cells/well. Cells were grown in a similar way as 
mentioned above and utilized for additional studies. 
Uptake Studies 
Confluent HCEC and D407 cells were utilized for uptake experiments. Following media 
removal, cells were rinsed thrice for 5 min each with 1–2 ml of Dulbecco’s phosphate-buffered 
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saline (DPBS) containing 130 mM NaCl, 0.03 mM KCl, 7.5 mM Na2HPO4, 1.5 mM KH2PO4, 1 
mM CaCl2, 0.5 mM MgSO4, 20 mM HEPES, and 5 mM glucose maintained at pH 7.4. Uptake 
studies were initiated by adding 250μl of solution containing 0.25 μCi/ml of [14C] AA in the 
presence and absence of various competing substrates. Following incubation, the solution was 
removed and uptake was terminated with 2 ml of ice-cold stop solution containing 200 mM KCl 
and 2 mM HEPES. The cell monolayer was washed thrice, 5 min each and 1ml of lysis buffer 
(0.1% Triton-X solution in 0.3% NaOH) was added to each well and plates were stored overnight 
at room temperature. Subsequently, the cell lysate (400μl) from each well was transferred to 
scintillation vials containing 3 ml of scintillation cocktail (Fisher Scientific, Fairlawn, NJ, USA). 
Samples were quantified by measuring the radioactivity using liquid scintillation counter 
(Beckman Instruments Inc., Fullerton, CA, USA, model LS-6500). Protein content of each sample 
was estimated by BioRad Protein Estimation Kit (BioRad Protein Estimation Kit, Hercules, CA, 
USA). 
Time And Temperature Dependency 
Optimum time for [14C] AA uptake was determined by performing the uptake studies over 
various time points (5, 10, 15, 30, 45 and 60 min). The uptake study was conducted according to 
previously published protocol [511-513].  
The effect of temperature on [14C] AA uptake was determined by carrying out the uptake 
study at different temperatures i.e. 4ºC, 25ºC and 37ºC. 
pH And Ion Dependency 
The effect of pH on [14C] AA uptake was observed by adjusting the buffer pH to 5, 6, 6.5, 
7.4 and 8. For delineating the role of sodium ions on [14C] AA uptake, sodium chloride (NaCl) and 
sodium phosphate dibasic (Na2HPO4) in DPBS were substituted with equimolar quantities of 
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choline chloride and potassium phosphate dibasic (KH2PO4), respectively. Hill coefficient for AA 
uptake, as function of Na+ was determined. In a similar way, buffer solution containing sodium 
(130 mM), potassium (0.03 mM), and calcium (1 mM) chlorides were replaced with equimolar 
quantities of sodium phosphate, potassium phosphate, and calcium acetate, respectively.  
In another study, cells were pre-incubated with 1 mM amiloride (sodium channel inhibitor) 
and the uptake study was carried out as mentioned earlier. 
Concentration Dependency 
  Several working concentrations of L-AA were prepared ranging from (0.12μM - 1000μM) 
in DPBS (pH 7.4) spiked with [14C] AA (0.25μCi/ml). The data was fitted to Michaelis -Menten 
equation and the maximum transport rate (Vmax) and Michaelis-Menten constant (Km) were 
calculated according to nonlinear least squares regression analysis program; GraphPad Prism 
version 5. 
Role Of Metabolic And Membrane Transport Inhibitors 
For energy dependency, simultaneous incubation of [14C] AA along with metabolic 
inhibitors such as ouabain (Na+/K+ ATPase inhibitor), 2,4-dinitrophenol (intracellular ATP 
reducer) and sodium azide (oxidative phosphorylation inhibitor) was performed for 1h. In order to 
examine the effect of anionic membrane transport inhibitors, cells were pre-incubated with 1mM 
SITC, DIDS and probenecid for 1h.  
Substrate Specificity 
The substrate specificity for SVCT was delineated by carrying out [14C] AA uptake in the 
presence of three different concentrations of (250, 500 and 1000µM) unlabeled L-AA and 
structural analogs such as D-Iso AA and DHAA. A similar study was carried out at three different 
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concentrations of (250, 500 and 1000µM) various structurally unrelated analogs such as glucose 
(Glucose transporter/GLUT substrate) and PAHA (organic anion transporter/OAT substrate). 
Intracellular Regulation 
The influence of various intracellular regulatory pathways such as Ca++/calmodulin, PTK 
(protein tyrosine kinase), PKC (protein kinase C) and PKA (protein kinase A) pathway on [14C] 
AA uptake was also investigated. Cells were pre-incubated with three different concentrations of 
modulators such as calmidazolium (CaM) and KN-62 to delineate if the process is dependent on 
Ca++/calmodulin pathway or not. In order to examine the role of PTK pathway in [14C] AA uptake, 
cells were pre-incubated with three different concentrations of genistin and tyrphostin A25. For 
studying the effect of PKC pathway, cells were pre-incubated with three different concentrations 
of BIS and PMA. The effect of PKA pathway was studied by incubating cells with three different 
concentrations of IBMX and forskolin. Uptake of [14C] AA was then performed according to the 
procedure. 
Reverse Transcription–Polymerase Chain Reaction 
Reverse transcription– polymerase chain reaction (RT-PCR) analysis was employed to 
determine the expression of SVCT2 on HCEC and D407 at the molecular level. TRIzol® reagent 
(Invitrogen, USA) was used to carry out the cell lysis and chloroform was added to the lysate for 
phase separation. Following separation of aqueous phase containing RNA, isopropanol was added 
to precipitate RNA. Obtained RNA was rinsed twice with 75% ethanol followed by resuspension 
in RNase-DNase free water. The concentration and purity of RNA was determined using Nanodrop 
(Thermo Fisher Scientific, Wilmington, DE, USA). RNA was reverse-transcribed to obtain cDNA 
using oligodT as a template and M-MLV reverse transcriptase. The conditions for reverse 
transcription were: denaturation of the template RNA for 5 min at 70°C; reverse transcription for 
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60 min at 42°C followed by final extension at 72°C for 5 min. cDNA obtained was then subjected 
to PCR for amplification of SVCT with specific primers. The primers (5′→3′) designed for SVCT2 
were: forward: CCAGCGGTGAGCAGGACAAT, reverse primer: 
TAGGGCCACCGTGGGTGTAA. These primers correspond to a 626 base pair (bp) product in 
human SVCT2 cDNA. The conditions of PCR amplification were: denaturation for 30 s at 94°C, 
annealing for 1 min at 56°C, and extension for 1 min at 72°C, for 45 cycles followed by a final 
extension for 5 min at 72°C. PCR product was analyzed by gel electrophoresis on 1.5% agarose in 
TAE buffer and visualized under UV [438]. 
Quantitative Real-Time PCR 
Following reverse transcription, quantitative real-time PCR (qPCR) was performed with 
LightCycler® SYBR green technology (Roche). cDNA equivalent to 80 ng in each well was 
subjected to amplification with specific primers. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was selected as an internal control to normalize the amount of cDNA in each well. The 
sequences of real-time primers (5′→3′) used for SVCT2 were: forward: 
CCAGCGGTGAGCAGGACAAT, reverse primer: TAGGGCCACCGTGGGTGTAA, GAPDH: 
forward—ATCCCTCCAAAATCAAGTGG and reverse—GTTGTCATGGATGACCTTGG. A 
preliminary experiment was performed to ensure that SVCT2 and GAPDH were amplified with 
equal efficiencies. The specificity of these primers was also confirmed with melting-curve 
analysis. The comparative threshold method was applied to calculate the relative amount of 
SVCT2 in HCEC and D407 cells [438, 532]. 
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Data Analysis 
Radioactive Sample Analysis 
 Uptake of [14C] AA was calculated using disintegrations per minute (DPM) of sample and 
donor solutions as represented in Eq. 1 
𝑪𝒔𝒂𝒎𝒑𝒍𝒆 =
𝑫𝑷𝑴𝒔𝒂𝒎𝒑𝒍𝒆 ∗ 𝑪𝒅𝒐𝒏𝒐𝒓
𝑫𝑷𝑴𝒅𝒐𝒏𝒐𝒓
                                                      𝐄𝐪. 𝟏 
  DPMsample and DPMdonor represent average values of DPM counts of sample and donor 
respectively (n=4); Cdonor denotes concentration of donor used and Csample represents the 
concentration of sample. 
Calculation Of Michaelis-Menten Kinetic Parameters 
In order to determine Km and Vmax associated with [
14C] AA uptake, concentration-
dependency data was fitted to a modified Michaelis–Menten equation (Eq.2) 
𝒗 =
𝑽𝒎𝒂𝒙[𝑪]
𝑲𝒎 + [𝑪]
+ 𝑲𝒅[𝑪]                                                                                      𝐄𝐪. 𝟐 
  v represents the total uptake, Vmax stands for the maximum uptake rate for the carrier-
mediated process, Km is Michaelis–Menten constant which represents the concentration at half 
saturation, Kd is a non-saturable diffusion rate constant and C is substrate concentration. In Eq. 
(2), (Vmax*C)/(Km+C) represents carrier mediated saturable process whereas Kd(C) gives the non-
saturable diffusion component. Data was fitted to a non-linear least-square regression analysis 
program (GraphPad Prism 5.0). Michaelis Menten kinetic parameters were calculated to determine 
saturable and non-saturable component of the total uptake. 
Calculation Of Hill Ratio 
Na+:L-Ascorbic acid coupling ratio was determined using the logarithmic form of the Hill 
equation (Eq. 3) 
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𝑳𝒐𝒈 [
𝒗′
𝑽𝒎𝒂𝒙
− 𝒗′] = 𝒏𝒍𝒐𝒈(𝑺) − 𝒍𝒐𝒈𝑲′                                                           𝐄𝐪. 𝟑 
  v’ denotes initial velocity, Vmax represents the maximal velocity, n is number of substrate 
binding sites, S denotes the substrate concentration, and K’ is a constant comprising multiple 
interaction factors and intrinsic dissociation constant. 
Statistical Analysis 
All the experiments were conducted at least in quadruplicate (n=4) and the outcomes were 
expressed as mean±standard deviation (SD). To calculate statistical significance, student’s t test 
was performed. Any difference between mean values is considered statistically significant for P 
value ≤0.05. 
Results 
Time And Temperature Dependency 
Time dependent uptake of [14C] AA (29.4µM) in HCEC and D407 cells is depicted in 
Fig.6.1. Linear uptake of [14C] AA was noticed upto 60 min of incubation period. Therefore, 30 
min uptake time was selected for further uptake experiments.  
Effect of temperature on the uptake of AA by HCEC and D407 cells was studied. Fig.6.2 
clearly depicts that the uptake of [14C] AA in HCEC and D407 cells was maximal at 37 °C. Uptake 
of [14C] AA in HCEC shows 45% and 80% decrease when the temperature was reduced to 25°C 
and 4°C respectively. In D407 cells, uptake was reduced to 60% and 20% when measured at 25°C 
and 4°C respectively, suggesting that the process may be carrier mediated in both cell lines. 
Activation energy (Ea) was calculated by plotting the temperature dependent data i.e. Uptake rate 
Ln(v) vs. 1/T (Fig.6.3) Ea was calculated to be 7.80 kcal/mol and 7.23 kcal/mol in HCEC and 
D407 cells respectively. 
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Fig.6.1: Time course of [14C] AA uptake across HCEC and D407 cells. Uptake of [14C] ascorbic 
acid ([14C] AA) was measured in DPBS buffer (pH 7.4) at 37ºC. Data is shown as mean±S.D. n=4. 
S.D. means standard derivation. 
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Fig.6.2: Temperature dependent uptake study of [14C] AA uptake across HCEC and D407 cells in 
DPBS (pH 7.4). The uptake is expressed as percentage of control (37°C). Data is shown as 
mean±S.D. n=4. Asterisk (*) represents significant difference from the control (*p<0.05, 
**p<0.01). 
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Fig.6.3: Arrhenius plot of the effect of temperature on [14C] AA uptake across HCEC and D407 
cells. Uptake of [14C] AA was measured in DPBS buffer (pH 7.4) for 30min at 37, 25 and 4°C, 
across HCEC and D407 cells. Data is shown as mean±S.D. n=4 
pH And Ion Dependency 
In order to determine the role of an inward driven proton gradient for [14C] AA uptake, the 
study was carried out at different pH ranging from 5-8 in HCEC and D407 cells. Uptake of [14C] 
AA elevated with a rise in extracellular pH from 5 to 8 in both cell lines. Relative to pH 7.4, uptake 
of [14C] AA diminshed to 40% and 50% at pH 5 and 6 respectively in HCEC and D407 cells 
(Fig.6.4). Based on these results, further uptake studies were carried out at pH 7.4 with both the 
cell lines.  
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Fig.6.4: Effect of pH on [14C] AA uptake across HCEC and D407cells. Uptake of [14C] AA was 
determined in the presence of different pH (5.0, 6.0, 6.5, 7.4 and 8.0) at 37°C for 30 min across 
HCEC and D407 cells. The uptake is expressed as percentage of control (pH 7.4). Data is shown 
as mean±S.D. n=4. (*p<0.05, **p<0.01). 
Uptake of [14C] AA was reduced to 35% and 50% respectively, in HCEC and D407 cells, 
in the presence of sodium-free media. Similarly uptake of AA was also diminished to 50% and 
60% in HCEC and D407 cells, in the presence of amiloride (Na+ transport inhibitor) indicating 
possible involvement of sodium ions in the translocation of AA (Fig.6.5).  
The effect of chloride ions was studied by replacing chloride ions with equimolar quantities 
of other monovalent cations in DPBS. A marked reduction (40% and 45%) in the uptake rate of 
[14C] AA was observed in the absence of chloride ions in HCEC and D407 cells respectively. This 
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study clearly delineates the involvement of sodium and chloride ions in active transport of AA 
(Fig.6.5). 
 
Fig.6.5: Uptake of [14C] AA across HCEC and D407 cells in the presence of amiloride and absence 
of sodium and chloride ions in DPBS buffer (pH 7.4) at 37°C. (*p<0.05, **p<0.01). 
Kinetics of AA in HCEC and D407 cells were also evaluated with various concentrations 
of sodium (0-140mM) in the DPBS. Elevated uptake of [14C] AA was observed with higher Na+ 
concentrations. Uptake data demonstrated saturation kinetics displaying the saturation of [14C] AA 
uptake at about 70 mM of Na+ concentration in both HCEC and D407 cells (Fig.6.6). Hill 
transformation of the Na+ saturation kinetics data showed 2:1 molar ratio of Na+:AA coupling in 
both cell lines (Fig.6.7). 
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Fig.6.6: Uptake of [14C] AA across HCEC and D407 cells as a function of sodium concentration 
in DPBS (pH 7.4) at 37°C. Data is shown as mean±S.D. n=4. 
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Fig.6.7: Hill plot of sodium-dependent uptake of [14C] AA across HCEC and D407 cells. 
Concentration Dependency 
Michaelis Menten saturation kinetics of AA uptake were investigated by incubating HCEC 
and D407 cells with various concentrations (0.12-1000µM) of unlabeled AA for 30 min at 37°C. 
The uptake process involves both the saturable carrier mediated pathway and non-saturable 
diffusional process in both HCEC and D407 cells.  
Uptake study performed at 4°C clearly delineated the passive diffusion component from 
the AA transport in both HCEC and D407 cells. The carrier mediated process of AA uptake in 
both the cell lines was plotted as the difference of total uptake of AA at 37°C and passive uptake 
of AA at 4°C. Uptake of [14C] AA in HCEC cells was found to be concentration-dependent and 
saturable with Km and Vmax values of 46.14±6.03 μM and 17.34±0.58 pmol/mg protein/min, 
respectively (Fig.6.8 and Table 6.1).  
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The kinetic parameters (Km and Vmax) estimated for D407 cells were higher than those 
observed with HCEC, although similar saturation kinetics plot was observed in D407 cells. The 
Km and Vmax values obtained from the saturation kinetics plot for D407 cells were 47.26±3.24 μM 
and 31.86±0.56 pmol/mg protein/min, respectively (Fig.6.9 and Table 6.1).  
Lineweaver-Burk (1/v vs. 1/[S]) plot, indicate the involvement of a single carrier in the 
uptake process of AA across HCEC and D407 cell lines (Fig.6.10). 
 
Fig.6.8: Concentration-dependent uptake of [14C] AA across HCEC cells. Data is shown as 
mean±S.D. n=4 (● represents total uptake, ▲ represents passive uptake/non-saturable component 
and ■ represents carrier mediated uptake/saturable component) 
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Fig.6.9: Concentration-dependent uptake of [14C] AA across D407 cells. Data is shown as 
mean±S.D. n=4 (● represents total uptake, ▲ represents passive uptake/non-saturable component 
and ■ represents carrier mediated uptake/saturable component) 
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Table 6.1: Michaelis–Menten kinetic parameters (Vmax and Km) and catalytic efficiency (Vmax/Km) 
estimated for SVCT2 transporter system in HCEC and D407 cell lines. Units of Km: micromolar 
(µM), Vmax: pmoles/mg protein/min and Vmax/Km: µl/mg protein/min. 
 
Kinetic Parameters of SVCT2 HCEC D407 
Km 46.14±6.03 47.26±3.24 
Vmax 17.34±0.58 31.86±0.56 
Vmax/Km 0.37 0.67 
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Fig.6.10: Lineweaver–Burk transformation of the data demonstrated involvement of a single 
carrier mediated process for the uptake of [14C] AA across HCEC and D407 cells. 
Role Of Metabolic And Membrane Transport Inhibitors 
In order to delineate the effect of metabolic inhibitors on [14C] AA uptake in both HCEC 
and D407 cells, uptake studies were carried out in the presence of metabolic inhibitors such as 
ouabain (Na+/K+ ATPase inhibitor), sodium azide (oxidative phosphorylation inhibitor), and 2,4-
DNP (intracellular ATP reducer). In the presence of these metabolic inhibitors, a significant 
reduction (40 to 60%) in the uptake of [14C] AA was observed (Fig 6.11). 
Further investigations were carried out in HCEC and D407 cells to investigate the effect of 
membrane inhibitors (SITC, DIDS and probenecid) on [14C] AA uptake. AA uptake was reduced 
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to 40% in the presence of SITC, DIDS and probenecid, showing the involvement of an anion 
exchanger in carrier mediated transport of [14C] AA (Fig.6.12). 
 
Fig.6.11: Uptake of [14C] AA across HCEC and D407 cells in the presence of 1 mM concentrations 
of metabolic inhibitors: ouabain, sodium azide, and 2,4-DNP. [14C] AA uptake was performed at 
37°C with DPBS buffer (pH 7.4) for 30 min. Data is shown as mean±S.D. n=4. (*p<0.05, 
**p<0.01). 
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Fig.6.12. Uptake of [14C] AA across HCEC and D407 cells in the presence of 1 mM concentrations 
of membrane inhibitors: SITC, DIDS and probenecid. [14C] AA uptake was performed at 37°C 
with DPBS buffer (pH 7.4) for 30 min. Data is shown as mean±S.D. n=4. (*p<0.05, **p<0.01). 
Substrate Specificity 
With increasing concentration (250, 500 and 1000 µM) of AA structural analogs, [14C] AA 
uptake in HCEC and D407 cells was significantly inhibited in the presence of L-AA and D-Iso 
AA whereas no significant change in the uptake of [14C] AA was observed in DHAA. Also, no 
significant change in the uptake of [14C] AA was observed in the presence of structurally unrelated 
analogs i.e. glucose and PAHA (250, 500 and 1000 µM) in both the cell lines (Fig.6.13). 
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Fig.6.13. Uptake of [14C] AA in presence of L-ascorbic acid (L-AA), D-isoascorbic acid (D-Iso 
AA), dehydro ascorbic acid (DHAA), D-glucose, and para-amino hippuric acid (PAHA) at three 
different concentrations across HCEC and D407 Cells. [14C] AA uptake was performed at 37°C 
with DPBS buffer (pH 7.4) for 30 min. Data is shown as mean±S.D. n=4. (*p<0.05, **p<0.01). 
Intracellular Regulation 
The role of different cellular regulation pathways on [14C] AA uptake was also 
investigated. With increasing concentrations of calmidazolium and KN-62 ( modulators of 
Ca++/calmodium (Ca++/CaM) pathway), reduced uptake of [14C] AA ranging from 25-41% and 27-
41% respectively in HCEC, and, 20-47% and 20-40% respectively in D407 cells were observed. 
PKC activator, PMA (10-100 µM), significantly inhibited uptake of AA in the HCEC and D407 
 182 
 
cells. Inhibitory effect of PMA was muted in both the cell lines by BIS (25-100 µM).  Involvement 
of a PKA-mediated pathway in the regulation of [14C] AA uptake was also examined by evaluating 
the effects of substrates at various concentrations. These compounds are known to induce 
intracellular cAMP levels (IBMX and forskolin) thus activating PKA in HCEC and D407 cells. 
Concentration dependent effect on the reduction of [14C] AA uptake was evident in the presence 
of IBMX and forskolin, indicating the involvement of cAMP regulated PKA pathways in AA 
transport.  Similarly, we examined the contribution of the PTK pathway on [14C] AA uptake by 
incubating cells with genistein and tyrphostinA25 for 1 hour. Significant inhibition was observed 
on the uptake of AA with genistein and tyrphostinA25 (modulators of PTK-mediated pathway) 
across HCEC and D407 cells (Table 6.2).  
Table 6.2:  Uptake of [14C] AA across HCEC and D407 cells in the presence of various 
concentrations of Ca++/calmodulin pathway, PKC pathway, PKA pathway and PTK pathway 
modulators in DPBS (pH 7.4) at 37 °C. The uptake is expressed as percentage of control (DPBS). 
Data is shown as mean±S.D. n=4. (*p<0.05, **p<0.01). 
Pathways Modulators Uptake as % of Control 
  HCEC D407 
 
 
 
Ca++/Calmodulin 
Pathway 
Control 100±0.26 100±1.09 
CaM (10µM) 41.02±4.03** 47.31±1.43** 
CaM (50µM) 39.35±7.18** 35.43±3.91** 
CaM (100µM) 25.06±0.87** 20.54±2.28** 
KN-62 (0.1µM) 51.19±5.48** 40.43±5.22** 
KN-62 (1µM) 36.33±3.71** 30.92±4.78** 
KN-62 (10µM) 27.75±2.50** 20.42±2.76** 
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PKC Pathway 
Control 100±4.25 100±4.91 
PMA (10µM) 50.19±5.56** 58.21±4.35** 
PMA (50µM) 46.47±3.83** 50.87±1.29** 
PMA (100µM) 45.43±17.43** 43.67±5.48** 
PMA (100µM) + BIS (25µM) 91.2±5.32 90.34±2.95 
PMA (100µM) + BIS (50µM) 93.85±3.49 92.69±3.45 
PMA (100µM) + BIS (100µM) 95.34±6.84 95.73±5.85 
    
 
 
 
PKA Pathway 
Control 100±3.24 100±2.65 
IBMX (0.1µM) 38.52±2.20** 43.67±3.12** 
IBMX (1µM) 34.42±3.16** 37.77±1.87** 
IBMX (5µM) 28.12±3.11** 30.43±5.21** 
Forskolin (1µM) 37.87±1.15** 35.63±2.35** 
Forkolin (10µM) 31.84±9.97** 33.22±4.98** 
Forskolin (50µM) 27.29±2.60** 30.87±3.65** 
Forskolin (100µM) 23.89±0.35** 20.89±5.44** 
    
 
 
 
PTK Pathway 
Control 100±3.24 100±2.65 
Genistein (10µM) 60.39±2.36* 53.41±2.43* 
Genistein (50µM) 48.47±4.83** 42.73±1.94** 
Genistein (100µM) 37.43±7.43** 33.47±3.68** 
Tyrphostin A25 (10µM) 55.23±6.59* 60.43±4.59* 
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Tyrphostin A25 (50µM) 44.85±1.84** 41.96±7.23** 
Tyrphostin A25 (100µM) 32.34±5.39** 35.36±2.58** 
 
Reverse Transcription–Polymerase Chain Reaction Analysis 
 For confirmation of the existence of AA transport system (SVCT) in HCEC and D407 
cells, RT-PCR analysis was carried out. Agarose gel electrophoresis using ethidium bromide was 
employed to analyze the PCR product. PCR amplification of cDNA produced from total RNA was 
done with primers specific for a human SVCT system. The PCR product obtained at 626 bp 
confirms the expression of the AA transport system (SVCT2) on HCEC as well as D407 cells 
(Fig.6.14). 
Quantitative Real-Time PCR Analysis 
RNA extraction and cDNA synthesis were carried out according to published protocol 
[333]. Quantitative estimates of the relative abundance of SVCT2 mRNA were obtained with 
qPCR analysis. mRNA levels of SVCT2 were analyzed in HCEC and D407 cells. Expression of 
SVCT2 mRNA in D407 was significantly higher relative to HCEC (Fig 6.15). 
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Fig.6.14: RT-PCR studies showing the molecular evidence of SVCT2 in HCEC and D407 cells. 
Lane 1 and 3 represents 100 bp molecular ladder and lane 2 and 4 represents 626 bp PCR product 
obtained from HCEC and D407 cells. 
 186 
 
 
Fig.6.15: Real time-PCR comparing the expression of SVCT2 in HCEC and D407 cells. Data is 
shown as mean±S.D. n=4. (*p<0.05, **p<0.01). 
Discussion 
AA (vitamin C) is a vital cellular nutrient responsible for normal metabolic and 
physiological functions. Due to their biosynthetic limitation, distribution of AA between extra- 
and intra-cellular fluids in all cells is strictly reliant on absorption through functional vitamin C 
transporters [533]. AA is present in highest concentration in ocular tissues and aqueous humor to 
protect retinal cells and lens from the deleterious effects of sunlight [534]. AA is responsible for 
absorption of 99.96% of radiation even before it reaches the lens [527]. Anti-cataract role of 
ascorbic acid justifies the presence of high ascorbic acid levels in aqueous humor. All these 
biological progressions put emphasis on having a thorough understanding of the mechanism of 
AA transport in ocular tissues [535, 536].  
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In the present study, we have evaluated the AA uptake process, as well as the expression, 
contribution, and regulation of the SVCT2 across HCEC and D407 cells.  Recently, in vitro culture 
models have been applied as prized tools to predict ocular drug permeation. These cell culture 
models have provided a platform for additional investigation on ocular drug delivery in lieu of in 
vivo studies. Evaluation of drug transport across ocular tissues has been traditionally done utilizing 
primary cultures of rabbit corneal (rPCEC) and human retinal pigment epithelial (ARPE-19). 
[537]. Unlike primary cultures, immortalized cell cultures can be subcultured many times without 
losing their metabolic and physiological characteristics including enzymatic activity and 
cytoskeletal polarization. These immortalized human ocular cell culture models have been utilized 
for cell biology, toxicity, ocular irritancy, drug delivery, drug permeability and transport studies 
[438, 537]. 
Time course of AA uptake showed the linear uptake till 60 min. Hence, an incubation time 
of 30 min is selected for further uptake studies in HCEC as well as D407 cells (Fig.6.1). AA uptake 
process appears to be temperature dependent with significant rapid rate at physiological 
temperature (37ºC) in comparison to 25ºC and 4ºC. Rise in pH results in enhanced uptake of AA 
(Figs. 6.2 & 6.3). Since the pKa1 of AA is 4.17, it exists primarily in ascorbate form (-1 charge) 
above the pH range of 5.0. As a result AA enhanced uptake with increase in pH may not be due to 
the ionic state of AA. It can be concluded from pH dependency results that SVCT2 shows higher 
affinity towards ascorbate at higher pH (Fig.6.4) [451, 463]. Ion–ion and/or ion–polarity 
interactions between SVCT and its substrates are the major forces responsible for the binding of 
SVCT2 with the ionized form of AA. At lower pH, protonation of histidine residues reduces the 
binding affinity of SVCT2 with its substrates [463].  
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In the absence of sodium and chloride ions, lower A uptake was noticed confirming that 
SVCT2 transporter system may be highly sodium and chloride dependent (Fig.6.5).  Moreover, 
presence of amiloride (a Na+ transport inhibitor) caused significant inhibition to AA uptake 
demonstrating that the transport system is highly sodium dependent (Fig.6.5). Transmembrane 
sodium gradient as well as the membrane potential are responsible for the uphill transport of 
SVCT2 substrates [458]. Hence, we studied whether the carrier mediated transport of AA via 
SVCT2 is coupled with the electrochemical gradient of Na+ ions in HCEC and D407 cells. In both 
cell lines, elevated uptake of AA was observed with rising concentrations of Na+ in the uptake 
buffer and was found to be saturated at higher concentrations. This results suggest that AA is 
coupled to Na+ and transported directly via SVCT2 (Fig.6.6). The Hill ratio analysis indicates that 
approximately two sodium ions (1.9 for HCEC and 2.3 for D407) are required for translocation of 
each AA molecule (Fig.6.7). 
Concentration dependency of AA uptake clearly reveals that the carrier mediated process 
is saturable at higher concentrations of unlabeled AA. In order to distinguish the passive diffusion 
component from the active AA transport, uptake study was carried out at 4ºC in both HCEC and 
D407 cells.  AA uptake was found to be saturable with Km and Vmax values of 46.14±6.03 μM and 
17.34±0.58 pmol/mg protein/min, respectively in HCEC cells and Km and Vmax values of 
47.26±3.24 μM and 31.86±0.56 pmol/mg protein/min, respectively in D407 cells (Figs. 6.8 & 6.9). 
Michaelis Menten kinetic parameters (Km and Vmax) are two important parameters responsible for 
defining the functional and kinetic constants of a transporter. Km defines the measure of apparent 
binding affinity of a substrate whereas Vmax represents a measure of translocation capacity of the 
carrier-mediated process. On the basis of Michaelis Menten kinetics, the Km value of SVCT2 was 
found to be similar in both HCEC and D407 cells, indicating a similar binding strength and affinity 
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of AA with both the cell lines. However comparison of Vmax values of SVCT2 for both cell lines 
suggest that transport capacity of SVCT2 in D407 cells is higher relative to HCEC cells 
(31.86±0.56 vs 17.34±0.58 pmol/mg protein/min). Catalytic efficiency of SVCT2 was estimated 
by the ratio of Michaelis Menten kinetic parameters (Vmax/Km). A variation in Vmax values results 
in higher transport efficiency (Vmax/Km) of SVCT2 for D407 (0.67 μl/mg protein/min) than HCEC 
(0.37 μl/mg protein/min) (Table 6.1). These kinetic parameters indicate possible involvement of 
a carrier mediated transport system for the translocation of AA in HCEC and D407 cell lines. 
When the kinetic data was plotted in the form of Lineweaver-Burk (1/v vs. 1/[S]) plot, a single 
line was obtained for HCEC and D407 cell respectively, which suggests the involvement of a 
single transporter for the translocation of AA across human corneal and retinal cells (Fig.6.10). 
These Michaelis Menten kinetic parameters of SVCT2 in D407 cells were in accordance with 
previously published reports showing the presence of SVCT2 across human RPE cells [531].  
AA uptake was significantly inhibited in HCEC and D407 cells in the presence of 
metabolic inhibitors such as sodium azide (oxidative phosphorylation inhibitor), 2,4-dinitrophenol 
(intracellular ATP reducer) and ouabain, (a known Na+/K+ ATPase inhibitor). These results 
confirms that the uptake of AA via SVCT2 is highly dependent on energy and directly coupled to 
ATP energy sources (Fig.6.11). Uptake of AA was also significantly inhibited in the presence of 
various membrane/anion inhibitors such as DIDS, SITC, and probenecid (Fig.6.12). Similar 
reports involving inhibition of AA uptake by membrane inhibitors has been published [460, 462]. 
These results indicate that uptake of AA is altered by the presence of specific anions and the site 
of the SVCT2 transport system may be the plasma membrane [460, 462].  
In HCEC and D407 cells, concentration dependent inhibition in SVCT2 mediated AA 
uptake was revealed in the presence of structural analogs of AA i.e. L-AA and D-Iso AA. No 
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significant inhibition in the SVCT2 mediated AA uptake was observed in the presence of DHAA 
(structural analog and GLUT substrate), glucose (GLUT substrate) and PAHA (OAT substrate) 
(Fig.6.13). Similar results with respect to substrate specificity have been published from our 
laboratory [462, 538]. These results in rabbit corneal epithelial cells corroborate our findings in 
HCEC and D407 cells. Due to a lack of 3D structure of SVCT2 transporter, it is difficult to 
postulate about structural requirements for the binding of SVCT2 with its substrates at this time 
and further investigations are required to address the issue. 
Several intracellular regulatory pathways such as Ca++/calmodulin, PKA, PTK and PKC 
are involved in the regulation of expression sodium-ascorbate cotransporters [462]. Five putative 
PKC phosphorylation sites in hSVCT1 and hSVCT2 and one additional PKA site in hSVCT1 have 
been identified based on the analysis of deduced primary amino acid sequence of SVCT [463]. It 
has also been reported that the uptake of AA mediated by SVCT2 expressed in COS-1 and MDCK-
MDR1 cells was under the regulation of PKC-mediated pathway [462, 539]. For this reason, we 
investigated the regulation of AA uptake by inter- and intra-cellular protein kinase-mediated 
pathways. Significant inhibition in the presence of calmidazolium and KN-62 in HCEC and D407 
cells was observed, leading to a hypothesis that the AA uptake process is under the regulation of 
Ca++/CaM mediated pathway. Treating both the cell lines with PMA led to a significant lowering 
in AA uptake, indicating the role of PKC-mediated pathway on the regulation of AA uptake. Also, 
addition of BIS (PKC pathway inhibitor) reverses the inhibitory effect of PMA signifying the 
contribution of PKC pathway in controlling this uptake process.  
On the other hand, significant inhibition on AA uptake by IBMX and forskolin treated 
HCEC and D407 cells confirms that PKA-mediated pathway plays a vital role in SVCT2 mediated 
uptake of AA. Significant inhibition was observed in presence of PTK pathway modulators 
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(genistein and tyrphostin A25) showing a possible role of PTK pathway in intracellular regulation 
of AA (Table 6.2). Molecular mechanism by which the protein kinase and calmodulin pathway 
exert their effect on AA uptake process is yet to be fully established.  
Finally, RT-PCR analysis confirms the molecular evidence of a vitamin C/AA specific 
carrier system in HCEC and D407 cells. The PCR product obtained at 626 bp is specific for the 
SVCT2 transporter system (Fig.6.14). qPCR analysis revealed that the expression of SVCT2 was 
significantly higher in D407 in comparison to HCEC cells (Fig.6.15). Higher expression of SVCT2 
in D407 provides the justification of greater catalytic transporter efficiency of SVCT2 in D407 
relative to HCEC cells. 
Conclusion 
In summary, this study clearly delineates the detailed study of functional activity and 
molecular evidence as well as the expression, contribution, and regulation of the sodium-
dependent vitamin C transporter 2 (SVCT2) across HCEC and D407 cell lines. AA uptake across 
HCEC and D407 cells involves a carrier-mediated active process that is modulated by both protein 
kinases as well as Ca++/CaM mediated pathways. This transporter is highly pH dependent and 
requires coupling to an electrochemical Na+ gradient and ATP sources for cellular uptake of AA.  
This membrane transporter (SVCT2) can be utilized as a potential target for enhancing ocular 
bioavailability of AA conjugated prodrugs. This investigation demonstrates complete profiling of 
SVCT2 mediated AA uptake showing its dependence on calmodulin, protein kinases and 
intracellular ions. Also, HCEC and D407 cell line can be utilized as a valuable in vitro model than 
primary culture models to investigate ocular drug absorption of AA-conjugated therapeutics. 
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CHAPTER 7 
MOLECULAR EXPRESSION AND FUNCTIONAL ACTIVITY OF VITAMIN C SPECIFIC 
TRANSPORT SYSTEM (SVCT2) IN HUMAN BREAST CANCER CELLS 
Rationale 
In United States, 1 in 8 women develop breast cancer during their lifespan. In 2013 about 
232,340 new cases of breast cancer were diagnosed among American women. Breast cancer 
represents 14.1% of all new cancer cases in the U.S (cancer.gov-recent statistics). Although, 
chemotherapy has shown promising results in treating breast cancer, it frequently leads to systemic 
side effects. Also, acquired drug resistance has been reported due to the frequent use of multiple 
chemotherapeutic drugs during treatment of advanced breast cancer [77, 540]. During lactating 
period, breast epithelial cells are responsible for transport of amino acids and vitamins across cell 
membranes in order to meet the requirements of accelerated milk-protein synthesis. However, 
information is still limited with respect to transport of amino acids and vitamins across breast 
epithelial cells and its regulation in various biological and pathological progressions [541] [542, 
543]. Presence of efflux transporter proteins i.e., P-glycoprotein (P-gp or MDR1), multidrug 
resistance proteins (MRPs) and breast cancer resistance protein (BCRP) render drug delivery to 
the breast cancer cells at therapeutic doses highly challenging [77, 543-548]. In cancer patients, 
overcoming multidrug resistance by exploring strategies such as evasion or modulation of these 
efflux transporters may play a vital role [153, 154, 543]. Several reports suggested high level 
expressions of influx/nutrient transporters, such as biotin [543], nucleoside/nucleobase [549, 550], 
glucose [551], monocarboxylic acid [552, 553], folate [554, 555], organic anion and cation 
transporters [556] on various breast cancer cells. This information, in turn, facilitates the rational 
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design of novel anti-cancer therapeutic targeting a specific carrier mediated transporter expressed 
in breast cancer cells [557]. 
Ascorbic acid (AA, vitamin C) is an essential water-soluble vitamin required for 
physiological and metabolic functions.  It is an important nutrient required as a cofactor by various 
metabolic enzymes [558-561].  Efficacy of AA in cancer treatment has a controversial history 
[561, 562]. Many published reports described beneficial effects of AA in cancer treatment. AA 
has shown inhibitory effects on various cancer cells including breast, brain, prostate and stomach 
[561, 563-566]. Also, pharmacologic doses of AA, 10 g daily, showed effective results in the 
average survival of advanced cancer patients, improved patient well-being and reduced pain [561, 
567-570]. In human breast carcinoma cells, AA appears to potentiate the antineoplastic activity of 
doxorubicin, cisplatin, and paclitaxel [571]. AA plays an important role in enhancing natural 
immunity and may cause lowest toxicity of all the vitamins [570]. 
AA cannot be synthesized by human and other primates, thus making this vitamin an 
essential dietary requirement. Therefore, AA is usually obtained from exogenous sources through 
the dietary intake [462]. AA uptake via specific transport system has already been reported in 
intestine [453], brain [457], kidney [454], skin [461], eye [458, 459] and bone [460]. Human 
SLC23A2 family consists of two isoforms of sodium-dependent vitamin C transporters (SVCT) 
namely SVCT1 and SVCT2 [529]. A relative study of two isoforms discloses that AA exhibits 
higher structural and functional tropisms towards SVCT2 than SVCT1. Both SVCT1 and SVCT2 
vary in distribution but express close sequence homology and functional similarity [458]. 
Structural and functional studies reveal that transport of AA across epithelial cells is primarily 
facilitated via SVCT [458, 462].  
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Transporter targeted drug delivery, in recent years, has been widely explored to improve 
targeted drug delivery across biological membranes. An active agent is chemically modified with 
transporter targeted moieties, this bioreversible conjugate enhances drug permeation and 
absorption. Facilitated transport of conjugated drug interacts with targeting moiety and the 
transporter resulting in elevated absorption [437].  SVCT2 has been exploited by many 
investigators as an important target for drug delivery across epithelial membranes. Higher 
absorptive permeability and metabolic stability compared to saquinavir alone has been observed 
with AA conjugated saquinavir [530]. Conjugation of nipecotic, kynurenic and diclophenamic 
acids with AA has been employed to enhance transport of therapeutic agents. This approach has 
provided a new perspective for transporter/receptor targeted prodrug design targeted to SVCT2 
transporter [531]. Hence, SVCT targeted drug delivery can be utilized as a vital strategy for 
enhancing intracellular accumulation of anti-cancer in cancer cells. The aim of this study is to 
investigate the expression of a specialized carrier mediated transport system (SVCT2) on the 
epithelia of breast cancer cells (MDA-MB231, T47D and ZR-75-1).  
The presence of SVCT on corneal cells and Madin-Darby canine kidney cells has been 
previously reported from our laboratory [458, 462]. Also, SVCT expression was shown on breast 
cancer epithelial cells (MDA-MB231 and T47D cells). However, no information currently exists 
regarding mechanistic and functional processes as well as molecular expression of AA carrier 
mediated uptake by breast cancer cells. In the present study, we evaluated the ascorbic acid uptake 
process, kinetics as well as expression, relative contribution, and regulation of SVCT2 in MDA-
MB231, T47D and ZR-75-1 cells. Results obtained from this study may indicate involvement of a 
specific and high affinity carrier transport system (SVCT2) for translocation of AA. 
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Material And Methods 
Materials 
[14C] Ascorbic acid ([14C] AA specific activity 8.5 mCi/mM) was procured from Perkin 
Elmer (Boston, MA, USA). Unlabeled L-ascorbic acid, D-iso-ascorbic acid, dehydro-ascorbic acid 
(DHAA), glucose, para amino hippuric acid (PAHA), sodium azide, ouabain, 2,4-dinitrophenol, 
choline chloride, HEPES, bovine insulin, human epidermal growth factor, Triton X-100, phorbol-
12-myristate-13-acetate (PMA), bisindolylmaleimide I (BIS), 3-isobutyl-1-methylxanthine 
(IBMX), 4,4’-di-isothiocyanatostilbene- 2,2’-disulphonic acid (DIDS), 4-acetamido-4’- 
isothiocyanostilbene-2,2’-disulfonic acid (SITC), and D-glucose were purchased from Sigma 
Chemical Co (St. Louis, MO, USA). Culture media (Dulbecco’s modified Eagle’s medium 
(DMEM), RPMI 1640 culture medium and DMEM/F-12) were procured from Invitrogen 
(Carlsbad, CA, USA). Fetal bovine serum (FBS) was obtained from Atlanta biologicals 
(Lawrenceville, GA, USA). Culture flasks (75 cm2 growth area) and uptake plates (3.8 cm2 growth 
area) were purchased from Corning Costar Corp. (Cambridge, MA, USA). The buffers for cDNA 
synthesis and amplification (oligodT, dNTP, MgCl2, M-MLV reverse transcriptase and Taq 
polymerase) were obtained from Promega Corporation (Madison, WI, USA). Light Cycler 480® 
SYBR I green master mix was obtained from Roche Applied Science (Indianapolis, IN, USA). 
Qualitative and quantitative primers used in the study were custom-designed and obtained from 
Invitrogen Life Technologies (Carlsbad, CA, USA). All other chemicals were obtained from Fisher 
Scientific Co. (Fair Lawn, NJ, USA) and utilized without further purification. 
Cell Culture 
T47D cells were obtained from American Type Culture Collection (ATCC). MDA-MB-
231 and ZR-75-1 cells were generous gifts from Dr. Walter Jäger University of Vienna, Austria) 
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and Dr. A.J. van Agthoven (Josephine Nefkens Institute, Netherlands), respectively. T47D cells 
were cultured according to a previously published protocol [543]. Cells of passage numbers 
between 20 and 30 were cultured at 37°C, humidified 5% CO2/95% air atmosphere in a DMEM 
culture medium supplemented with 10% (v/v) FBS (heat inactivated), 1% nonessential amino 
acids, 20 mM HEPES, 29 mM sodium bicarbonate, 100 mg of penicillin and streptomycin. 
 ZR-75-1 cells were cultured at 37°C, humidified 5% CO2/95% air atmosphere in a RPMI 1640 
culture medium supplemented with 10% (v/v) FBS (heat inactivated), 29 mM NaHCO3, 20 mM 
HEPES, 100 mg of penicillin and streptomycin each, and 1 nM estradiol. (0.5 ml/ 500 ml medium) 
at pH 7.4 [514, 515]. The growth medium was changed every alternate day.  
MDA-MB-231 cells were cultured at 37°C, humidified 5% CO2/95% air atmosphere in a 
DMEM/F12 culture medium supplemented with 10% (v/v) FBS, 29 mM NaHCO3, 20 mM 
HEPES, 100 mg of penicillin and streptomycin each. 
All breast cancer cell lines were cultured in 75 cm2 flasks, harvested at 80–90% confluency 
with TrypLE™ Express (Invitrogen, Carlsbad, CA, USA). Cells were then plated in 24-well uptake 
plates at a density of 300,000 cells/well. Cells were grown in a similar way as mentioned above 
and utilized for additional studies. 
Uptake Studies 
Confluent breast cancer cells were employed for uptake experiments. Following media 
removal, cells were rinsed thrice for 5 min each with 1–2 ml of Dulbecco’s phosphate-buffered 
saline (DPBS) containing 140 mM NaCl, 0.03 mM KCl, 7.5 mM Na2HPO4, 1.5 mM KH2PO4, 1 
mM CaCl2, 0.5 mM MgSO4, 20 mM HEPES, and 5 mM glucose maintained at pH 7.4. Uptake 
studies were initiated by adding 250μl of solution containing 0.25 μCi/ml (29.4µM) of [14C] AA 
in the presence and absence of various competing substrates. Following specific period of 
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incubation, the solution was removed and uptake process was terminated with 2 ml of ice-cold 
stop solution containing 200 mM KCl and 2 mM HEPES. The cell monolayer was washed thrice, 
5 min each and 1ml of lysis buffer (0.1% Triton-X solution in 0.3% NaOH) was added to each 
well and plates were stored overnight at room temperature. Subsequently, the cell lysate (400μl) 
from each well was transferred to scintillation vials containing 3 ml of scintillation cocktail (Fisher 
Scientific, Fairlawn, NJ, USA). Samples were quantified by measuring the radioactivity using 
liquid scintillation spectrophotometer coulter (Beckman Instruments Inc., Fullerton, CA, USA, 
model LS-6500). Protein content of each sample was estimated by BioRad Protein Estimation Kit 
(BioRad Protein Estimation Kit, Hercules, CA, USA). 
Time And Temperature Dependency 
 The optimum time for uptake studies of [14C] AA were determined by performing the 
uptake studies over various time points (5, 10, 15, 30, 45 and 60 min). The uptake study was 
conducted as per method described earlier.  
 The effect of temperature on [14C] AA uptake was determined by carrying out the uptake 
study at different temperatures i.e. 4ºC, 25ºC and 37ºC. The buffer temperature was adjusted to 
4ºC, 25ºC and 37ºC prior to the initiation of [14C] AA uptake. 
pH And Ion Dependency 
The effect of pH on [14C] AA uptake was observed by adjusting the pH to 5, 6, 6.5, 7.4 and 
8. For delineating the role of sodium ions on [14C] AA uptake, sodium chloride (NaCl) and sodium 
phosphate dibasic (Na2HPO4) in DPBS were substituted with equimolar quantities of choline 
chloride and potassium phosphate dibasic (KH2PO4), respectively. Hill coefficient for uptake of 
AA as function of Na+ was determined. In a similar manner, buffer solution containing sodium 
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(140 mM), potassium (0.03 mM), and calcium (1 mM) chlorides were replaced with equimolar 
quantities of sodium phosphate, potassium phosphate, and calcium acetate, respectively.  
In another study, cells were pre-incubated with 1 mM amiloride (sodium channel inhibitor) 
and the uptake study was carried out as mentioned earlier. 
Concentration Dependency 
Several concentrations of L-AA were prepared ranging from (0.12-2000μM) in DPBS (pH 
7.4) and spiked with [14C] AA (29.4µM). The uptake studies were performed according to a 
previously described method [543]. The data was fitted to Michaelis-Menten equation as shown 
in section 3.2 and the maximum transport rate (Vmax) and Michaelis-Menten constant (Km) were 
calculated according to nonlinear least squares regression analysis program; GraphPad Prism 
version 5. 
Role Of Metabolic And Membrane Transport Inhibitors 
For energy dependency studies, simultaneous incubation of [14C] AA along with metabolic 
inhibitors such as ouabain (Na+/K+ ATPase inhibitor), 2,4-dinitrophenol (intracellular ATP 
reducer) and sodium azide (oxidative phosphorylation inhibitor) were performed for 1h. In order 
to examine the effect of anionic membrane transport inhibitors, cells were pre-incubated with 1mM 
SITC, DIDS and probenecid for 1h.  
Substrate Specificity 
The substrate specificity for SVCT was delineated by carrying out [14C] AA uptake in the 
presence of three concentrations of (500, 1000 and 2000µM) unlabeled L-AA and structural 
analogs such as D-Iso AA and DHAA. A similar study was carried out at three different 
concentrations of (500, 1000 and 2000µM) of various structurally unrelated analogs such as 
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glucose (Glucose transporter/GLUT substrate) and PAHA (organic anion transporter/OAT 
substrate). 
Intracellular Regulation 
Involvement of various intracellular regulatory pathways such as Ca++/calmodulin, PTK 
(protein tyrosine kinase), PKC (protein kinase C) and PKA (protein kinase A) pathway on [14C] 
AA uptake was also investigated. Cells were pre-incubated with modulators such as calmidazolium 
(CaM) and KN-62 to delineate the process. In order to examine the role of PTK pathway in [14C] 
AA uptake, cells were pre-incubated with genistin and tyrphostin A25. For studying the effect of 
PKC pathway, cells were pre-incubated with BIS and PMA (modulators of PKC pathway). The 
effect of PKA pathway was studied by incubating the cells with IBMX and forskolin (modulators 
of PKA pathway). Uptake of [14C] AA was then performed according to the procedure as 
previously described. 
Reverse Transcription–Polymerase Chain Reaction 
Reverse transcription– polymerase chain reaction (RT-PCR) analysis was carried out to 
determine the expression of SVCT2 on T47D, MDA-MD-231 and ZR-75-1 at molecular level. 
TRIzol® reagent (Invitrogen, USA) was used to perform cell lysis. Chloroform was added to the 
lysate for phase separation. Following separation of aqueous phase containing RNA, isopropanol 
was added to precipitate RNA which was rinsed twice with 75% ethanol followed by resuspension 
in RNase-DNase free water. The concentration and purity of RNA was determined with Nanodrop 
(Thermo Fisher Scientific, Wilmington, DE, USA). RNA was reverse-transcribed to obtain cDNA 
using oligodT as a template and M-MLV reverse transcriptase. The conditions for reverse 
transcription were: denaturation of the template RNA for 5 min at 70°C; reverse transcription for 
60 min at 42°C followed by final extension at 72°C for 5 min. cDNA obtained was then subjected 
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to PCR for amplification of SVCT using specific set of primers. Set of primers (5′→3′) designed 
for SVCT2 were: forward: CCAGCGGTGAGCAGGACAAT, reverse primer: 
TAGGGCCACCGTGGGTGTAA. These primers correspond to a 626 base pair (bp) product in 
human SVCT2 cDNA. The conditions of PCR amplification were: denaturation for 30 s at 94°C, 
annealing for 1 min at 56°C, and extension for 1 min at 72°C, for 45 cycles followed by a final 
extension for 5 min at 72°C. PCR product obtained was analyzed by gel electrophoresis on 1.5% 
agarose in TAE buffer and visualized under UV [438]. 
Quantitative Real-Time PCR 
Following reverse transcription, quantitative real-time PCR (qPCR) was performed with 
LightCycler® SYBR green technology (Roche). cDNA equivalent to 80 ng in each well was 
subjected to amplification with specific primers. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as an internal standard to normalize the amount of cDNA in each well. The 
sequences of real-time primers (5′→3′) used for SVCT2 were: forward: 
GCCAGCTAGGTCTTGACTCC, reverse primer: GATGTGGCGTAGACCTGTCC, GAPDH: 
forward—ATCCCTCCAAAATCAAGTGG and reverse—GTTGTCATGGATGACCTTGG. A 
preliminary experiment was performed to ensure that SVCT2 and GAPDH were amplified with 
equal efficiencies. The specificity of these primers was also confirmed by melting-curve analysis. 
The comparative threshold method was used to calculate the relative amount of SVCT2 in breast 
cancer cell lines [438, 532]. 
Data Analysis 
 Radioactive Sample Analysis 
 The uptake of [14C] AA was calculated using disintegrations per minute (DPM) of sample 
and donor solutions as shown in Eq. 1 
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𝑪𝒔𝒂𝒎𝒑𝒍𝒆 =
𝑫𝑷𝑴𝒔𝒂𝒎𝒑𝒍𝒆 ∗ 𝑪𝒅𝒐𝒏𝒐𝒓
𝑫𝑷𝑴𝒅𝒐𝒏𝒐𝒓
                                                      𝐄𝐪. 𝟏 
 
 where, DPMsample and DPMdonor represent average values of DPM counts of sample and 
donor (n=4) respectively; Cdonor denotes the concentration of donor used and Csample represents the 
concentration of sample. 
Calculation of Michaelis-Menten Kinetic Parameters 
In order to determine Km and Vmax associated with [
14C] AA uptake, concentration-
dependency data was fitted in a modified Michaelis–Menten equation as shown in Eq.2 
𝒗 =
𝑽𝒎𝒂𝒙[𝑪]
𝑲𝒎 + [𝑪]
+ 𝑲𝒅[𝑪]                                                                                      𝐄𝐪. 𝟐 
 
v represents the total uptake, Vmax stands for the maximum uptake rate for the carrier-
mediated process, Km is Michaelis–Menten constant which represents the concentration at half 
saturation, Kd is a non-saturable diffusion rate constant and C is substrate concentration. In Eq. 
(2), (Vmax*C)/(Km+C) represents carrier mediated saturable process whereas Kd(C) denotes the 
non-saturable component. Data was fitted to a non-linear least-square regression analysis program 
(GraphPad Prism 5.0). The Michaelis-Menten kinetic parameters were calculated to determine 
saturable and non-saturable component of the total uptake. 
 Calculation Of Hill Ratio 
Na+:L-Ascorbic acid coupling ratio was determined using the logarithmic form of the Hill 
equation (Eq. 3) 
𝑳𝒐𝒈 [
𝒗′
𝑽𝒎𝒂𝒙
− 𝒗′] = 𝒏𝒍𝒐𝒈(𝑺) − 𝒍𝒐𝒈𝑲′                                                           𝐄𝐪. 𝟑 
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v’ denotes initial velocity, Vmax represents the maximal velocity, n is number of substrate 
binding sites, S denotes the substrate concentration, and K’ is a constant comprising multiple 
interaction factors and the intrinsic dissociation constant. 
 Statistical Analysis 
All the experiments were conducted at least in quadruplicate (n=4) and the outcomes were 
expressed as mean±standard deviation (SD). To calculate statistical significance, student’s t test 
was applied and the difference between mean values is considered statistically significant for P 
value ≤0.05. 
Results 
Time And Temperature Dependency 
Time dependent uptake of [14C] AA (29.4µM)  in MDA-MB231, T47D and ZR-75-1 cells 
is depicted in Fig.7.1. Linear uptake of [14C] AA was noticed upto 60 min of incubation period. 
Therefore, 30 min uptake time was selected for all uptake experiments.  
Effect of temperature on the uptake of AA was studied on MDA-MB231, T47D and ZR-
75-1 cells. Uptake of [14C] AA in the three breast cancer cell lines was maximal at 37°C (Fig.7.2). 
Uptake of [14C] AA in MDA-MB231 showed ~40% and 70% decrease when the temperature was 
reduced to 25°C and 4°C respectively. In T47D cells, uptake was reduced to ~55% and 25% when 
measured at 25°C and 4°C respectively, whereas, in ZR-75-1 cells uptake of [14C] AA diminished 
to ~50% and 20% respectively, at 25°C and 4°C, suggesting that the process may be carrier 
mediated in all the studied breast cancer cell lines. Activation energy (Ea) was calculated by 
plotting the temperature dependent data i.e. Uptake rate Ln(v) vs. 1/T (Fig.7.3) Ea was calculated 
to be 8.08, 9.71 and 9.99 kcal/mol in MDA-MB231, T47D and ZR-75-1 cells respectively. 
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Fig.7.1: Time course of [14C] AA uptake across MDA-MB231, T47D and ZR-75-1 cells. Uptake 
of [14C] ascorbic acid ([14C] AA) was measured in DPBS buffer (pH 7.4) at 37ºC. Data is shown 
as mean±S.D. n=4. S.D. means standard derivation. 
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Fig.7.2: Temperature dependent uptake study of [14C] AA uptake across MDA-MB231, T47D and 
ZR-75-1 cells in DPBS (pH 7.4). The uptake is expressed as percentage of control (37°C). Data is 
shown as mean±S.D. n=4. Asterisk (*) represents significant difference from the control 
(*p<0.05). 
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Fig.7.3: Arrhenius plot of the effect of temperature on [14C] AA uptake across MDA-MB231, 
T47D and ZR-75-1 cells. Uptake of [14C] AA was measured in DPBS buffer (pH 7.4) for 30min 
at 37, 25 and 4°C, across MDA-MB231, T47D and ZR-75-1 cells. Data is shown as mean±S.D. 
n=4 
pH And Ion Dependency 
In order to delineate the role of an inward driven proton gradient for [14C] AA uptake, the 
study was carried out with pH ranging from 5-8 in MDA-MB231, T47D and ZR-75-1 cells. Uptake 
of [14C] AA elevated with a rise in extracellular pH from 5 to 8 in all cell lines. In comparison to 
pH 7.4, uptake of [14C] AA diminished to ~40% and 50% at pH 5 and 6 respectively in MDA-
MB231, T47D and ZR-75-1 cells (Fig.7.4). Based on these results, further uptake studies were 
carried out at pH 7.4 with all the cell lines.  
In sodium free media, uptake of [14C] AA was reduced to ~50%, 25% and 30% 
respectively, in MDA-MB231, T47D and ZR-75-1 cells (Fig.7.5). Similarly, uptake of AA was 
also diminished to ~%60, 50% and 50% in MDA-MB231, T47D and ZR-75-1 cells respectively 
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in the presence of amiloride (Na+ transport inhibitor), indicating possible involvement of sodium 
ions in translocation of AA (Fig.7.5).  
The effect of chloride ions was studied by replacing chloride ions with equimolar quantities 
of other monovalent cations in DPBS. A marked reduction (45%, 40% and 40%) in the uptake rate 
of [14C] AA was observed in the absence of chloride ions in MDA-MB231, T47D and ZR-75-1 
cells respectively. This study evidently defines the involvement of sodium and chloride ions in 
active transport of AA (Fig.7.5). 
 
Fig.7.4: Effect of pH on [14C] AA uptake across MDA-MB231, T47D and ZR-75-1 cells. Uptake 
of [14C] AA was determined in the presence of different pH (5.0, 6.0, 6.5, 7.4 and 8.0) at 37°C for 
30 min across MDA-MB231, T47D and ZR-75-1 cells. The uptake is expressed as percentage of 
control (pH 7.4). Data is shown as mean±S.D. n=4. (*p<0.05). 
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Fig.7.5: Uptake of [14C] AA across MDA-MB231, T47D and ZR-75-1 cells in the presence of 
amiloride and absence of sodium and chloride ions in DPBS buffer (pH 7.4) at 37°C. (*p<0.05). 
Role of sodium on AA absorption kinetics of AA was also evaluated with various 
concentrations of sodium (0-140mM) in the DPBS. Reduced uptake of [14C] AA was observed 
with lower Na+ concentrations. Uptake data displayed saturation kinetics of [14C] AA uptake at 
about 70 mM of Na+ concentration in MDA-MB231, T47D and ZR-75-1 cells (Fig.7.6). Hill 
transformation of Na+ saturation kinetics data showed 2:1 molar ratio of Na+:AA coupling in these 
breast cancer cell lines (Fig.7.7). 
 Concentration Dependency 
Breast cancer cells were incubated with various concentrations (0.12-2000µM) of 
unlabeled AA for 30 min at 37°C, in order to investigate Michaelis-Menten saturation kinetics. 
The uptake process involves both the saturable carrier mediated pathway and non-saturable 
diffusional process in all three breast cancer cell lines. Uptake of [14C] AA was reduced at 4°C 
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compared to 37°C indicating the role of passive diffusion component involved in AA transport in 
breast cancer cells. The carrier mediated process of AA uptake in breast cancer cell lines was 
plotted as the difference of total uptake of AA at 37°C and passive uptake of AA at 4°C. [14C] AA 
uptake in MDA-MB231 cells was found to be concentration-dependent and saturable with Km and 
Vmax values of 53.85±6.24 μM and 18.45±0.50 pmol/mg protein/min, respectively (Fig.7.8). The 
kinetic parameters (Km and Vmax) estimated for T47D and ZR-75-1 cells were also concentration 
dependent and saturable with a relatively lower Km and higher Vmax than MDA-MB231 cells. Km 
and Vmax values obtained from the saturation kinetics plot for T47D cells were 49.69±2.83 μM and 
32.50±0.43 pmol/mg protein/min (Fig.7.9), and for ZR-75-1 cell were 45.44±3.16 μM and 
33.25±0.53 pmol/mg protein/min respectively (Fig.7.10). Lineweaver-Burk (1/v vs. 1/[S]) plot, 
indicate the involvement of a single carrier in the uptake process of AA across these breast cancer 
cell lines (data not shown). 
 
Fig.7.6: Uptake of [14C] AA across MDA-MB231, T47D and ZR-75-1 cells as a function of 
sodium concentration in DPBS (pH 7.4) at 37°C. Data is shown as mean±S.D. n=4.  
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Fig.7.7: Hill plot of sodium-dependent uptake of [14C] AA across MDA-MB231, T47D and ZR-
75-1 cells. 
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Fig.7.8: Concentration-dependent uptake of [14C] AA across MDA-MB231 cells. Data is shown 
as mean±S.D. n=4 (● represents total uptake, ▲ represents passive uptake/non-saturable 
component and ■ represents carrier mediated uptake/saturable component) 
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Fig.7.9: Concentration-dependent uptake of [14C] AA across T47D cells. Data is shown as 
mean±S.D. n=4 (● represents total uptake, ▲ represents passive uptake/non-saturable component 
and ■ represents carrier mediated uptake/saturable component) 
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Fig.7.10: Concentration-dependent uptake of [14C] AA across ZR-75-1 cells. Data is shown as 
mean±S.D. n=4 (● represents total uptake, ▲ represents passive uptake/non-saturable component 
and ■ represents carrier mediated uptake/saturable component) 
Role Of Metabolic And Membrane Transport Inhibitors 
Uptake studies were carried out in the presence of metabolic inhibitors such as ouabain 
(Na+/K+ ATPase inhibitor), sodium azide (oxidative phosphorylation inhibitor), and 2,4-DNP 
(intracellular ATP reducer) in MDA-MB231, T47D and ZR-75-1 cells to delineate the effect of 
metabolic inhibitors on [14C] AA uptake. These metabolic inhibitors caused significant reduction 
(50% to 60%) in the uptake of [14C] AA was observed (Fig.7.11). 
Additional studies were carried out to investigate the effect of membrane inhibitors (SITC, 
DIDS and probenecid). AA uptake was also reduced to 35% to 45% in the presence of SITC, DIDS 
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and probenecid, suggesting a role of an anion exchanger in carrier mediated transport of [14C] AA 
(Fig.7.12). 
 
Fig.7.11: Uptake of [14C] AA across MDA-MB231, T47D and ZR-75-1 cells in the presence of 
metabolic inhibitors (ouabain, sodium azide, and 2,4-DNP). [14C] AA uptake was performed at 
37°C with DPBS buffer (pH 7.4) for 30 min. Data is shown as mean±S.D. n=4. (*p<0.05). 
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Fig.7.12. Uptake of [14C] AA across MDA-MB231, T47D and ZR-75-1 cells in the presence of 
membrane inhibitors (SITC, DIDS and probenecid). [14C] AA uptake was performed at 37°C with 
DPBS buffer (pH 7.4) for 30 min. Data is shown as mean±S.D. n=4. (*p<0.05). 
 Substrate Specificity 
[14C] AA uptake in these breast cancer cells was significantly inhibited in the presence of 
increasing concentration (500, 1000 and 2000µM) of structural analogs (L-AA and D-Iso AA) 
whereas no substantial alteration in the uptake was observed with DHAA. Also, presence of 
structurally unrelated analogs i.e. glucose and PAHA (500, 1000 and 2000µM) did not change the 
uptake of [14C] AA significantly (Fig.7.13). 
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Fig.7.13. Uptake of [14C] AA in presence of L-ascorbic acid (L-AA), D-isoascorbic acid (D-Iso 
AA), dehydro ascorbic acid (DHAA), D-glucose, and para-amino hippuric acid (PAHA) at three 
different concentrations across MDA-MB231, T47D and ZR-75-1 cells. [14C] AA uptake was 
performed at 37°C with DPBS buffer (pH 7.4) for 30 min. Data is shown as mean±S.D. n=4. 
(*p<0.05). 
Intracellular Regulation 
The role of different intracellular regulation pathways on [14C] AA uptake was also 
investigated. With higher concentrations of calmidazolium and KN-62 (modulators of 
Ca++/calmodium (Ca++/CaM) pathway), significantly reduced uptake of [14C] AA was observed in 
breast cancer cells. PKC activator, PMA (10-100 µM) also caused significant inhibition of AA 
uptake in all breast cancer cell lines. Inhibitory effect of PMA was muted by BIS (25-100 µM) 
across all breast cancer cells (Table 7.1).  
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Involvement of a PKA-mediated pathway in the regulation of [14C] AA uptake was 
examined by evaluating the effects of substrates at various concentrations. These compounds are 
known to induce intracellular cAMP levels (IBMX and forskolin) thus activating PKA in these 
cells. Concentration dependent effect on the reduction of [14C] AA uptake was evident with IBMX 
and forskolin, indicating the involvement of cAMP regulated PKA pathways in AA transport. 
Similarly, we examined the contribution of the PTK pathway on [14C] AA uptake by incubating 
cells with genistein and tyrphostinA25 for 1 hour. Significantly diminished uptake was observed 
in the presence of genistein and tyrphostinA25 (modulators of PTK-mediated pathway) across 
these cell lines (Table 7.1).  
Table 7.1:  Uptake of [14C] AA across MDA-MB231, T47D and ZR-75-1 cells in the presence of 
various concentrations of Ca++/calmodulin pathway, PKC pathway, PKA pathway and PTK 
pathway modulators in DPBS (pH 7.4) at 37 °C. The uptake is expressed as percentage of control 
(DPBS). Data is shown as mean±S.D. n=4. (*p<0.05). 
Pathways Modulators Uptake as % of Control 
  MDA-MB231 T47D ZR-75-1 
 
 
 
Ca++/Calmodulin 
Pathway 
Control 100 ± 1.57  100 ± 2.89  100 ± 4.12 
CaM (10µM) 38.55 ± 3.56* 32.89 ± 2.48* 31.49 ± 1.56* 
CaM (50µM) 35.18 ± 2.15* 27.69 ± 4.25* 25.78 ± 3.53* 
CaM (100µM) 24.45 ± 3.18* 18.46± 3.85* 15.63± 2.17* 
KN-62 (0.1µM) 48.68 ± 2.89* 38.14 ± 2.59* 40.14 ± 3.19* 
KN-62 (1µM) 38.45 ± 4.51* 25.91± 4.21* 28.76± 1.05* 
KN-62 (10µM) 25.26 ± 6.72* 21.83± 2.43* 19.45± 2.35* 
     
 218 
 
 
 
 
PKC Pathway 
Control 100 ± 5.52   100 ± 3.19  100 ± 2.69 
PMA (10µM) 52.35 ± 4.65* 54.82 ± 3.54* 55.46 ± 2.89* 
PMA (50µM) 50.23 ± 2.38* 47.61 ± 2.19* 50.12 ± 3.67* 
PMA (100µM) 44.98 ± 6.34* 40.75 ± 4.85* 42.15 ± 5.48* 
PMA (100µM) + BIS (25µM) 89.23 ± 6.35 90.25 ± 5.92 88.68 ± 7.89 
PMA (100µM) + BIS (50µM) 92.85 ± 4.39 92.68 ± 3.45 93.63 ± 5.67 
PMA (100µM) + BIS (100µM) 95.34 ± 3.48 93.15 ± 4.85 94.19 ± 2.11 
     
 
 
 
PKA Pathway 
Control 100 ± 3.24 100 ± 2.65 100 ± 6.32 
IBMX (0.1µM) 36.23 ± 4.21* 40.13 ± 4.21* 39.65 ± 2.12* 
IBMX (1µM) 30.64 ± 2.87* 35.84 ± 2.78* 36.48 ± 5.87* 
IBMX (5µM) 25.96 ± 5.12* 32.67 ± 4.51* 30.76 ± 2.15* 
Forskolin (1µM) 33.14 ± 4.29* 38.21 ± 3.53* 40.12 ± 5.33* 
Forkolin (10µM) 30.97 ± 7.19* 32.49 ± 7.89* 38.94 ± 6.98* 
Forskolin (50µM) 25.73 ± 4.28* 31.96 ± 4.56* 35.69 ± 3.65* 
Forskolin (100µM) 22.81 ± 2.16* 25.78 ± 2.55* 30.87 ± 5.22* 
     
 
 
 
PTK Pathway 
Control 100 ± 5.52   100 ± 3.19  100 ± 2.69 
Genistein (10µM) 52.35 ± 4.65* 54.82 ± 3.54* 55.46 ± 2.89* 
Genistein (50µM) 50.23 ± 2.38* 47.61 ± 2.19* 50.12 ± 3.67* 
Genistein (100µM) 44.98 ± 6.34* 40.75 ± 4.85* 42.15 ± 5.48* 
Tyrphostin A25 (10µM) 54.65 ± 6.35* 50.25 ± 5.92* 48.68 ± 7.89* 
Tyrphostin A25 (50µM) 45.78 ± 4.39* 42.68 ± 3.45* 43.63 ± 5.67* 
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Tyrphostin A25 (100µM) 33.21 ± 3.48* 36.15 ± 4.85* 34.19 ± 2.11* 
 
Reverse Transcription–Polymerase Chain Reaction Analysis 
 RT-PCR analysis was carried out for the confirmation of AA transport system (SVCT2) in 
all three breast cancer cell lines. Agarose gel electrophoresis using ethidium bromide was 
employed to analyze the PCR product. PCR amplification of cDNA from total RNA was 
performed with a set of primers specific for a human SVCT2 system. The PCR product obtained 
at 626 bp confirms the expression of the AA transport system (SVCT2) on MDA-MB231, T47D 
and ZR-75-1 cells. Higher intensity of 626 bp was detected in ZR-75-1 and T47D cell lines relative 
to MDA-MB231 cells (Fig.7.14). 
 Quantitative Real-Time PCR Analysis 
Quantitative estimates of the relative abundance of SVCT2 mRNA were obtained with 
qPCR analysis. mRNA levels of SVCT2 were also analyzed in MDA-MB231, T47D and ZR-75-
1 cells. Average Ct values for SVCT2 were around 38-42 and the average Ct values for GAPDH 
were observed to be 16-19. Significantly higher expression of SVCT2 mRNA in T47D and ZR-
75-1 cells was observed relative to MDA-MB231 cells (Fig.15). 
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Fig.7.14: RT-PCR studies showing the molecular evidence of SVCT2 in MDA-MB231, T47D and 
ZR-75-1 cells. Lane 1 represents ZR-75-1, lane 2: T47D, lane 3: MDA-MB231 and lane 4: 1 Kb 
molecular ladder. 
 
Fig.7.15: Real time-PCR comparing the expression of SVCT2 in MDA-MB231, T47D and ZR-
75-1 cells. Data is shown as mean±S.D. n=4. (*p<0.05). 
 221 
 
Discussion 
AA (vitamin C) is a vital cellular nutrient responsible for normal metabolic and 
physiological functions. Due to biosynthetic limitation, distribution of AA between extra- and 
intra-cellular fluids in cells is highly dependent on absorption through functional vitamin C 
transporters [533]. Due to its antioxidant nature causing neutralization of free radicals, AA has 
been postulated to inhibit cancer initiation and promotion [572]. Several reports have suggested 
the cytotoxic action of vitamin C against cancer cells [573, 574].  Also, the evidence from various 
epidemiologic studies cited the role of vitamin C as controversial in breast cancer [572]. All these 
biological progressions put emphasis on having a thorough understanding of the mechanism of 
AA transport in breast cancer cell lines. The main goal of this study was to investigate the 
functional and molecular expression of SVCT2 in human derived breast cancer cells (MDA-
MB231, T47D and ZR-75-1). We have selected these cell lines as an in vitro cell culture model 
because of their aggressive phenotype [575, 576]. Hence, in this study we have investigated the 
functional and molecular aspects of carrier mediated system responsible for AA uptake on these 
breast carcinoma cells. Another purpose was to delineate the mechanism of uptake and 
intracellular regulation. 
 Since time course of AA uptake showed the linear uptake till 60 min, an incubation time of 30 
min was selected for all AA uptake studies in MDA-MB231, T47D and ZR-75-1 cells (Fig.7.1). 
AA uptake appears to be temperature dependent with significant rapid rate at physiological 
temperature (37ºC) relative to 25ºC and 4ºC (Figs.7.2 & 7.3). Rise in pH resulted in enhanced AA 
uptake (Fig.7.4). Since the pKa1 of AA is 4.17, it exists primarily in ascorbate form (-1 charge) 
above the pH 5.0. As a consequence, enhanced AA uptake observed with rise in pH may not be 
due to the ionic state of AA. It can be concluded from pH dependency results that SVCT2 shows 
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higher affinity towards ascorbate at higher pH (Fig.7.4) [451, 463]. The major forces between 
SVCT2 and its substrates, responsible for the binding of SVCT2 with the ionized form of AA are 
ion–ion and/or ion–polarity interactions. At lower pH, protonation of histidine residues reduces 
the binding affinity of SVCT2 [463].  
In the absence of sodium and chloride ions, lower AA uptake was noticed confirming that 
SVCT2 transporter system may be highly sodium and chloride dependent (Fig.7.5).  Additionally, 
significant inhibition to AA uptake was observed in the presence of amiloride (a Na+ transport 
inhibitor) demonstrating that the transport system is highly sodium dependent (Fig.7.5). 
Transmembrane sodium gradient as well as the membrane potential are responsible for the uphill 
transport of SVCT2 substrates [458]. Therefore, we studied whether the carrier mediated transport 
via SVCT2 is coupled with the electrochemical gradient of Na+ ions in MDA-MB231, T47D and 
ZR-75-1 cells. In all these breast cancer cell lines, diminished uptake of AA was observed with 
decreasing concentrations of Na+ in the uptake buffer and was found to be saturated at higher 
concentrations. These results suggest that AA is coupled to Na+ and transported directly via 
SVCT2 (Fig.7.6). The Hill ratio analysis indicates that approximately two sodium ions (1.90 for 
MDA-MB231, 2.05 for T47D and 2.27 for ZR-75-1) are required for translocation of each AA 
molecule (Fig.7.7). 
Concentration dependent uptake of AA clearly reveals that a carrier mediated saturable 
process is present. In order to distinguish the passive diffusion component from the active AA 
transport, uptake study was carried out at 4ºC in all the breast carcinoma cells. [14C] AA uptake at 
4ºC was significantly lower than that at 37ºC. This suggest the involvement of passive diffusion 
of AA in thse cell lines. AA uptake was found to be saturable with Km values of 53.85±6.24, 
49.69±2.83 and 45.44±3.16 μM and Vmax values of 18.45±0.50, 32.50±0.43 and 33.25±0.53 
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pmol/mg protein/min in MDA-MB231, T47D and ZR-75-1 cells, respectively (Figs.7.8, 7.9 & 
7.10). Michaelis-Menten kinetic parameters (Km and Vmax) are two vital parameters accountable 
for functional and kinetic constants of a transporter. Km defines the measure of apparent binding 
affinity of a substrate whereas Vmax represents a measure of translocation capacity of the carrier-
mediated process. On the basis of Michaelis-Menten kinetics, the Km value of SVCT2 was found 
to be higher in MDA-MB231 in comparison to T47D and ZR-75-1 cells, indicating a higher 
binding strength and affinity of AA for MDA-MB231 cells. However comparison of Vmax values 
of SVCT2 suggest that transport capacity of SVCT2 in T47D and ZR-75-1 is higher relative to 
MDA-MB231 cells (32.50±0.43 and 33.25±0.53 vs 18.45±0.50 pmol/mg protein/min). Catalytic 
efficiency of SVCT2 was estimated by the ratio of Michaelis- Menten kinetic parameters 
(Vmax/Km). A variation in Vmax values results in higher transport efficiency (Vmax/Km) of SVCT2 
for T47D and ZR-75-1 (0.65 and 0.73 μl/mg protein/min, respectively) than MDA-MB231 (0.34 
μl/mg protein/min). These kinetic parameters indicate possible involvement of a carrier mediated 
transport system for the translocation of AA in MDA-MB231, T47D and ZR-75-1 cell lines. When 
the kinetic data was plotted in the form of Lineweaver-Burk (1/v vs. 1/[S]) plot, a single line was 
obtained for MDA-MB231, T47D and ZR-75-1 cells respectively, which suggests possible 
involvement of a single transporter for the translocation of AA across breast carcinoma cells (data 
not shown). These Michaelis-Menten kinetic parameters of SVCT2 in MDA-MB231, T47D and 
ZR-75-1 cells were in accordance with previously published reports showing the presence of 
SVCT2 across human retinal cells [531].  
AA uptake was significantly inhibited in all breast cancer cells in the presence of metabolic 
inhibitors such as sodium azide (oxidative phosphorylation inhibitor), 2,4-dinitrophenol 
(intracellular ATP reducer) and ouabain, (a known Na+/K+ ATPase inhibitor). This result suggest 
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that uptake of AA via SVCT2 is highly dependent on energy and directly coupled to ATP energy 
sources (Fig.7.11). Uptake of AA was also significantly inhibited in the presence of various 
membrane/anion inhibitors such as DIDS, SITC, and probenecid (Fig.7.12). Similar reports 
involving inhibition of AA uptake by membrane inhibitors has been published [460, 462]. These 
results suggest that AA uptake is altered by the presence of specific anions and the site of the 
SVCT2 transport system may be the plasma membrane [460, 462].  
In MDA-MB231, T47D and ZR-75-1 cells, concentration dependent inhibition of AA 
uptake mediated via SVCT2 was evident in the presence of structural analogs of AA (L-AA and 
D-Iso AA). No statistically significant inhibition in the AA uptake via SVCT2 was found in the 
presence of DHAA (structural analog and GLUT substrate), glucose (GLUT substrate) and PAHA 
(OAT substrate) (Fig.13). Similar results with respect to substrate specificity have been reported 
previously from our laboratory [462, 538]. Due to a lack of 3D structure of SVCT2 transporter, it 
is difficult to postulate about structural requirements for the binding of SVCT2 with its substrates 
and further investigations are required to address the issue. 
Several intracellular regulatory pathways such as Ca++/calmodulin, PKA, PTK and PKC 
are known to be involved in the regulation of AA transport system [462]. Five putative PKC 
phosphorylation sites in hSVCT1 and hSVCT2 and one additional PKA site in hSVCT1 have been 
identified based on the analysis of primary amino acid sequence of SVCT [463]. It has also been 
reported that AA uptake by SVCT2 expressed in COS-1 and MDCK-MDR1 cells was under the 
regulation of PKC-mediated pathway [462, 539]. For the same reason, we investigated the 
regulation of AA uptake by inter- and intra-cellular protein kinase-mediated pathways. Significant 
inhibition of AA uptake in the presence of calmidazolium and KN-62 was observed in these cell 
lines suggesting that the AA uptake process is under the regulation of Ca++/CaM mediated 
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pathway. Cell tretament with PMA led to a significant lowering in AA uptake, indicating the role 
of PKC-mediated pathway on the regulation of AA uptake. Conversely, addition of BIS (PKC 
pathway inhibitor) reverses the inhibitory effect of PMA signifying the contribution of PKC 
pathway in controlling this uptake process (Table.7.1).  
On the other hand, significant inhibition on AA uptake by IBMX and forskolin treated breast 
cancer cells confirms that PKA-mediated pathway plays a vital role in SVCT2 mediated. 
Significant inhibition was observed in presence of genistein and tyrphostin A25 (PTK pathway 
modulators) showing a possible role of PTK pathway in intracellular regulation of AA (Table.7.1). 
Molecular mechanism by which the protein kinase and calmodulin pathway exert their effect on 
AA uptake process is yet to be fully delineated.  
Finally, RT-PCR analysis confirms the molecular evidence of a vitamin C/AA specific 
carrier system in MDA-MB231, T47D and ZR-75-1 cells. An expression of SVCT2 on breast 
carcinoma cell lines were verified by a specific primer set for the gene. The expression was 
confirmed by the presence of strong bands of desired size. The PCR product obtained at 626 bp is 
specific for the SVCT2 transporter system (Fig.7.14). There was a non-specific band of a slightly 
lower molecular weight observed in the primer set for T47D. qPCR analysis revealed that the 
expression of SVCT2 was significantly higher in T47D and ZR-75-1 cells in comparison to MDA-
MB231 cells (Fig.7.15). Higher expression of SVCT2 in T47D and ZR-75-1 provides the 
justification of greater catalytic transporter efficiency of SVCT2 in T47D and ZR-75-1 relative to 
MDA-MB231 cells. 
Conclusion 
In summary, this work clearly delineates the functional activity and molecular evidence as 
well as the expression, contribution, and regulation of the sodium-dependent vitamin C transporter 
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2 (SVCT2) across MDA-MB231, T47D and ZR-75-1 cell lines. AA uptake across MDA-MB231, 
T47D and ZR-75-1 cells involves a carrier-mediated active process which is controlled by both 
Ca++/CaM mediated as well as protein kinases pathways. This transporter is highly pH dependent 
and requires coupling to an electrochemical Na+ gradient and ATP sources for cellular uptake.  
This membrane transporter (SVCT2) can be utilized as a potential target for enhancing 
permeability and bioavailability of highly potent anti-cancer drugs. Our investigation demonstrates 
complete profiling of SVCT2 mediated AA uptake and its dependence on calmodulin, protein 
kinases and intracellular ions. Demarcation of AA uptake and transport mechanism by SVCT2 can 
aid in achieving therapeutic drug concentrations at the target site. The results may help in providing 
cancer chemotherapy by evasion of efflux pumps in cancer cells and overcoming 
chemotherapeutic resistance which is an obstacle in the treatment of breast cancer.  Also, MDA-
MB231, T47D and ZR-75-1 cell lines can be utilized as a valuable in vitro model to investigate 
absorption and permeability of AA-conjugated chemotherapeutics. 
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CHAPTER 8 
SUMMARY AND RECOMMENDATIONS 
Summary 
Currently, hepatic transport processes has been recognized as a vital factor in determining 
drug disposition. Hence, evaluation of the hepatic transport and biliary excretion properties of 
prospective drug candidates plays a major role in drug development process. This information 
provides understanding of any altered hepatic disposition of therapeutic agents due to drug 
interactions and diseased states. Translocation of drug molecules across the sinusoidal membrane 
is mediated via basolateral transport system, whereas the biliary excretion of therapeutic agents 
and metabolites is mediated via active canalicular transport. Basolateral transport proteins consist 
of several membrane transporters including organic anion transporting polypeptides [OATPs 
(SLCO family)], organic anion and cation transporters [OATs, OCTs (SLC22A family)], Na+-
taurocholate co-transporting polypeptide [NTCP (SLC10A1)] and multidrug resistance-associated 
proteins [MRPs (ABCC family)]. P-glycoprotein (ABCB1), MRP2 (ABCC2), breast cancer 
resistance protein [BCRP (ABCG2)] and the bile salt export pump [BSEP (ABCB11)] forms the 
active canalicular transport system [1]. 
Metabolism of tyrosine kinase inhibitors (TKIs) is mainly mediated via hepatic route, but 
the mechanism responsible for their hepatocellular accumulation is still unknown. This study was 
designed to understand the contribution of organic anion transporting polypeptides (OATPs) in the 
hepatic uptake of selected TKIs - pazopanib, canertinib, erlotinib, vandetanib and nilotinib 
(Chapter 2). Michaelis-Menten (MM) kinetic parameters for TKIs were determined by 
concentration dependent cellular accumulation of selected TKIs using Chinese Hamster Ovary 
(CHO) cells - wild type as well as transfected with humanized OATP-1B1 and OATP-1B3 
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transporter proteins. The MM constant, Km values of OATP-1B1 for nilotinib and vandetanib are 
10.14±1.91 and 2.72±0.25µM respectively and Vmax values of OATP-1B1 for nilotinib and 
vandetanib were 6.95±0.47 and 75.95±1.99 nmoles/mg protein/min respectively. Likewise, Km 
values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 
4.37±0.79µM respectively and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib 
were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmoles/mg protein/min respectively. Canertinib 
did not exhibit any substrate specificity towards OATP-1B1. Also, erlotinib and pazopanib did not 
exhibit any substrate specificity towards OATP-1B1 and -1B3. Since selected TKIs are the 
substrates of OATP-1B1 and -1B3 expressed in hepatic tissue, these compounds can be regarded 
as molecular targets for transporter mediated DDIs. Any alteration in the function of these hepatic 
OATPs might account for the pharmacokinetic variability of TKIs. 
The potential of tyrosine kinase inhibitors (TKIs) as interacting drugs through hepatic 
uptake transporter inhibition has not been fully exploited in drug-drug interactions (DDIs). This 
study was designed to estimate the half maximal inhibitory concentration (IC50) values of 5 small 
molecule TKIs (pazopanib, nilotinib, vandetanib, canertinib and erlotinib) for organic anion 
transporting polypeptides (OATPs): OATP-1B1 and -1B3 (Chapter 3). The half maximal 
inhibitory concentration (IC50) values of TKIs and rifampicin (positive control) were determined 
by concentration dependent inhibition of TKIs on cellular accumulation of probe radiolabelled 
substrates [3H] ES and [3H] CCK-8. Chinese Hamster Ovary (CHO) cells transfected with 
humanized OATP-1B1 and OATP-1B3 transporter proteins, respectively, were utilized to carry 
out these studies. Pazopanib and nilotinib shows its inhibitory activity on OATP-1B1 transporter 
protein. The IC50 values for rifampicin, pazopanib and nilotinib were 10.46±1.15, 3.89±1.21 and 
2.78±1.13 µM respectively for OATP-1B1 transporter. Vandetanib, canertinib and erlotinib did 
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not exhibit any inhibitory potency towards OATP-1B1 transporter protein. Only vandetanib 
showed tis inhibitory potential towards OATP-1B3 transporter proteins out of the 5 selected TKIs. 
The IC50 values for rifampicin and vandetanib for OATP-1B3 transporter inhibition were 
3.67±1.20 and 18.13±1.21 µM respectively. No significant inhibition in the presence of increasing 
concentrations of pazopanib, nilotinib, canertinib and erlotinib were observed towards OATP-1B3 
transporter. Since selected TKIs are the inhibitors of OATP-1B1 and -1B3 expressed in hepatic 
tissue, these compounds can be regarded as molecular targets for transporter mediated DDIs. These 
finding provide the basis of further pre-clinical and clinical studies investigating the transporter 
based DDI potential of TKIs. 
Expression of drug transporters across various tissues like brain, ocular, liver, kidney and 
intestine has been reported before. These membrane transporters play an important role in drug 
absorption, distribution, metabolism and excretion. Also, the functionality of these transporters 
can be exploited and explored in terms of drug delivery in order to improve the absorption and 
permeation of drug across membrane by targeting specific transporter proteins [577]. Corneal 
epithelium and blood-retina barrier (i.e. retinal capillaries and retinal pigment epithelium (RPE)) 
acts as vital membranes governing the admittance of xenobiotics into the ocular tissues. Following 
topical administration, corneal epithelium limits the absorption of drug from the lacrimal fluid into 
the anterior chamber, while restriction of drug entry from systemic circulation to the posterior 
segment is regulated via blood-retina barrier. Involvement of membrane transporters for 
translocating drug across the membranes is quite limited relative to passive diffusion. However, 
after revelation of functionality of these membrane transporters, it has been attributed that these 
transporters play a vital role in modulating the pharmacokinetics of the therapeutic agent. Many 
drugs are known substrates of the transporters, however, the understanding about studies involving 
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expression and functionality of these transporters in ocular tissues is limited. Hence, these 
transporters have a vital role in regulating the ocular pharmacokinetics of a drug molecule [508]. 
The main aim of this study was to design novel pentablock (PB) (PLA–PCL–PEG–PCL–
PLA) polymer to prepare nanoparticles (NP) in order to achieve sustain delivery of pazopanib with 
minimal burst effect for the treatment of ocular neovascularization. Another purpose was to 
evaluate the effect of pazopanib loaded NP to bypass drug efflux (Chapter 5). PB copolymer was 
successfully synthesized using ring opening polymerization reaction mechanism and characterized 
using 1H NMR, GPC and XRD analysis. Synthesized PB copolymer was found to non-cytotoxic, 
non-immunogenic and biocompatible with ocular cell lines. Also, several parameters such as 
entrapment efficiency, drug loading, in vitro drug release profiling and effect of pazopanib NP in 
evading efflux transporters were examined. PB copolymer-based NP exhibited continuous release 
of pazopanib. It can be utilized to achieve continuous first order delivery of pazopanib upto 100 
days from nanoparticles without any significant burst effect. Pazopanib loaded NP were successful 
in evading drug efflux mediated via efflux transporters. This formulation can be employed to 
circumvent ocular barriers without altering ocular protective mechanisms. Our results indicated 
that PB copolymer based drug delivery systems can serve as a platform technology for the 
development of sustained release therapy for the treatment of ocular neovascularization. This drug 
delivery system can also be applicable for other ocular complications. 
Ascorbic Acid (AA, Vitamin C) is an essential vitamin responsible for normal cellular 
growth and physiological and metabolic functions. AA act as an anti-oxidant and absorbs the UV 
radiation, thus protecting the cornea, retina and other intraocular tissues against radiation induced 
damage. AA relieves the oxidative stress accompanying various eye infections. However, the 
uptake mechanism of AA in human corneal and retinal cells along with its cellular translocation 
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and intracellular trafficking are poorly understood. The main goal of this study is to investigate the 
existence of sodium dependent vitamin C transport system (SVCT2) and to define time dependent 
uptake mechanism and intracellular regulation of AA in human corneal epithelial (HCEC) and 
human retinal pigment epithelial (D407) cells (Chapter 6). Uptake of [14C] AA was observed to be 
sodium, chloride, temperature, pH and energy dependent in both cell lines. [14C] AA uptake was 
found to be saturable, with Km values of 46.14±6.03 and 47.26±3.24 μM and Vmax values of 
17.34±0.58 and 31.86±0.56 pmol/min/mg protein, across HCEC and D407 cells, respectively. The 
process is inhibited by structural analogs (L-AA and D-Iso AA) but not by structurally unrelated 
substrates (glucose and PAHA). Ca++/calmodulin and protein kinase C (PKC) pathways play an 
important role in modulating uptake of AA. A 626 bp band corresponding to a vitamin C 
transporter (SVCT2) has been identified by RT-PCR analysis in both the cell lines. This study 
reports the ascorbic acid uptake mechanism, kinetics, and regulation by sodium dependent vitamin 
C transporter (SVCT2) in HCEC and D407 cells. Also, SVCT2 can be utilized for targeted delivery 
in enhancing ocular permeation and bioavailability of highly potent ophthalmic drugs. 
The main goal of this study is to investigate the existence of sodium dependent vitamin C 
transport system (SVCT2) and to define uptake mechanism and intracellular regulation of ascorbic 
acid (AA) in human breast cancer cells (MDA-MB231, T47D and ZR-75-1) (Chapter 7). Uptake 
of [14C] AA was studied in MDA-MB231, T47D and ZR-75-1 cells. Functional aspects of [14C] 
AA uptake were studied in the presence of different concentrations of unlabeled AA, pH, 
temperature, metabolic inhibitors, substrates and structural analogs. Molecular identification of 
SVCT2 was examined with reverse transcription–polymerase chain reaction (RT-PCR). Uptake of 
[14C] AA was observed to be sodium, chloride, temperature, pH and energy dependent in all the 
breast cancer cell lines. [14C] AA uptake was found to be saturable, with Km values of 53.85±6.24, 
 232 
 
49.69±2.83 and 45.44±3.16 μM and Vmax values of 18.45±0.50, 32.50±0.43 and 33.25±0.53 
pmol/min/mg protein, across MDA-MB231, T47D and ZR-75-1, respectively. The process is 
inhibited by structural analogs (L-AA and D-Iso AA) but not by structurally unrelated substrates 
(glucose and PAHA). Ca++/calmodulin and protein kinase pathways were found to play a crucial 
role in modulating uptake of AA. A 626 bp band corresponding to a vitamin C transporter (SVCT2) 
based on the primer design was observed by RT-PCR analysis in all the breast cancer cell lines. 
This study reports AA uptake mechanism, kinetics, and regulation by sodium dependent vitamin 
C transporter (SVCT2) in MDA-MB231, T47D and ZR-75-1 cells. Also, SVCT2 can be utilized 
for designing targeted delivery to circumvent efflux and enhance permeation and bioavailability 
of highly potent chemotherapeutic drugs. 
Recommendations 
The above studies aimed at understanding the disposition of tyrosine kinase inhibitors (TKIs) on 
interaction with hepatic OATP-1B1 and -1B3. A few recommendations that can be made based on 
the results obtained from the above studies are: 
 To study transcellular transport of TKIs across a double-transfected MDCKII cell 
monolayer expressing both Human OATP and MRP2. This study can help in delineating 
the role of hepatic uptake and efflux transporters in governing disposition of TKIs. 
 To study transcellular transport of TKIs across a double-transfected MDCKII cell 
monolayer expressing both Human OATP and CYP3A4. This study can help in delineating 
the role of hepatic uptake and metabolizing enzymes in governing disposition of TKIs. 
 These are proof of concept studies performed on in vitro transfected cell culture model. 
Further in vivo studies on transgenic mouse model are required for better understanding of 
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the contribution of OATP-1B1 and/or -1B3 transporter proteins in the hepatic disposition 
of TKIs and for predicting any adverse drug reactions associated with DDIs. 
The other project was aimed at enhancing the bioavailability of therapeutic agents by evading drug 
efflux by formulating into NPs. The influx transporters were also characterized across ocular and 
breast cancer cells. These transporters can be utilized as a target for designing of better therapeutic 
agents. 
 A novel approach of a NPs embedded in thermosensitive gel can be utilized to further 
sustain the release of small and macromolecules and it will also imparts stability to the 
drug molecule. 
 Since Pazopanib is a substrate for efflux transporter. Surface modified NPs can be utilized 
for targeted drug delivery. Ascorbic acid surface modified PB NPs might be recognized by 
vitamin C transporter (SVCT2) located on the apical site of the corneal and retinal pigment 
epithelial cells. Hence via surface modification approach, uptake of NPs across target site 
can be enhanced. Our composite formulation approach may serve as a platform technology 
for the delivery of small and macro molecules in the treatment of ocular diseases. 
 Also, these surface modified PB NPs can be utilized to target breast cancer cells expressing 
vitamin C transporter (SVCT2). Targeted delivery to SVCT2 will not only circumvent 
efflux but also enhance permeation and bioavailability of highly potent chemotherapeutic 
drugs. 
 Ascorbic acid prodrugs of pazopanib can be synthesized to circumvent efflux. These 
ascorbic acid conjugated pazopanib may enhance permeability and bioavailability of 
pazopanib across targeted tissue. 
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